

Solid-Phase Synthesis and Chemical Space Analysis of a 190-Membered Library of Alkaloid/Terpenoid-like Small Molecules

Gustavo Moura-Letts,^a Christine M. DiBlasi,^a Renato A. Bauer^b and Derek S. Tan^{*a,b}

^a Molecular Pharmacology & Chemistry Program,
^b Tri-Institutional Training Program in Chemical Biology,
and Tri-Institutional Research Program,
Memorial Sloan-Kettering Cancer Center
1275 York Avenue, Box 422, New York, New York 10065

Supporting Information

A. Materials and methods	S2
B. Synthesis of sulfinimine alcohols (S1 , S2)	S3
C. Preparation of TBDAS polystyrene resin	S4
D. Summary of library synthesis results (Table S1)	S5
E. Analytical data for <i>R</i> -series library members	S7
1. Pauson–Khand reaction products (R-11–13)	S7
2. Krische reductive cyclization products (R-14–19)	S10
3. Evans butadiene [4+2+2] cycloaddition products (R-20)	S14
4. Enyne metathesis products (R-21–23)	S15
5. Maleimide Diels–Alder products (R-24)	S17
6. DMAD Diels–Alder products (R-25)	S18
7. Alkyne [2+2+2] cyclotrimerization products (R-30–35)	S19
8. Isocyanate [2+2+2] cyclotrimerization products (R-36–41)	S23
9. Nitrile [2+2+2] cyclotrimerization products (R-42–44)	S27
10. Saito [3+2+2] cycloaddition products (R-45–50)	S29
F. Analytical data for <i>S</i> -series library members	S35
1. Pauson–Khand reaction products (S-11–13)	S35
2. Krische reductive cyclization products (S-14–19)	S37
3. Evans butadiene [4+2+2] cycloaddition products (S-20)	S41
4. Enyne metathesis products (S-21–23)	S42
5. Maleimide Diels–Alder products (S-24)	S45
6. DMAD Diels–Alder products (S-25)	S46
7. Alkyne [2+2+2] cyclotrimerization products (S-30–35)	S46
8. Isocyanate [2+2+2] cyclotrimerization products (S-36–41)	S50
9. Nitrile [2+2+2] cyclotrimerization products (S-42–44)	S53
10. Saito [3+2+2] cycloaddition products (S-45–50)	S56
G. Principal component analysis (PCA) (Figures S1–S6)	S62
H. Principal moments of inertia (PMI) analysis (Figures S7–S9)	S69
I. ¹ H-NMR and selected ¹³ C-NMR spectra	S71

A. MATERIALS AND METHODS

Reagents were obtained from Aldrich Chemical (www.sigma-aldrich.com) or Acros Organics (www.fishersci.com) and used without further purification. Poly(bromostyrene) resin (150–300 µm) was purchased from Polymer Laboratories (www.polymerlabs.com). Optima grade solvents were obtained from Fisher Scientific (www.fishersci.com), degassed with Ar, and purified on a solvent drying system as described¹ unless otherwise indicated. Solution-phase reactions were performed in flame-dried glassware under positive Ar pressure with magnetic stirring. Solid-phase reactions were performed in flame-dried glassware under positive Ar pressure with magnetic stirring or in a Mettler-Toledo AutoChem MiniBlock XT™ solution-phase synthesizer, or in a Radleys Carousel 12 solution-phase synthesizer. After each reaction, the resin was washed using a standard wash protocol as previously described.²

TLC was performed on 0.25 mm E. Merck silica gel 60 F254 plates and visualized under UV light (254 nm) or by staining with potassium permanganate (KMnO₄). Silica flash chromatography was performed on E. Merck 230–400 mesh silica gel 60. Parallel chromatography was performed on an ISCO CombiFlash OptiX 10 instrument with RediSep silica gel normal phase columns using a flow rate of 16.0 mL/min and a gradient of 10–100% EtOAc in hexanes over 20 min with UV detection at 254 nm. HPLC analysis was carried out on a Waters analytical HPLC with an XTerra C18 reverse phase column (150 mm x 4.6 mm, 5 µm, 120 Å) using a flow rate of 1.0 mL/min and a gradient of 50–100% CH₃CN in 0.1% aq TFA over 10 min with UV detection at 254 nm. Preparative scale HPLC purification was carried out on a Waters Prep HPLC using an XTerra C18 reverse phase column (150 mm x 19 mm) using a flow rate of 16.0 mL/min and a gradient of 50–100%, 75–100%, or 90–100% CH₃CN in 0.1% aq TFA over 16 min with UV detection at 254 nm. LC–MS analysis was carried out on a Waters 2695 LC system with a 996 diode array detector and a Micromass ZQ4000 mass spectrometer in ESI mode, with an XTerra C18 reverse phase column (150 mm x 4.6 mm) using a flow rate of 1.0 mL/min and a gradient of 50–100% CH₃CN in 0.1% aq TFA over 8 min. Lyophilization of aqueous samples was performed using a GeneVac HT-4X centrifugal evaporator. Lyophilization of larger aqueous samples was performed using a Labconco Freezone 2.5 instrument.

NMR spectra were recorded on Bruker Avance II 500 or Avance II 600 instruments at 24 °C in CDCl₃ unless otherwise indicated. Chemical shifts are expressed in ppm relative to TMS (¹H, 0 ppm) or solvent signals: CDCl₃ (¹³C, 77.0 ppm); coupling constants are expressed in Hz. Mass spectra were obtained at the MSKCC Analytical Core Facility on a PE SCIEX API 100 or Waters 2505 mass spectrometer by electrospray (ESI) ionization or atmospheric pressure chemical ionization (AP-CI). Elemental analyses were carried out by Robertson Microlit Laboratories (www.roberston-microlit.com) and are reported in percent atomic abundance.



Resin loading levels are expressed in *mequiv/g* (not *mmol/g*), which are the appropriate units for a functionalized polymer. Theoretical maximum loading levels (*LL*) were calculated to account for the expected change in mass per unit of resin after each transformation:

$$LL_2 = \frac{LL_1}{1 + (LL_1 \times [MW_2 - MW_1])}$$

¹ Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. *Organometallics* **1996**, *15*, 1518–1520.

² DiBlasi, C. M.; Macks, D. E.; Tan, D. S. *Org. Lett.* **2005**, *7*, 1777–1780.


B. SYNTHESIS OF SULFINIMINE ALCOHOLS (S1, S2)



(*R,E*)-*N*-(3-Hydroxypropylidene)-2-methylpropane-2-sulfinamide (*R*-S1**).** In a 250 mL roundbottom flask, 3-(*tert*-butyldiphenylsilyloxy)propanal (16.2 g, 51.9 mmol, 1.0 equiv) was dissolved in 100 mL anhyd THF. $\text{Ti}(\text{OEt})_4$ (2.99 mL, 13.0 mmol, 2.5 equiv) was added by syringe and solid (*R*)-*tert*-butylsulfinamide (6.92 g, 57.1 mmol, 1.1 equiv) was then added in one portion. The resulting orange solution was stirred at rt for 75 min. The reaction mixture was poured into 500 mL of vigorously stirred brine, and the flask was rinsed with EtOAc (500 mL). The resulting biphasic mixture was filtered through a pad of celite and transferred to a separatory funnel. The layers were separated and the aq layer was extracted with EtOAc (3 x 300 mL). The combined organic extracts were dried (Na_2SO_4), filtered, and concentrated by rotary evaporation. Purification by silica flash chromatography (5:1 hexanes/EtOAc) yielded the *tert*-butylsulfinylimine TBDPS ether³ (18.2 g, 86%) as a colorless oil.

In a 200 mL roundbottom flask, the (*R*)-*tert*-butylsulfinylimine above (18 g, 50 mmol, 1.0 equiv) was dissolved in 100 mL THF. TBAF (1 M in THF, 75 mL, 1.5 equiv) was added at 0 °C and the resulting solution was stirred for 10 min, then warmed to rt and stirred for 2 h. The reaction was quenched with aqueous NH_4Cl (100 mL), then extracted with EtOAc (3 x 200 mL). The combined organic extracts were dried (Na_2SO_4), filtered, and concentrated by rotary evaporation. Purification by silica flash chromatography (1:1 hexanes/EtOAc) yielded the *tert*-butylsulfinylimine alcohol **R-S1** (12 g, 80%) as a colorless oil.


TLC: R_f 0.25 (1:4 hexanes/EtOAc). **¹H-NMR** (500 MHz): δ 8.16 (t, 1H, J = 4.7), 3.89 (t, 2H, J = 6.1), 2.74–2.78 (m, 2H), 1.10 (s, 9H). **¹³C-NMR** (125 MHz): δ 168.2, 62.2, 55.9, 41.2, 25.8. **ESI-MS** m/z (rel int): (pos) 200.1 ([M+Na]⁺, 100).



(*S,E*)-*N*-(3-Hydroxypropylidene)-2-methylpropane-2-sulfinamide (*S*-S2**).** Light yellow oil (12 g, 80%). **TLC:** R_f 0.25 (1:4 hexanes/EtOAc). **¹H-NMR** (500 MHz): δ 8.16 (t, 1H, J = 4.7), 3.89 (t, 2H, J = 6.1), 2.74–2.78 (m, 2H), 1.10 (s, 9H). **¹³C-NMR** (125 MHz): δ 168.2, 62.2, 55.9, 41.2, 25.8. **ESI-MS** m/z (rel int): (pos) 200.1 ([M+Na]⁺, 100).

³ DiBlasi, C. M.; Macks, D. E.; Tan, D. S. *Org. Lett.* **2005**, 7, 1777–1780.

C. PREPARATION OF TBDAS POLYSTYRENE RESIN



Resin-bound *t*-butyldiarylsilyl hydride (TBDAS-H).² Poly(bromostyrene) resin (30.3 g, 2.2 mequiv/g, 66.7 mequiv) was placed in a roundbottom flask with a stirbar under Ar atmosphere. The resin was swelled with anhyd benzene (500 mL) for 15 min at rt. *t*-BuLi (1.5 M in pentane, 202 mL, 303 mmol, 5 equiv) was added by syringe over 10 min, then the reaction was stirred for 1 h. Anhyd benzene (200 mL) was added and the excess *t*-BuLi was drained out under positive Ar pressure. The yellowish resin was rinsed with 2 x 300 mL anhyd benzene and resuspended in 400 mL anhyd benzene. *tert*-Butylchlorophenylsilane (48.1 g, 242 mmol, 4 equiv) was added by syringe and the resulting slurry was stirred at rt for 20 h. The resin was washed thoroughly: THF (2 x 500 mL), 3:1 THF/isopropanol (2 x 500 mL), 3:1 THF/H₂O (2 x 500 mL), 3:1 THF/isopropanol (2 x 500 mL), THF (2 x 500 mL), trimethyl-orthoformate (2 x 100 mL), CH₂Cl₂ (2 x 50 mL). The resin was then dried under high vacuum for 6 h. The TBDAS loading level was determined to be 1.53 mequiv/g by Si elemental analysis (82% of theoretical maximum 1.86 mequiv/g).

D. SUMMARY OF LIBRARY SYNTHESIS RESULTS

Library members were synthesized, cleaved, and purified as described in the manuscript. Due to the highly diverse nature of the library, the individual compounds exhibited similarly diverse retention properties during HPLC purification. Rather than optimize HPLC methods for each of the 190 library members individually, a series of three general HPLC methods was used, based primarily on the nature of the *N*-substituent, with minor variations based on predicted polarity. This allowed purification of the library in a timely fashion, although at the cost of some material losses.

Purified mass recoveries, overall yields (5–8 steps on solid support from sulfinimine alcohol loading through product cleavage), and average per-step yields are summarized in Table S1 below. The mean overall yield was 20.2% and the mean average per-step yield was 74.0%. All 190 compounds were recovered in sufficient quantities for high-throughput screening at the Rockefeller University High-Throughput Screening Resource Center and 94 compounds were also submitted to the NIH Molecular Libraries Small Molecule Repository under the auspices of the NIH Molecular Libraries Program.

Table S1. Summary of library synthesis results.

		 Alkaloid/Terpenoid Library	
		R ³ = (S)- or (R)-SO ₂ Bu R ² = H R ¹ = SO ₂ t-Bu	
		E (a) P (b) H (d)	
		(S) (R) sidechain = (S)- or (R)-CH ₂ CH ₂ OH	

a) Molecular weights (g/mol).

R ¹	R ²	sidechain	Precursor / Reaction	A (from enynes 3)							P (from diynes 4)							
				K (11–13)	R-R (14–16)	R-S (17–19)	B (20)	G (21–23)	G-M (24)	G-D (25)	P-O-M (30–32)	P-O-O (33–35)	I-B-O (36–38)	I-B-M (39–41)	N-E-M (42–44)	N-E-O (na)	M-W-E (45–47)	M-W-Z (48–50)
S R	E (a)			315.4	315.4	289.4	289.4	287.4	287.4		341.5	341.5	418.6	418.6	384.5	384.5	426.6	426.6
	P (b)			347.5	347.5	321.5	321.5	321.5			373.5	373.5	373.5	373.5	458.6	458.6	458.6	458.6
	H (d)			271.4	271.4	245.3	245.3				297.4	297.4	297.4	297.4	416.5	416.5	458.6	458.6
				211.3	211.3	185.3	185.3	185.3			243.3	243.3			340.4	340.4	382.6	382.6
H	E (a)	(S) (R)		211.3	211.3	185.3	185.3	185.3			243.3	243.3	237.3	237.3	312.4	312.4	354.4	354.4
	P (b)	(S) (R)		243.3	243.3	217.3	217.3	217.3			215.3	215.3	269.3	269.3	346.4	346.4	382.6	382.6
	H (d)			167.2	167.2	141.2	141.2				139.2	139.2	193.2	193.2	270.3	270.3	322.4	322.4
				331.4	331.4	305.4	305.4	305.4			303.4	303.4	476.6	476.6	443.5	443.5	442.6	442.6
O	E (a)			363.5	363.5	337.5	337.5	337.5			357.5	357.5	357.5	357.5	434.6	434.6	442.6	442.6
	P (b)			287.4	287.4	261.4	261.4				308.6	308.6	335.5	335.5	508.6	508.6	474.6	474.6
	H (d)										325.5	325.5	475.6	475.6	389.5	389.5	474.6	474.6
											313.5	313.5	399.5	399.5	313.4	313.4	398.6	398.6

b) Theoretical maximum resin loading levels for products (mequiv/g). Calculated based on initial TBDAS linker loading level of 1.53 mequiv/g (Si elemental analysis).

R ¹	R ²	sidechain	Precursor / Reaction	A (from enynes 3)							P (from diynes 4)							
				K (11–13)	R-R (14–16)	R-S (17–19)	B (20)	G (21–23)	G-M (24)	G-D (25)	P-O-M (30–32)	P-O-O (33–35)	I-B-O (36–38)	I-B-M (39–41)	N-E-M (42–44)	N-E-O (na)	M-W-E (45–47)	M-W-Z (48–50)
S R	E (a)			1.04	1.04	1.06	1.06	1.06			1.01	1.01	0.94	0.94	0.97	0.97	0.93	0.93
	P (b)			1.00	1.00	1.03	1.03	1.03			0.98	0.98	0.98	0.98	0.94	0.94	0.90	0.90
	H (d)			1.09	1.09	1.12	1.12				1.12	1.12	1.06	1.06	1.01	1.01	0.97	0.97
				1.16	1.16	1.20	1.20	1.20			1.20	1.20	1.13	1.13	1.08	1.08	1.03	1.03
H	E (a)	(S) (R)		1.12	1.12	1.15	1.15	1.15			1.16	1.16	1.09	1.09	1.00	1.00	1.00	1.00
	P (b)	(S) (R)		1.22	1.22	1.26	1.26				1.27	1.27	1.19	1.19	1.09	1.09	1.08	1.08
	H (d)			1.02	1.02	1.05	1.05	1.05			0.99	0.99	1.05	1.05	0.92	0.92	0.92	0.92
				0.99	0.99	1.01	1.01	1.01			0.96	0.96	1.01	1.01	0.90	0.90	0.89	0.89
O	E (a)			1.07	1.07	1.10	1.10				1.04	1.04	1.10	1.10	0.92	0.92	0.95	0.95
	P (b)										0.95	0.95	1.04	1.04	0.96	0.96	0.99	0.99
	H (d)										0.95	0.95	1.04	1.04	0.96	0.96	0.99	0.99
											0.95	0.95	1.04	1.04	0.96	0.96	0.99	0.99

c) Masses of resin cleaved (mg). Blue cells represent reactions from which two isomers were isolated separately.

R ³	R ²	sidechain	Precursor / Reaction	A (from enynes 3)						P (from diynes 4)					
			K (11-13) R-R (14-16) R-S (17-19)	B (20)	G (21-23)	G-M (24)	G-D (25)	P-O-M (30-32)	P-O-O (33-35)	I-B-O (36-38)	I-B-M (39-41)	N-E-M (42-44)	N-E-O (na)	M-W-E (45-47) M-W-Z (48-50)	
S R	E (a)		75 76 77 74 73 75	75 78	76 78	76 76	76 76	299 301							
	P (b)		100 100 100 101 100 104	100 97	73 74			200 200	99 100	75 77	101 102	101 102	298 299		
	H (d)		75 75 76 75					151 148	149 151	76 76	75 77	74 75	294 298		
H	E (a)		73 75 75 77 74 72		75 72			201 200	101 102	75 77	74 75	74 75	297 299		
	P (b)		99 98 100 99 100 97	101 99	75 75	147 150	152 150	152 154	152 150	76 75	79 77	74 75	298 300		
	H (d)		74 75 82 80							102 101	102 101	100 103	402 400		
O	E (a)		76 76 75 76 75 74	76 75	74 75	147 150	152 150	148 152	148 152	76 77	74 75	74 75	294 298		
	P (b)		99 97 101 102 98 99	102 101	99 97	200 200	198 201	202 202	201 202	76 75	79 77	74 75	298 300		
	H (d)		75 73 77 76	73 76	74 73	150 152	149 150	148 152	148 152	75 73	75 73	75 73	298 294		

d) Masses of purified products recovered (mg). Yields of individual isomers shown separately.

R ³	R ²	sidechain	Precursor / Reaction	A (from enynes 3)						P (from diynes 4)						
			K (11-13) R-R (14-16) R-S (17-19)	B (20)	G (21-23)	G-M (24)	G-D (25)	P-O-M (30-32)	P-O-O (33-35)	I-B-O (36-38)	I-B-M (39-41)	N-E-M (42-44)	N-E-O (na)	M-W-E (45-47) M-W-Z (48-50)		
S R	E (a)		7.0 7.3 8.2 8.3 8.1 8.1	8.8 9.1	8.9 9.1	7.5 7.0	7.4 7.0	1.7 4.4	2.2 3.7							
	P (b)		7.5 7.9 8.8 7.9 8.3 7.7	8.6 8.1	8.3 8.0	4.9 3.4	4.3 3.9	4.1 4.0	5.1 3.9	4.2 3.1						
	H (d)		7.3 7.3 7.4 7.2	7.8 8.2	7.8 8.1	7.2 7.6	8.1 8.3	8.5 7.0	4.6 4.9	4.9 4.1	4.5 3.3					
H	E (a)		3.1 3.7 4.1 5.6 4.0 4.9	0.9 0.8	1.1 1.5	4.9 3.1	3.5 4.1	2.5 2.1	2.1 1.6	1.4 0.6						
	P (b)		1.4 3.3 8.1 7.0 8.0 7.1	1.5 1.1	1.2 0.7	2.1 1.7	1.0 0.8	2.6 2.1	2.1 1.6	1.4 0.6						
	H (d)		2.4 3.1 7.5 7.1					7.9 7.5	3.5 4.1	7.9 8.1	7.5 8.1	4.5 3.0	3.5 3.3			
O	E (a)		7.4 7.2 8.3 8.9 7.3 8.1	4.5 3.9	7.7 8.0	8.1 8.6	4.2 2.1	7.8 7.0	8.0 7.3	3.9 2.1	3.9 2.9	3.3 3.1				
	P (b)		7.0 7.5 9.2 8.8 8.5 8.2	7.2 7.1 7.6 7.3	5.0 3.5	4.8 5.0	2.3 2.3	7.5 8.1	7.5 8.1	4.1 3.3	4.1 3.3	3.1 2.9	TOTALS			
	H (d)		7.1 7.2 9.1 8.2	7.0 7.5 7.0 7.2	7.5 7.1	8.6 8.0	7.1 7.4	7.3 7.0	3.1 3.5	2.9 1.9	3.1 3.6	0 0	0 0	180 94		
Rockefeller			0.5	18	18	12	6	18	6	18	6	18	0	18	18	
Rockefeller + NIH			6.0	12	16	10	4	12	4	12	4	8	2	8	0	

e) Overall yields over 5–8 steps. Blue cells indicate combined yields for the two individual isomers, which were recovered separately.

R ³	R ²	sidechain	Precursor / Reaction	A (from enynes 3)						P (from diynes 4)					
			K (11-13) R-R (14-16) R-S (17-19)	B (20)	G (21-23)	G-M (24)	G-D (25)	P-O-M (30-32)	P-O-O (33-35)	I-B-O (36-38)	I-B-M (39-41)	N-E-M (42-44)	N-E-O (na)	M-W-E (45-47) M-W-Z (48-50)	AVERAGE
S R	E (a)		29% 29% 35% 36% 36% 35%	38% 38%	34% 34%	25% 24%	26% 25%	17.4%	16%	11% 10%	11% 10%	6% 4%	6% 4%		
	P (b)		22% 23% 27% 24% 25% 22%	26% 25%	39% 41%	32% 34%	30% 28%	17.9%	19%	16% 18%	16% 18%	5% 4%	5% 4%	24.4%	
	H (d)		33% 32% 36% 35%					5% 7%	20% 12%	16% 18%	16% 18%	5% 4%	5% 4%	14.8%	
H	E (a)		17% 9% 25% 33% 33% 31%	5% 5%	19% 20%	9% 7%	22% 23%	8% 6%	2% 2%	2% 2%	2% 2%	2% 2%	15.8%		
	P (b)		5% 12% 32% 28% 32% 29%	6% 4%	19% 20%	9% 7%	17% 14%	35% 37%	3% 3%	3% 3%	3% 3%	3% 3%	19.8% 16.7%		
	H (d)		16% 20% 51% 50%					25% 23%	28% 26%	19% 20%	19% 20%	5% 4%	5% 4%	14.3%	
O	E (a)		29% 28% 35% 37% 30% 34%	17% 15% 33% 34%	13% 14%	7% 3%	33% 31%	25% 23%	25% 23%	73% 75%	73% 75%	6% 5%	6% 5%	22.0% 19.7%	
	P (b)		20% 22% 27% 25% 25% 24%	19% 19% 23% 21%	6% 6%	6% 6%	5% 7%	6% 6%	9% 9%	19% 20%	19% 20%	6% 6%	6% 6%		
	H (d)		31% 32% 41% 38%	29% 30% 33% 35%	13% 12%	15% 14%	30% 29%	11% 9%	12% 14%	12% 14%	12% 14%	6% 6%	6% 6%	22.0% 19.7%	
			AVERAGE	22% 23% 34% 34% 29% 21%	21% 23%	10% 10%	8% 8%	19% 16%	19% 15%	19% 16%	19% 15%	5% 4%	5% 4%	20.2%	
				23%	34%	29%	21%	18%	18%	18%	19%	5%	5%		


f) Average yields per solid-phase step. Blue cells indicate average yields calculated based on combined overall yields for the two individual isomers in part c above.

R ³	R ²	sidechain	Precursor / Reaction	A (from enynes 3)						P (from diynes 4)					
			K (11-13) R-R (14-16) R-S (17-19)	B (20)	G (21-23)	G-M (24)	G-D (25)	P-O-M (30-32)	P-O-O (33-35)	I-B-O (36-38)	I-B-M (39-41)	N-E-M (42-44)	N-E-O (na)	M-W-E (45-47) M-W-Z (48-50)	AVERAGE
S R	E (a)		78% 78% 81% 82% 82% 81%	83% 82%	81% 81%	76% 75%	76% 75%	57% 64%	64% 62%	64% 64%	62% 59%	66% 64%	66% 64%		
	P (b)		74% 74% 77% 75% 76% 74%	76% 76%	73% 73%	79% 80%	79% 77%	69.8% 74.4%	70% 72%	70% 72%	73% 75%	65% 62%	65% 62%	71.0%	
	H (d)		80% 80% 81% 81%					62% 65%	62% 65%	76% 71%	73% 75%	65% 62%	65% 62%	70.8%	
H	E (a)		75% 67% 79% 83% 79% 82%	62% 61%	63% 60%	76% 76%	78% 78%	66% 63%	66% 63%	66% 63%	66% 63%	59% 55%	59% 55%		
	P (b)		61% 71% 83% 81% 83% 81%	63% 60%	67% 61%	67% 64%	74% 72%	84% 85%	62% 61%	62% 61%	62% 61%	62% 61%	73.3% 71.6%		
	H (d)		74% 77% 89% 89%	74% 73% 83% 83%	75% 75%	71% 66%	83% 82%	79% 78%	81% 80%	81% 80%	81% 80%	67% 65%	67% 65%	71.5%	
O	E (a)		81% 81% 84% 85% 82% 84%	74% 73% 83% 83%	75% 75%	71% 66%	83% 82%	79% 78%	81% 80%	81% 80%	81% 80%	67% 65%	67% 65%	77.8%	
	P (b)		76% 77% 80% 79% 80% 79%	76% 76% 78% 77%	66% 63%	70% 69%	64% 56%	67% 61%	76% 76%	76% 76%	76% 76%	65% 63%	65% 63%	77.4% 75.5%	
	H (d)		82% 83% 86% 85%	82% 82% 83% 84%	74% 74%	79% 78%	82% 81%	70% 68%	70% 72%	70% 72%	70% 72%	67% 66%	67% 66%	74.0%	
			AVERAGE	76% 76% 82% 82% 80% 80%	77% 77% 75% 75%	71% 71%	72% 73%	76% 76%	73% 74%	73% 74%	73% 74%	63% 62%	63% 62%		
				76%	82%	80%	77%	75%	71%	72%	73%	73%	63%		


E. ANALYTICAL DATA FOR R-SERIES LIBRARY MEMBERS

¹H-NMR and mass spectral data are provided for all 190 library members (95 in the (*R*)-*tert*-butylsulfinimine-derived series below). Comprehensive analytical data, including optical rotation, IR, and ¹³C-NMR data, is provided for a representative subset of 20 compounds from the *R*-series, including at least one compound from each of the 10 scaffold classes: **R-11a**, **R-14b**, **R-17b**, **R-20b**, **R-23d**, **R-24a**, **R-25b**, **R-30a**, **R-30b**, **R-32d**, **R-33d**, **R-35d**, **R-36a**, **R-36d**, **R-39d**, **R-42a**, **R-42b**, **R-44a**, **R-44b**, **R-45b**.


1. PAUSON-KHAND REACTION PRODUCTS (R-11–13)




(*–*)(1*R*,3*aR*)-2-((*R*)-*tert*-Butylsulfinyl)-1,6-bis(2-hydroxyethyl)-2,3,3*a*,4-tetrahydrocyclopenta[c]pyrrol-5(1*H*)-one (R-11a). Clear oil (7.3 mg). TLC: *R*_f 0.40 (1:9 hexanes/EtOAc) [α]_D²⁰: -18.0° (c 0.48, CHCl₃). IR (NaCl, film): 3388 (O-H st), 3021, 2998, 2882, 1712 (C=O st), 1661, 1452, 1351, 1265, 1131 (S-O st), 910, 836. ¹H-NMR (600 MHz): δ 5.85 (dt, 1H, *J* = 8.8, 6.1), 5.16 (d, 1H, *J* = 10.0), 5.03 (d, 1H, *J* = 8.2), 4.51 (s, 1H), 3.92 (dd, 1H, *J* = 12.5, 8.2), 3.78–3.72 (m, 2H), 3.56–3.52 (m, 2H), 2.48 (t, 1H, *J* = 5.6), 1.83–1.78 (m, 3H), 1.64–1.62 (m, 1H), 1.21 (s, 9H). ¹³C-NMR (150 MHz, CDCl₃): δ 208.7, 178.1, 134.6, 60.4, 60.2, 58.2, 57.2, 47.9, 40.2, 40.0, 36.3, 27.9, 25.9. ESI-MS *m/z* (rel int): (pos) 310.4 ([M-CO+Na]⁺, 100).




(1*R*,3*R*)-2-((*R*)-*tert*-Butylsulfinyl)-1-(2-hydroxyethyl)-6-phenyl-2,3,3*a*,4-tetrahydrocyclopenta[c]pyrrol-5(1*H*)-one (R-11b). Clear oil (7.9 mg). TLC: *R*_f 0.24 (1:4 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 7.39–7.31 (m, 5H), 6.02 (dt, 1H, *J* = 8.4, 2.4), 5.30 (d, 1H, *J* = 14.3), 5.16 (d, 1H, *J* = 8.8), 4.82 (t, 1H, *J* = 8.8), 3.98 (dd, 1H, *J* = 10.2, 4.4), 3.89 (dd, 1H, *J* = 8.8, 3.5), 3.70–3.65 (m, 2H), 2.04–1.98 (m, 2H), 1.31 (s, 9H). ESI-MS *m/z* (rel int): (pos) 370.5 ([M+Na]⁺, 100).




(1*R*,3*R*)-2-((*R*)-tert-Butylsulfinyl)-1-(2-hydroxyethyl)-2,3,3a,4-tetrahydrocyclopenta[c]pyrrol-5(1*H*)-one (*R*-11d**).** Light yellow oil (7.1 mg). TLC: R_f 0.27 (1:6 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 5.92 (dt, 1H, J = 5.5, 2.6), 5.16 (d, 1H, J = 12.0), 5.03 (d, 1H, J = 8.2), 4.59 (t, 1H, J = 8.7), 3.98 (s, 1H), 3.96 (dd, 1H, J = 10.7, 8.6), 3.85 (dd, 1H, J = 9.1, 10.7), 3.54–3.49 (m, 2H), 1.81–1.76 (m, 2H), 1.21 (s, 9H). ESI-MS m/z (rel int): (pos) 240.4 ([M+Na]⁺, 100).




(1*R*,3*aR*)-1,6-Bis(2-hydroxyethyl)-2,3,3a,4-tetrahydrocyclopenta[c]pyrrol-5(1*H*)-one (*R*-12a**).** Clear oil (3.3 mg). TLC: R_f 0.31 (1:5 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 5.96 (dt, 1H, J = 8.8, 6.2), 5.18 (d, 1H, J = 10.0), 5.05 (d, 1H, J = 8.2), 4.62 (s, 1H), 4.08 (dd, 1H, J = 12.5, 8.2), 3.92–3.88 (m, 1H), 3.76–3.72 (m, 1H), 3.52–3.50 (m, 1H), 2.96–2.92 (m, 1H), 2.48 (t, 1H, J = 5.6), 1.89–1.85 (m, 1H), 1.74–1.70 (m, 1H), 1.61–1.58 (m, 2H). ESI-MS m/z (rel int): (pos) 234.4 ([M+Na]⁺, 100).




(1*R*,3*aR*)-1-(2-Hydroxyethyl)-6-phenyl-2,3,3a,4-tetrahydrocyclopenta[c]pyrrol-5(1*H*)-one (*R*-12b**).** Clear oil (3.5 mg). TLC: R_f 0.48 (1:9 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 7.34–7.32 (m, 2H), 7.29–7.27 (m, 3H), 6.02 (dt, 1H, J = 8.8, 6.2), 5.21 (d, 1H, J = 10.0), 5.16 (d, 1H, J = 8.2), 4.82 (s, 1H), 4.04 (bs, 1H), 3.98 (dd, 1H, J = 12.5, 8.2), 3.88 (dd, 1H, J = 10.0, 6.2), 3.67–3.61 (m, 2H), 3.46–3.42 (m, 1H), 2.06–2.02 (m, 1H), 1.70 (bs, 1H). ESI-MS m/z (rel int): (pos) 267.2 ([M+Na]⁺, 100).




(1*R*,3*aR*)-1-(2-Hydroxyethyl)-2,3,3a,4-tetrahydrocyclopenta[c]pyrrol-5(1*H*)-one (*R*-12d**).** Clear oil (3.1 mg). TLC: R_f 0.26 (1:5 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 5.86 (dt, 1H, J = 8.8, 6.2), 5.12 (d, 1H, J = 10.0), 5.03 (d, 1H, J = 8.2), 4.52 (s, 1H), 4.17 (dt, 1H, J = 12.5, 8.2), 3.92–3.88 (m, 1H), 3.76–3.72 (m, 1H), 3.52–3.50 (m, 1H), 2.96–2.92 (m, 1H), 2.37 (s, 1H), 1.78–1.74 (m, 2H). ESI-MS m/z (rel int): (pos) 190.2 ([M+Na]⁺, 100).



(1*R*,3*aR*)-2-(*tert*-Butylsulfonyl)-1,6-bis(2-hydroxyethyl)-2,3,3*a*,4-tetrahydrocyclopenta[*c*]-pyrrol-5(1*H*)-one (*R*-13*a*). Clear oil (7.2 mg). TLC: R_f 0.40 (1:6 hexanes/EtOAc). $^1\text{H-NMR}$ (600 MHz): δ 5.92 (dt, 1H, J = 8.8, 6.1), 5.16 (d, 1H, J = 10.0), 5.03 (d, 1H, J = 8.2), 4.62–4.57 (m, 1H), 4.13–4.04 (m, 1H), 3.92 (dd, 1H, J = 14.3, 8.2), 3.68–3.61 (m, 1H), 3.50–3.45 (m, 1H), 2.99 (dd, 1H, J = 5.6, 3.5), 1.93–1.87 (m, 1H), 1.81 (dd, 2H, J = 7.5, 6.8), 1.61–1.56 (m, 2H), 1.31 (s, 9H). **ESI-MS** m/z (rel int): (pos) 354.4 ([M+Na] $^+$, 100).




(1*R*,3*aR*)-2-(*tert*-Butylsulfonyl)-1-(2-hydroxyethyl)-6-phenyl-2,3,3*a*,4-tetrahydrocyclopenta-[*c*]pyrrol-5(1*H*)-one (*R*-13*b*). Clear oil (7.5 mg). TLC: R_f 0.24 (1:6 hexanes/EtOAc). $^1\text{H-NMR}$ (600 MHz): δ 7.39–7.31 (m, 5H), 5.98 (dt, 1H, J = 8.4, 2.4), 5.21 (d, 1H, J = 14.3), 5.03 (d, 1H, J = 8.8), 4.91 (dd, 1H, J = 8.8, 6.1), 4.13 (d, 1H, J = 10.2), 4.02 (t, 1H, J = 8.0), 3.81–3.76 (m, 1H), 3.56–3.52 (m, 1H), 2.91 (s, 1H), 2.04–1.98 (m, 1H), 1.65 (dt, 1H, J = 10.1, 8.8), 1.44 (s, 9H). **ESI-MS** m/z (rel int): (pos) 386.5 ([M+Na] $^+$, 100).




(1*R*,3*aR*)-2-(*tert*-Butylsulfonyl)-1-(2-hydroxyethyl)-2,3,3*a*,4-tetrahydrocyclopenta[*c*]pyrrol-5(1*H*)-one (*R*-13*d*). Light yellow oil (7.2 mg). TLC: R_f 0.27 (1:4 hexanes/EtOAc). $^1\text{H-NMR}$ (600 MHz): δ 5.92 (dt, 1H, J = 5.5, 1.5), 5.16 (d, 1H, J = 12.0), 5.03 (d, 1H, J = 8.2), 4.69 (dd, 1H, J = 5.3, 8.7), 4.13 (d, 1H, J = 12.0), 3.96 (dd, 1H, J = 10.7, 8.6), 3.68 (dt, 1H, J = 9.1, 10.7), 3.50 (dt, 1H, J = 6.3, 6.1), 2.80 (s, 1H), 1.98 (dd, 1H, J = 7.1, 5.5), 1.81–1.78 (m, 1H), 1.41 (s, 9H). **ESI-MS** m/z (rel int): (pos) 310.4 ([M+Na] $^+$, 100).


2. KRISCHE REDUCTIVE CYCLIZATION PRODUCTS (**R-14–19**)




(Z)-3-((2*R*,4*R*)-1-((*R*)-tert-Butylsulfinyl)-2-(2-hydroxyethyl)-4-methylpyrrolidin-3-ylidene)propan-1-ol (R-14a**).** Colorless oil (8.3 mg). TLC: R_f 0.53 (1:2 hexanes/EtOAc). **¹H-NMR** (600 MHz): δ 5.02 (t, 1H, *J* = 7.1), 4.49 (t, 1H, *J* = 7.6), 4.09–4.03 (m, 1H), 3.68–3.62 (m, 2H), 3.19 (d, 1H, *J* = 8.8), 3.04–2.98 (m, 2H), 2.78–2.71 (m, 1H), 2.31 (s, 1H), 1.91–1.87 (m, 2H), 1.82–1.76 (m, 2H), 1.21 (s, 9H), 1.05 (d, 3H, *J* = 6.8). **ESI-MS** *m/z* (rel int): (pos) 312.2 ([M+Na]⁺, 100).



(-)-2-((2*R*,4*R*,*Z*)-3-Benzylidene-1-((*R*)-tert-butylsulfinyl)-4-methylpyrrolidin-2-yl)ethanol (R-14b**).** Colorless oil (7.9 mg). TLC: R_f 0.40 (1:1 hexanes/EtOAc). $[\alpha]_D^{20}$: -33.2° (c 0.35, CHCl₃). **IR** (NaCl, film): 3401 (O–H st), 3016, 2990, 2864, 1432, 1351, 1111 (S–O st), 942, 826. **¹H-NMR** (600 MHz): δ 7.43–7.40 (m, 2H) 7.36 (d, 1H, *J* = 4.0), 7.23–7.18 (m, 2H), 6.41 (s, 1H), 5.43 (bs, 1H), 4.95 (s, 1H), 3.82–3.79 (m, 1H), 3.76–3.71 (m, 1H), 3.65–3.61 (m, 1H), 3.03 (s, 1H), 2.83 (t, 1H, *J* = 9.5), 1.95–1.89 (m, 1H), 1.87–1.81 (m, 1H) 1.19 (s, 9H), 1.16 (d, 3H, *J* = 6.5). **¹³C-NMR** (150 MHz, CDCl₃): δ 149.2, 137.1, 128.5, 128.2, 126.7, 120.9, 65.8, 59.8, 58.3, 48.6, 41.5, 36.4, 23.7, 19.0. **ESI-MS** *m/z* (rel int): (pos) 218.2 ([M+H]⁺, 100).




2-((2*R*,4*R*)-1-((*R*)-tert-Butylsulfinyl)-4-methyl-3-methylenepyrrolidin-2-yl)ethanol (R-14d**).** Colorless oil (7.2 mg). TLC: R_f 0.33 (1:1 hexanes/EtOAc). **¹H-NMR** (600 MHz): δ 4.91 (s, 2H), 4.21 (t, 1H, *J* = 5.5), 3.73–3.69 (m, 2H), 3.11 (t, 1H, *J* = 9.3), 3.00 (t, 1H, *J* = 9.3), 2.76–2.61 (m, 1H), 1.94–1.86 (m, 1H), 1.77–1.72 (m, 1H), 1.16 (s, 9H), 1.08 (d, 3H, *J* = 6.7). **ESI-MS** *m/z* (rel int): (pos) 268.1 ([M+Na]⁺, 100).




(Z)-3-((2*R*,4*R*)-2-(2-Hydroxyethyl)-4-methylpyrrolidin-3-ylidene)propan-1-ol (*R*-15a).

Colorless oil (5.6 mg). TLC: R_f 0.53 (1:10 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 5.11 (t, 1H, J = 7.1), 4.48 (t, 1H, J = 5.8), 3.71–3.63 (m, 2H), 3.61–3.58 (m, 2H), 3.10 (t, 1H, J = 9.6), 2.96 (t, 1H, J = 8.3), 2.64 (s, 1H), 2.30–2.23 (m, 2H), 1.78 (q, 2H, J = 6.5), 1.06 (d, 3H, J = 6.7). ESI-MS m/z (rel int): (pos) 208.2 ([M+Na]⁺, 100).




2-((2*R*,4*R*,*Z*)-3-Benzylidene-4-methylpyrrolidin-2-yl)ethanol (*R*-15b). Colorless oil (7.0 mg).

TLC: R_f 0.40 (1:20 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 7.31–7.25 (m, 3H) 7.19–7.14 (m, 2H), 6.43 (s, 1H), 4.93 (d, 1H, J = 9.2), 3.76 (t, 1H, J = 8.6), 3.68–3.54 (m, 2H), 3.05 (t, 1H, J = 6.7), 2.78 (t, 1H, J = 7.5), 1.92–1.90 (m, 1H), 1.79–1.76 (m, 1H), 1.30 (d, 3H, J = 6.5). ESI-MS m/z (rel int): (pos) 218.0 ([M+H]⁺, 100).




2-((2*R*,4*R*)-4-Methyl-3-methylenepyrrolidin-2-yl)ethanol (*R*-15d). Colorless oil (7.1 mg).


TLC: R_f 0.33 (1:20 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 5.10 (d, 1H, J = 11.8), 5.03 (d, 1H, J = 11.8), 4.24 (t, 1H, J = 5.7), 3.90 (t, 1H, J = 6.7), 3.78 (t, 1H, J = 6.6), 3.58 (t, 1H, J = 6.4), 3.30 (bs, 1H), 2.92 (dd, 1H, J = 9.5, 7.1), 2.75 (dd, 1H, J = 7.1, 5.2), 2.01–1.96 (m, 2H), 1.18 (d, 3H, J = 6.7). ESI-MS m/z (rel int): (pos) 164.1 ([M+Na]⁺, 100).




(Z)-3-((2*R*,4*R*)-1-(tert-Butylsulfonyl)-2-(2-hydroxyethyl)-4-methylpyrrolidin-3-ylidene)propan-1-ol (*R*-16a). Colorless oil (8.9 mg). TLC: R_f 0.53 (1:1 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 4.89 (t, 1H, J = 7.1), 4.51 (d, 1H, J = 7.6), 4.22 (t, 2H, J = 6.9), 3.72–3.66 (m, 2H), 3.55 (d, 1H, J = 8.8), 2.55–2.49 (m, 1H), 2.41–2.38 (m, 1H), 1.98–1.95 (m, 1H), 1.89–1.85 (m, 2H), 1.76 (t, 1H, J = 6.5), 1.52 (bs, 1H), 1.21 (s, 12H). ESI-MS m/z (rel int): (pos) 328.4 ([M+Na]⁺, 100).




2-((2*R*,4*R*,*Z*)-3-Benzylidene-1-(*tert*-butylsulfonyl)-4-methylpyrrolidin-2-yl)ethanol (*R*-16b). Colorless oil (8.8 mg). **TLC:** R_f 0.40 (3:2 hexanes/EtOAc). **¹H-NMR** (600 MHz): δ 7.36–7.31 (m, 2H), 7.28–7.23 (m, 2H), 7.20–7.16 (m, 1H), 6.35 (s, 1H), 5.15 (d, 1H, *J* = 10.1), 3.97 (dd, 1H, *J* = 10.1, 7.1), 3.79–3.76 (m, 1H), 3.64–3.61 (m, 1H), 3.11–3.03 (m, 1H), 3.01–2.98 (m, 1H), 2.48 (bs, 1H), 1.88–1.83 (m, 1H), 1.52–1.48 (m, 1H), 1.24 (d, 3H, *J* = 6.9), 1.18 (s, 9H). **ESI-MS** *m/z* (rel int): (pos) 360.2 ([M+Na]⁺, 100).



2-((2*R*,4*R*)-1-(*tert*-Butylsulfonyl)-4-methyl-3-methylenepyrrolidin-2-yl)ethanol (*R*-16d). Colorless oil (8.2 mg, 74%). **TLC:** R_f 0.33 (3:2 hexanes/EtOAc). **¹H-NMR** (600 MHz): δ 4.92 (s, 2H), 4.28 (t, 1H, *J* = 5.5), 3.81–3.69 (bm, 2H), 3.18 (t, 1H, *J* = 6.7), 3.05 (t, 1H, *J* = 7.4), 2.79 (s, 1H), 1.92–1.86 (m, 2H), 1.82–1.78 (m, 1H), 1.25 (s, 9H), 1.11 (d, 3H, *J* = 6.7). **ESI-MS** *m/z* (rel int): (pos) 284.4 ([M+Na]⁺, 100).




(*Z*)-3-((2*R*,4*S*)-1-((*R*)-tert-Butylsulfinyl)-2-(2-hydroxyethyl)-4-methylpyrrolidin-3-ylidene)-propan-1-ol (*R*-17a). Colorless oil (8.1 mg). **TLC:** R_f 0.53 (1:2 hexanes/EtOAc). **¹H-NMR** (600 MHz): δ 5.21 (t, 1H, *J* = 7.3), 4.47 (d, 1H, *J* = 9.3), 3.91 (t, 1H, *J* = 10.9), 3.71–3.68 (m, 2H), 3.62–3.58 (m, 2H), 2.64–2.61 (m, 1H), 2.51 (dd, 1H, *J* = 9.0, 11.2), 2.31–2.25 (m, 2H), 1.96–1.92 (m, 2H), 1.08 (s, 9H), 1.02 (d, 3H, *J* = 6.9). **ESI-MS** *m/z* (rel int): (pos) 312.2 ([M+Na]⁺, 100).




(*-*)-2-((2*R*,4*S*,*Z*)-3-Benzylidene-1-((*R*)-tert-butylsulfinyl)-4-methylpyrrolidin-2-yl)ethanol (*R*-17b). Colorless oil (7.7 mg). **TLC:** R_f 0.40 (1:1 hexanes/EtOAc). $[\alpha]_D^{20}$: -21.1° (c 0.32, CHCl₃). **IR** (NaCl, film): 3409 (O–H st), 3023, 2988, 1428, 1348, 1101 (S–O st), 950, 817. **¹H-NMR** (600 MHz): δ 7.43–7.40 (m, 2H), 7.36 (d, 1H, *J* = 4.2), 7.23–7.18 (m, 2H), 6.44 (s,

1H), 5.81 (bs, 1H), 4.93 (s, 1H), 3.75–3.73 (m, 1H), 3.71–3.67 (m, 1H), 3.65–3.61 (m, 1H), 3.05 (s, 1H), 2.77 (t, 1H, $J = 6.5$), 1.95–1.89 (m, 1H), 1.87–1.81 (m, 1H) 1.21 (s, 9H), 1.16 (d, 3H, $J = 6.5$). $^{13}\text{C-NMR}$ (150 MHz, CDCl_3): δ 146.2, 137.0, 128.6, 128.3, 126.8, 120.4, 64.2, 59.4, 57.9, 47.4, 37.9, 37.4, 24.1, 15.5. **ESI-MS** m/z (rel int): (pos) 218.2 ($[\text{M}+\text{H}]^+$, 100).




(Z)-3-((2R,4S)-2-(2-Hydroxyethyl)-4-methylpyrrolidin-3-ylidene)propan-1-ol (R-18a).

Colorless oil (4.9 mg). TLC: R_f 0.53 (1:10 MeOH/EtOAc). $^1\text{H-NMR}$ (600 MHz): δ 5.21 (t, 1H, $J = 7.1$), 4.44 (t, 1H, $J = 5.8$), 3.92 (dt, 1H, $J = 9.6, 5.3$), 3.71–3.63 (m, 2H), 3.61–3.58 (m, 2H), 2.71 (s, 1H), 2.59 (dd, 1H, $J = 8.3, 7.1$), 2.30–2.23 (m, 2H), 1.83 (q, 2H, $J = 6.5$), 1.06 (d, 3H, $J = 6.7$). **ESI-MS** m/z (rel int): (pos) 208.2 ($[\text{M}+\text{Na}]^+$, 100).




2-((2R,4S,Z)-3-Benzylidene-4-methylpyrrolidin-2-yl)ethanol (R-18b). Colorless oil (7.1 mg).

TLC: R_f 0.40 (1:20 MeOH/EtOAc). $^1\text{H-NMR}$ (600 MHz): δ 7.30–7.25 (m, 3H) 7.20–7.15 (m, 2H), 6.47 (s, 1H), 4.96 (d, 1H, $J = 9.2$), 4.01 (br, 1H), 3.76 (t, 1H, $J = 8.6$), 3.64–3.62 (m, 1H), 3.48 (t, 1H, $J = 8.2$), 3.04 (t, 1H, $J = 6.5$), 2.93 (t, 1H, $J = 7.2$), 1.79–1.73 (m, 1H), 1.69–1.62 (m, 1H), 1.39 (d, 3H, $J = 6.5$). **ESI-MS** m/z (rel int): (pos) 218.1 ($[\text{M}+\text{H}]^+$, 100).



(Z)-3-((2R,4S)-1-(tert-Butylsulfonyl)-2-(2-hydroxyethyl)-4-methylpyrrolidin-3-ylidene)propan-1-ol (R-19a). Colorless oil (8.1 mg). TLC: R_f 0.53 (1:1 hexanes/EtOAc). $^1\text{H-NMR}$ (600 MHz): δ 5.08 (dt, 1H, $J = 2.0, 7.1$), 4.49 (t, 1H, $J = 7.6$), 4.97 (t, 1H, $J = 6.9$), 3.69–3.62 (m, 2H), 3.60–3.55 (m, 2H), 3.08 (dd, 1H, $J = 3.1, 8.8$), 3.01 (dd, 1H, $J = 3.2, 6.5$), 2.98–2.93 (m, 1H), 2.76 (bs, 1H), 2.24–2.19 (m, 1H), 2.15 (bs, 1H), 1.88–1.85 (m, 1H), 1.77–1.72 (m, 1H), 1.19 (s, 12H). **ESI-MS** m/z (rel int): (pos) 328.4 ($[\text{M}+\text{Na}]^+$, 100).




2-((2R,4S,Z)-3-Benzylidene-1-(tert-butylsulfonyl)-4-methylpyrrolidin-2-yl)ethanol (R-19b).


Colorless oil (8.2 mg). TLC: R_f 0.40 (3:2 hexanes/EtOAc). $^1\text{H-NMR}$ (600 MHz): δ 7.44–7.39

(m, 2H), 7.33–7.28 (m, 2H), 7.22–7.18 (m, 1H), 6.41 (s, 1H), 5.24 (s, 1H), 4.01 (t, 1H, $J = 8.0$), 3.78–3.65 (m, 1H), 3.10–3.01 (m, 2H), 2.05–1.96 (m, 2H), 1.54–1.51 (m, 1H), 1.36 (d, 3H, $J = 6.9$), 1.30 (s, 9H). **ESI-MS** m/z (rel int): (pos) 360.2 ($[M+Na]^+$, 100).


3. EVANS BUTADIENE [4+2+2] CYCLOADDITION PRODUCTS (R-20)



2,2'-(1*R*,3*aR*,6*Z*,9*Z*)-2-(*tert*-Butylsulfonyl)-2,3,3*a*,4,5,8-hexahydro-1*H*-cycloocta[*c*]pyrrole-1,9-diyl diethanol (R-20a). Light yellow oil (3.9 mg). TLC: R_f 0.39 (1:1 hexanes/EtOAc). **¹H-NMR** (600 MHz): δ 5.78–5.74 (m, 1H), 5.67–5.61 (m, 1H), 4.82 (s, 1H), 3.79–3.76 (m, 2H), 3.70 (t, 1H, $J = 6.8$), 3.67–3.58 (m, 2H), 3.36 (dd, 1H, $J = 12.5, 6.8$), 3.14 (bs, 1H), 2.93 (dd, 1H, $J = 7.9, 14.6$), 2.53–2.48 (m, 3H), 2.38 (dd, 1H, $J = 6.8, 14.7$), 2.31–2.26 (m, 3H), 1.83–1.78 (m, 3H), 1.43 (s, 9H). **ESI-MS** m/z (rel int): (pos) 358.3 ($[M+H]^+$, 100).




(+)-2-(1*R*,3*aR*,6*Z*,9*Z*)-2-(*tert*-Butylsulfonyl)-9-phenyl-2,3,3*a*,4,5,8-hexahydro-1*H*-cycloocta[*c*]pyrrol-1-yl)ethanol (R-20b). Light yellow oil (7.1 mg). TLC: R_f 0.36 (1:1 hexanes/EtOAc). $[\alpha]_D^{20}: +35.4^\circ$ (c 0.42, CHCl₃). **IR** (NaCl, film): 3373 (O–H st), 3021, 2991, 2856, 1428, 1351 (SO₂ st), 1106 (SO₂ st), 970. **¹H-NMR** (600 MHz): δ 7.36–7.31 (m, 3H), 7.18–7.09 (m, 2H), 5.65–5.62 (m, 1H), 5.60–5.56 (m, 1H), 4.91 (s, 1H), 3.50 (s, 1H), 3.44–3.38 (m, 2H), 3.31–3.28 (m, 1H), 2.81 (dd, 1H, $J = 6.1, 15.2$), 2.47–2.41 (m, 1H), 1.88–1.69 (m, 2H), 1.65–1.58 (m, 3H), 1.42–1.36 (m, 3H), 1.33 (s, 9H). **¹³C-NMR** (150 MHz, CDCl₃): δ 143.3, 139.4, 135.5, 133.7, 129.6, 128.3, 127.6, 126.8, 60.4, 60.3, 60.1, 56.5, 44.0, 37.2, 36.4, 26.3, 24.5, 19.0. **ESI-MS** m/z (rel int): (pos) 270.2 ($[M-SO_2tBu+H]^+$, 15); 390.2 ($[M+H]^+$, 100).




2-(1*R*,3*aR*,6*Z*,9*E*)-2-(*tert*-Butylsulfonyl)-2,3,3*a*,4,5,8-hexahydro-1*H*-cycloocta[*c*]pyrrol-1-yl)ethanol (R-20d). Light yellow oil (7.5 mg). TLC: R_f 0.40 (1:1 hexanes/EtOAc). **¹H-NMR** (600 MHz): δ 5.69–5.61 (m, 1H), 5.58–5.49 (m, 1H), 5.38 (s, 1H), 3.65–3.49 (bm, 2H), 3.73–3.70 (m, 2H), 3.43 (d, 1H, $J = 11.1$), 3.24 (dd, 1H, $J = 6.5, 12.1$), 3.19–3.11 (m, 1H), 2.88–2.65 (bm, 2H), 2.40–2.33 (m, 1H), 1.93–1.81 (m, 2H), 1.66–1.61 (m, 1H), 1.55–1.49 (m, 1H), 1.49 (s, 9H). **ESI-MS** m/z (rel int): (pos) 336.2 ($[M+Na]^+$, 100).


4. ENYNE METATHESIS PRODUCTS (**R-21–23**)




3-((R)-1-((R)-tert-Butylsulfinyl)-2-(2-hydroxyethyl)-2,5-dihydro-1*H*-pyrrol-3-yl)but-3-en-1-ol (R-21a**).** Clear colorless oil (9.1 mg). TLC: R_f 0.46 (1:2 hexanes/EtOAc). $^1\text{H-NMR}$ (600 MHz): δ 5.79 (s, 1H), 5.06 (s, 1H), 5.01 (s, 1H), 4.91 (t, 1H, J = 6.8), 4.50 (d, 2H, J = 15.7), 3.61–3.55 (m, 3H), 3.52 (d, 1H, J = 12.6) 2.51–2.49 (m, 1H), 2.41–2.37 (m, 1H), 2.01–1.95 (m, 1H), 1.92–1.88 (m, 1H), 1.09 (s, 9H). **ESI-MS** m/z (rel int): (pos) 310.4 ([M+Na] $^+$, 100).




2-((R)-1-((R)-tert-Butylsulfinyl)-3-(1-phenylvinyl)-2,5-dihydro-1*H*-pyrrol-2-yl)ethanol (R-21b**).** Clear oil (8.1 mg). TLC: R_f 0.31 (1:1 hexanes/EtOAc). $^1\text{H-NMR}$ (600 MHz): δ 7.45–7.34 (m, 3H), 7.32–7.28 (m, 2H), 5.49 (s, 1H), 5.26 (s, 1H), 5.24 (s, 1H), 4.99–4.95 (m, 1H), 4.48 (d, 1H, J = 15.2), 4.13 (t, 1H, J = 5.3), 3.85–3.78 (m, 1H), 3.75–3.70 (m, 1H), 3.09 (s, 1H), 2.20–2.13 (m, 1H), 1.86–1.77 (m, 1H), 1.07 (s, 9H). **ESI-MS** m/z (rel int): (pos) 342.5 ([M+Na] $^+$, 100).




2-((R)-1-((R)-tert-Butylsulfinyl)-3-vinyl-2,5-dihydro-1*H*-pyrrol-2-yl)ethanol (R-21d**).** Yellow oil (8.2 mg). TLC: R_f 0.28 (1:1 hexanes/EtOAc). $^1\text{H-NMR}$ (600 MHz): δ 6.32 (dd, 1H, J = 17.3, 11.0), 5.71 (s, 1H), 5.20 (d, 1H, J = 17.8), 5.09 (d, 1H, J = 11.0), 4.85 (s, 1H), 4.49 (d, 1H, J = 15.1), 3.72–3.68 (m, 2H), 3.50 (d, 1H, J = 15.3), 1.98–1.89 (m, 2H), 1.12 (s, 9H). **ESI-MS** m/z (rel int): (pos) 266.3 ([M+Na] $^+$, 100).




(R)-3-(2-(2-Hydroxyethyl)-2,5-dihydro-1*H*-pyrrol-3-yl)but-3-en-1-ol (R-22a**).** Clear colorless oil (0.8 mg). TLC: R_f 0.46 (1:10 MeOH/EtOAc). $^1\text{H-NMR}$ (600 MHz): δ 5.81 (ddd, 1H, J = 10.0, 7.9, 6.8), 5.25 (d, 1H, J = 11.0), 5.16 (d, 1H, J = 8.4), 4.48 (t, 1H, J = 9.7), 3.99–3.94 (m, 2H), 3.70–3.66 (m, 2H), 3.41 (dd, 1H, J = 10.9, 4.4), 2.15–2.11 (m, 1H) 1.92–1.87 (m, 2H), 1.54–1.47 (m, 2H). **ESI-MS** m/z (rel int): (pos) 206.8 ([M+Na] $^+$, 100).




(R)-2-(3-(1-Phenylvinyl)-2,5-dihydro-1H-pyrrol-2-yl)ethanol (R-22b). Clear yellow oil (1.1 mg). TLC: R_f 0.31 (1:20 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 7.45–7.34 (m, 5H), 5.81 (dd, 1H, J = 7.1, 6.8), 5.30 (d, 1H, J = 14.3), 5.21 (d, 1H, J = 10.6), 4.60 (dd, 1H, J = 8.8, 7.1), 4.04 (dd, 1H, J = 15.2, 7.1), 3.85–3.78 (m, 2H), 3.47 (dd, 1H, J = 14.3, 7.1), 2.20–2.13 (m, 1H), 2.04–2.00 (m, 1H), 1.52 (s, 1H). ESI-MS m/z (rel int): (pos) 216.3 ([M+H]⁺, 100).




(R)-2-(3-Vinyl-2,5-dihydro-1H-pyrrol-2-yl)ethanol (R-22d). Clear oil (0.7 mg). TLC: R_f 0.28 (1:20 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 6.37 (ddd, 1H, J = 17.8, 11.0, 8.0), 5.69 (s, 1H), 5.21 (d, 1H, J = 17.8), 5.17 (d, 1H, J = 11.0), 4.88 (s, 1H), 4.48 (d, 1H, J = 15.9), 3.78–3.74 (m, 1H), 3.73–3.68 (m, 1H), 3.45 (d, 1H, J = 15.9), 2.12–2.05 (m, 1H), 1.78–1.71 (m, 1H). ESI-MS m/z (rel int): (pos) 162.3 ([M+Na]⁺, 100).



(R)-3-(1-(tert-Butylsulfonyl)-2-(2-hydroxyethyl)-2,5-dihydro-1H-pyrrol-3-yl)but-3-en-1-ol (R-23a). Clear colorless oil (8.0 mg). TLC: R_f 0.46 (1:2 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 5.65 (t, 1H, J = 7.1), 5.08 (d, 2H, J = 11.0), 4.93 (t, 1H, J = 4.4), 4.49 (d, 1H, J = 8.1), 4.16 (d, 1H, J = 7.8), 3.73–3.69 (m, 1H), 3.68–3.61 (m, 2H), 2.99–2.96 (m, 1H), 2.49–2.47 (m, 1H), 2.05–2.01 (m, 1H), 1.68–1.64 (m, 1H), 1.53–1.47 (m, 1H), 1.03 (s, 9H). ESI-MS m/z (rel int): (pos) 326.4 ([M+Na]⁺, 100).




(R)-2-(1-(tert-Butylsulfonyl)-3-(1-phenylvinyl)-2,5-dihydro-1H-pyrrol-2-yl)ethanol (R-23b). Clear yellow oil (7.1 mg). TLC: R_f 0.31 (1:1 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 7.45–7.34 (m, 3H), 7.32–7.28 (m, 2H), 5.49 (s, 1H), 5.19 (s, 1H), 5.12 (s, 1H), 4.98 (s, 1H), 4.40 (d, 1H, J = 13.2), 4.07–4.01 (m, 1H), 3.75–3.70 (m, 2H), 3.49 (s, 1H), 2.15–2.08 (m, 2H), 1.25 (s, 9H). ESI-MS m/z (rel int): (pos) 358.5 ([M+Na]⁺, 100).




(+)-(R)-2-(1-(tert-Butylsulfonyl)-3-vinyl-2,5-dihydro-1H-pyrrol-2-yl)ethanol (R-23d).

Yellow oil (7.2 mg). **TLC:** R_f 0.28 (1:1 hexanes/EtOAc). $[\alpha]_D^{20} : +12.5^\circ$ (c 0.37, CHCl_3). **IR** (NaCl, film): 3364 (O-H st), 2998, 2895, 1428, 1351 (SO_2 st), 1265, 1131 (SO_2 st), 910. **$^1\text{H-NMR}$** (600 MHz): δ 6.41 (dd, 1H, $J = 17.8, 11.0$), 5.73 (s, 1H), 5.16 (dd, 2H, $J = 17.8, 11.3$), 5.01 (s, 1H), 4.47 (d, 1H, $J = 15.9$), 4.01 (d, 1H, $J = 12.8$), 3.80–3.76 (m, 1H), 3.65–3.61 (m, 1H), 2.05–1.97 (m, 1H), 1.53–1.48 (m, 1H), 1.41 (s, 9H). **$^{13}\text{C-NMR}$** (150 MHz, CDCl_3): δ 135.6, 129.5, 124.1, 116.8, 63.2, 61.3, 59.8, 56.0, 36.5, 26.7. **ESI-MS** m/z (rel int): (pos) 282.4 ($[\text{M}+\text{Na}]^+$, 100).


5. MALEIMIDE DIELS–ALDER PRODUCTS (R-24)



(+)-(3aS,6R,8aS,8bR)-7-(tert-Butylsulfonyl)-5,6-bis(2-hydroxyethyl)-2-phenyl-3a,4,6,7,8,8a-hexahydropyrrolo[3,4-e]isoindole-1,3(2H,8bH)-dione (R-24a). Clear oil (8.6 mg). **TLC:** R_f 0.50 (1:2 hexanes/EtOAc). $[\alpha]_D^{20} : +62.4^\circ$ (c 0.40, CHCl_3). **IR** (NaCl, film): 3351 (O-H st), 2992, 2886, 1712 (C=O st), 1445, 1375 (SO_2 st), 1265, 1025 (SO_2 st), 772. **$^1\text{H-NMR}$** (600 MHz): δ 7.49–7.36 (m, 5H), 5.92 (t, 1H, $J = 6.8$), 4.51 (d, 1H, $J = 12.0$), 4.49–4.32 (m, 2H), 4.09 (dd, 1H, $J = 7.9, 13.0$), 3.98 (t, 1H, $J = 10.0$), 3.82–3.78 (m, 2H), 3.63–3.59 (m, 1H), 3.40–3.32 (m, 1H), 2.99 (dd, 1H, $J = 7.4, 12.5$), 2.71–2.63 (m, 1H), 1.75–1.70 (m, 2H), 1.66–1.59 (m, 2H), 1.45 (s, 9H). **$^{13}\text{C-NMR}$** (150 MHz, CDCl_3): δ 178.2, 178.0, 138.8, 133.6, 131.6, 129.7, 129.1, 126.4, 61.6, 60.6, 60.5, 58.2, 52.8, 44.4, 39.9, 39.4, 37.5, 36.9, 29.2, 26.0. **ESI-MS** m/z (rel int): (pos) 499.6 ($[\text{M}+\text{Na}]^+$, 100).




(3aS,6R,8aR,8bR)-7-(tert-Butylsulfonyl)-6-(2-hydroxyethyl)-2,5-diphenyl-3a,4,6,7,8,8a-hexahydropyrrolo[3,4-e]isoindole-1,3(2H,8bH)-dione (R-24b). Light yellow oil (3.5 mg). **TLC:** R_f 0.40 (1:2 hexanes/EtOAc). **$^1\text{H-NMR}$** (600 MHz): δ 7.49–7.43 (m, 3H), 7.41–7.38 (m, 4H), 7.36–7.34 (m, 3H), 5.83 (s, 1H), 4.91 (dd, 1H, $J = 13.1, 2.1$), 4.13 (d, 1H, $J = 13.1$), 3.74–3.70 (m, 1H), 3.48 (dd, 1H, $J = 8.0, 9.1$), 3.23–3.21 (m, 1H), 3.14–3.12 (m, 2H), 3.05–3.01 (m, 1H), 2.73–2.68 (m, 1H), 2.53–2.48 (m, 1H), 1.62–1.57 (m, 1H), 1.41 (s, 9H). **ESI-MS** m/z (rel int): (pos) 531.3 ($[\text{M}+\text{Na}]^+$, 100).




(3a*S*,6*R*,8a*R*,8b*R*)-7-(*tert*-Butylsulfonyl)-6-(2-hydroxyethyl)-2-phenyl-3*a*,4,6,7,8,8*a*-hexahydropyrrolo[3,4-*e*]isoindole-1,3(2*H*,8b*H*)-dione (*R*-24d). Clear oil (7.1 mg). TLC: R_f 0.32 (1:2 hexanes/EtOAc). **¹H-NMR** (600 MHz): δ 7.99 (s, 1H), 7.63–7.67 (m, 2H), 7.50–7.37 (m, 3H), 5.98–5.95 (m, 1H), 5.01 (d, 1H, J = 11.8), 4.52 (d, 1H, J = 12.5), 4.48–4.35 (m, 2H), 3.55–3.49 (m, 2H), 3.29–3.24 (m, 2H), 1.88–1.65 (bm, 2H), 1.64–1.59 (m, 1H), 1.45 (s, 9H). **ESI-MS** m/z (rel int): (pos) 433.4 ([M+H]⁺, 100).


6. DMAD DIELS–ALDER PRODUCTS (*R*-25)



(*R*)-Dimethyl 2-(*tert*-butylsulfonyl)-1,7-bis(2-hydroxyethyl)isoindoline-4,5-dicarboxylate (*R*-25a). Colorless oil (2.1 mg). TLC: R_f 0.43 (1:3 hexanes/EtOAc). **¹H-NMR** (600 MHz): δ 7.63 (s, 1H), 5.62 (s, 1H), 5.03 (d, 1H, J = 16.0), 4.51 (d, 1H, J = 16.0), 3.88 (s, 6H), 3.85–3.81 (m, 2H), 3.65–3.61 (m, 2H), 2.86–2.79 (m, 2H), 2.11–1.99 (m, 2H), 1.31 (s, 9H). **ESI-MS** m/z (rel int): (pos) 466.3 [M+Na]⁺, 100).




(-)-(R)-Dimethyl 2-(*tert*-butylsulfonyl)-1-(2-hydroxyethyl)-7-phenylisoindoline-4,5-di-carboxylate (*R*-25b). Colorless oil (4.1 mg). TLC: R_f 0.38 (1:2 hexanes/EtOAc). $[\alpha]_D^{20}$: -8.8° (*c* 0.32, CHCl₃). **IR** (NaCl, film): 3388 (O–H st), 3005, 2990, 2881, 1725 (C=O st), 1430, 1393 (SO₂ st), 1265, 1025 (SO₂ st), 968. **¹H-NMR** (600 MHz): δ 7.61 (s, 1H), 7.45–7.37 (m, 5H), 5.89 (s, 1H), 5.12 (d, 1H, J = 16.4), 4.53 (d, 1H, J = 15.8), 3.91 (s, 6H), 3.47–3.43 (m, 1H), 3.39–3.35 (m, 1H), 1.80–1.74 (m, 1H), 1.57–1.51 (m, 1H), 1.38 (s, 9H). **¹³C-NMR** (150 MHz, CDCl₃): δ 167.4, 166.9, 139.8, 139.1, 138.1, 133.4, 133.3, 131.7, 130.2, 128.3, 127.9, 127.5, 62.8, 62.7, 59.7, 54.6, 52.7 (2 OMe), 36.4, 26.6. **ESI-MS** m/z (rel int): (pos) 476.5 [M+H]⁺, 100).




(R)-Dimethyl 2-(tert-butylsulfonyl)-1-(2-hydroxyethyl)isoindoline-4,5-dicarboxylate (R-25d). Colorless oil (8.0 mg). TLC: R_f 0.34 (1:2 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 7.74 (d, 1H, J = 4), 7.42 (d, 1H, J = 3.9), 5.49 (s, 1H), 5.08 (d, 1H, J = 15.1), 4.64 (d, 1H, J = 15.2), 3.91 (s, 6H), 3.69–3.62 (m, 1H), 2.40 (s, 1H), 2.05–1.98 (m, 1H), 1.84–1.79 (m, 1H), 1.35 (s, 9H). ESI-MS m/z (rel int): (pos) 422.5 ([M+Na]⁺, 100).


7. ALKyne [2+2+2] CYCLOTRIMERIZATION PRODUCTS (R-30–35)




(-)-2,2'-(R)-2-((R)-tert-Butylsulfinyl)-5-(hydroxymethyl)isoindoline-1,7-diyl diethanol (R-30a). Light brown oil (9.1 mg). TLC: R_f 0.31 (1:3 hexanes/EtOAc). $[\alpha]_D^{20}$: -7.1° (c 0.42, CHCl₃). IR (NaCl, film): 3409 (O–H st), 2995, 2878, 1408, 1115 (S–O st), 884, 758. ¹H-NMR (600 MHz): δ 7.09 (s, 1H), 7.05 (s, 1H), 5.30 (d, 1H, J = 7.9), 4.93 (d, 1H, J = 14.3), 4.57 (s, 2H), 3.94 (d, 1H, J , 14.3), 3.84 (t, 2H, J = 7.0), 3.80–3.72 (m, 1H), 3.63–3.59 (m, 1H), 2.85 (dt, 2H, J = 12.5, 6.0), 2.15–2.07 (m, 1H), 1.92–1.84 (m, 1H), 1.15 (s, 9H). ¹³C-NMR (150 MHz, CDCl₃): δ 141.3, 139.7, 139.6, 133.1, 127.0, 119.0, 69.1, 64.6, 62.7, 58.9, 58.3, 46.8, 39.7, 35.7, 23.9. ESI-MS m/z (rel int): (pos) 364.5 ([M+Na]⁺, 100).




(+)-2-((R)-2-((R)-tert-Butylsulfinyl)-5-(hydroxymethyl)-7-phenylisoindolin-1-yl)ethanol (R-30b). Brown oil (8.0 mg). TLC: R_f 0.22 (1:3 hexanes/EtOAc). $[\alpha]_D^{20}$: +23.1° (c 0.42, CHCl₃). IR (NaCl, film): 3384 (O–H st), 3079, 2928, 2878, 1455, 1408, 1106 (S–O st), 1063 (S–O st), 1009, 964, 758. ¹H-NMR (600 MHz): δ 7.40–7.34 (m, 5H), 7.18 (s, 1H), 7.16 (s, 1H), 5.58 (d, 1H, J = 8.0), 5.08 (d, 1H, J = 14.3), 4.69 (d, 2H, J = 5.7), 3.99 (dd, 1H, J = 14.0, 4.0), 3.61 (ddd, 1H, J = 10.0, 8.5, 6.2), 3.38–3.34 (m, 1H), 1.68–1.63 (m, 1H), 1.44–1.38 (m, 1H), 0.91 (s, 9H). ¹³C-NMR (150 MHz, CDCl₃): δ 141.4, 140.1, 140.0, 137.3, 137.2, 128.7, 128.2, 127.7, 127.3, 120.1, 69.1, 64.9, 59.1, 58.0, 46.4, 37.6, 23.9. ESI-MS m/z (rel int): (pos) 374.4 ([M+H]⁺, 100).




2-((R)-2-((R)-tert-Butylsulfinyl)-5-(hydroxymethyl)isoindolin-1-yl)ethanol (R-30d). Light brown oil (8.1 mg). TLC: R_f 0.15 (1:2 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 7.18 (s, 1H), 7.05 (d, 1H, J = 7.0), 6.99 (d, 1H, J = 7.0), 5.03 (t, 1H, J = 6.0), 4.53 (s, 2H), 3.96 (d, 1H, J = 14.9), 3.72 (ddd, 1H, J = 10.4, 7.5, 5.5), 3.63 (dt, 1H, J = 10.4, 6.6), 2.77 (s, 1H), 1.99–1.93 (m, 2H), 1.26 (t, 1H, J = 7.1), 1.21 (s, 9H). ESI-MS m/z (rel int): (pos) 320.4 ([M+Na]⁺, 100).




(R)-2,2'-(5-(Hydroxymethyl)isoindoline-1,7-diyl)diethanol (R-31a). Light brown oil (1.5 mg). TLC: R_f 0.31 (1:3 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 7.04 (s, 1H), 7.02 (s, 1H), 5.52 (d, 1H, J = 14.5), 4.61 (d, 2H, J = 7.1), 3.96 (d, 1H, J = 14.6), 3.86 (t, 1H, J = 7.0), 3.85–3.79 (m, 1H), 3.69–3.64 (m, 1H), 2.85 (dt, 2H, J = 12.6, 6.5), 2.15–2.07 (m, 1H), 1.88–1.84 (m, 1H), 1.78–1.76 (m, 2H). ESI-MS m/z (rel int): (pos) 238.2 ([M+H]⁺, 100).



(R)-2-(5-(Hydroxymethyl)-7-phenylisoindolin-1-yl)ethanol (R-31b). Light brown oil (7.5 mg). TLC: R_f 0.22 (1:2 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 7.42 (s, 1H), 7.34–7.26 (m, 6H), 5.71 (t, 1H, J = 7.1), 5.01 (d, 2H, J = 14.1), 4.39 (d, 2H, J = 14.0), 4.38–4.34 (m, 2H), 2.20–2.13 (m, 2H). ESI-MS m/z (rel int): (pos) 292.2 ([M+Na]⁺, 100).




(R)-2-(5-(Hydroxymethyl)isoindolin-1-yl)ethanol (R-31d). Light brown oil (1.7 mg). TLC: R_f 0.15 (1:2 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 7.18–7.14 (m, 2H), 7.09 (d, 1H, J = 7.2), 5.18 (d, 1H, J = 6.0), 4.95 (d, 1H, J = 14.0), 4.55–4.51 (m, 3H), 3.96 (d, 1H, J = 15.6), 3.81 (ddd, 1H, J = 10.7, 7.6, 5.6), 3.72 (ddd, 1H, J = 10.7, 7.6, 5.6), 2.07–1.95 (m, 1H). ESI-MS m/z (rel int): (pos) 270.3 ([M+H]⁺, 100).




(R)-2,2'-(2-(tert-Butylsulfonyl)-5-(hydroxymethyl)isoindoline-1,7-diyl)diethanol (R-32a).

Brown oil (8.2 mg). TLC: R_f 0.31 (1:2 hexanes/EtOAc). **¹H-NMR** (600 MHz): δ 6.99 (s, 1H), 6.93 (s, 1H), 5.17 (d, 1H, J = 7.8), 4.83 (d, 1H, J = 12.5), 4.51 (s, 2H), 3.91 (d, 1H, J = 14.6), 3.79 (t, 2H, J = 7.3), 3.78–3.73 (m, 1H), 3.65–3.62 (m, 1H), 2.83 (dt, 2H, J = 12.6, 6.5), 2.07–1.99 (m, 1H), 1.78–1.71 (m, 1H), 1.08 (s, 9H). **ESI-MS** m/z (rel int): (pos) 380.5 ([M+Na]⁺, 100).




(R)-2-(2-(tert-Butylsulfonyl)-5-(hydroxymethyl)-7-phenylisoindolin-1-yl)ethanol (R-32b).


Brown oil (2.3 mg). TLC: R_f 0.22 (1:1 hexanes/EtOAc). **¹H-NMR** (600 MHz): δ 7.38–7.32 (m, 5H), 7.18 (s, 1H), 7.14 (s, 1H), 5.58 (d, 1H, J = 8.0), 5.08 (d, 1H, J = 14.3), 4.71 (d, 2H, J = 6.2), 3.99 (d, 1H, J = 14.0), 3.63 (ddd, 1H, J = 10.0, 8.5, 6.2), 3.38–3.34 (m, 1H), 1.68 (t, 1H, J = 6.0), 1.44–1.38 (m, 1H), 1.19 (s, 9H). **ESI-MS** m/z (rel int): (pos) 390.3 ([M+H]⁺, 100).




(+)-(R)-2-(2-(tert-Butylsulfonyl)-5-(hydroxymethyl)isoindolin-1-yl)ethanol (R-32d). Light brown oil (7.4 mg). TLC: R_f 0.15 (1:1 hexanes/EtOAc). $[\alpha]_D^{20}$: +53.8° (c 0.32, CHCl₃). **IR** (NaCl, film): 3362 (O–H st), 3067, 2961, 1652, 1403 (SO₂ st), 1180 (SO₂ st), 988, 763. **¹H-NMR** (500 MHz): δ 7.01 (d, 1H, J = 7.0), 6.94 (d, 1H, J = 7.0), 6.89 (s, 1H), 5.01 (t, 1H, J = 6.0), 4.78 (d, 1H, J = 12.0), 4.46 (s, 2H), 3.79 (d, 1H, J = 12.5), 3.64 (ddd, 1H, J = 10.1, 7.3, 5.6), 3.56 (dt, 1H, J = 10.0, 6.9), 1.91–1.86 (m, 2H), 1.08 (s, 9H). **¹³C-NMR** (150 MHz, CDCl₃): δ 141.3, 138.8, 127.0, 122.7, 121.2, 121.1, 65.1, 63.5, 63.4, 60.8, 59.0, 39.6, 25.5. **ESI-MS** m/z (rel int): (pos) 336.4 ([M+Na]⁺, 100).




2-((R)-2-((R)-tert-Butylsulfinyl)-6-(hydroxymethyl)isoindolin-1-yl)ethanol (R-33b). Light brown oil (3.4 mg). TLC: R_f 0.22 (4:6 hexanes/EtOAc). **¹H-NMR** (600 MHz): δ 7.49–7.41 (m, 5H), 7.19 (t, 2H, J = 4.0), 5.58 (d, 1H, J = 8.0), 5.12 (d, 1H, J = 14.3), 4.71 (d, 2H, J = 8.8), 4.55 (dd, 1H, J = 8.5, 6.2), 4.04 (d, 1H, J = 14.0), 3.38–3.34 (m, 1H), 1.99 (s, 1H), 1.80 (s, 1H), 1.68–1.63 (m, 1H), 1.44–1.38 (m, 1H), 1.20 (s, 9H). **ESI-MS** m/z (rel int): (pos) 396.5 ([M+Na]⁺, 100).



(+)-2-((R)-tert-Butylsulfinyl)-6-(hydroxymethyl)isoindolin-1-yl)ethanol (R-33d). Clear oil (7.6 mg). TLC: R_f 0.15 (1:2 hexanes/EtOAc). $[\alpha]_D^{20}$: +4.4° (c 0.35, CHCl₃). **IR** (NaCl, film): 3401 (O–H st), 3014, 2928, 1652, 1408, 1110 (S–O st), 1065 (S–O st), 964, 758. **¹H-NMR** (600 MHz): δ 7.20 (d, 1H, J = 7.0), 7.16 (d, 1H, J = 7.0), 7.09 (s, 1H), 5.16 (t, 1H, J = 6.0), 5.01 (d, 1H, J = 14.0), 4.62 (s, 2H), 3.98 (d, 1H, J = 14.9), 3.81 (ddd, 1H, J = 10.6, 7.9, 5.7), 3.71 (dt, 1H, J = 10.2, 6.6), 2.71 (s, 1H), 2.07–2.01 (m, 2H), 1.56 (s, 1H), 1.19 (s, 9H). **¹³C-NMR** (150 MHz, CDCl₃): δ 140.9, 137.3, 136.2, 126.7, 122.4, 120.9, 64.8, 63.2, 63.0, 60.2, 58.6, 39.3, 22.7. **ESI-MS** m/z (rel int): (pos) 320.4 ([M+Na]⁺, 100).




(R)-2-(6-Hydroxymethyl)-7-phenylisoindolin-1-yl)ethanol (R-34b). Clear oil (4.1 mg). TLC: R_f 0.22 (1:2 hexanes/EtOAc). **¹H-NMR** (600 MHz): δ 7.42–7.37 (m, 6H), 7.18 (d, 1H, J = 7.1), 5.21 (dd, 1H, J = 8.0, 6.4), 4.88 (d, 1H, J = 14.3), 4.62 (d, 2H, J = 3.9), 3.92 (d, 1H, J = 14.0), 3.79 (ddd, 1H, J = 10.0, 8.5, 6.2), 3.68–3.64 (m, 1H), 2.11–2.08 (m, 1H), 1.83–1.81 (m, 1H). **ESI-MS** m/z (rel int): (pos) 269.6 ([M+Na]⁺, 100).




(R)-2-(6-hydroxymethyl)isoindolin-1-yl)ethanol (R-34d). Light brown oil (0.8 mg). TLC: R_f 0.15 (1:2 hexanes/EtOAc). **¹H-NMR** (600 MHz): δ 7.21 (d, 1H, J = 7.2), 7.09 (d, 1H, J =

7.2), 7.11 (s, 1H), 5.18 (t, 1H, $J = 6.0$), 4.98 (d, 1H, $J = 14.0$), 4.55–4.51 (m, 3H), 3.96 (d, 1H, $J = 15.6$), 3.81 (ddd, 1H, $J = 10.7, 7.6, 5.6$), 3.72 (ddd, 1H, $J = 10.7, 7.6, 5.6$), 2.07–1.95 (m, 2H), 1.26 (tt, 1H, $J = 7.1, 6.2$). **ESI-MS** m/z (rel int): (pos) 270.3 ([M+H]⁺, 100).




(+)-(R)-2-(tert-Butylsulfonyl)-6-(hydroxymethyl)isoindolin-1-yl)ethanol (R-35d). Light brown oil (7.0 mg). **TLC:** R_f 0.15 (1:1 hexanes/EtOAc). $[\alpha]_D^{20}: +29.1^\circ$ (c 0.35, CHCl₃). **IR** (NaCl, film): 3388 (O–H st), 3023, 2989, 1643, 1221 (SO₂ st), 1095 (SO₂ st), 992, 842. **¹H-NMR** (600 MHz): δ 7.08 (s, 2H), 6.99 (d, 1H, $J = 7.2$), 5.08 (t, 1H, $J = 6.2$), 4.93 (d, 1H, $J = 14.0$), 4.52 (d, 2H, $J = 13.5$), 3.90 (dd, 1H, $J = 14.9, 6.7$), 3.80 (ddd, 1H, $J = 10.7, 7.6, 5.6$), 3.73 (dt, 1H, $J = 10.4, 6.6$), 1.96–1.83 (m, 2H), 1.26 (t, 1H, $J = 7.1$), 1.08 (s, 9H). **¹³C-NMR** (150 MHz, CDCl₃): δ 141.0, 137.1, 136.2, 126.7, 122.5, 120.9, 64.9, 63.3, 63.2, 60.4, 59.6, 39.4, 25.2. **ESI-MS** m/z (rel int): (pos) 336.4 ([M+Na]⁺, 100).

8. ISOCYANATE [2+2+2] CYCLOTRIMERIZATION PRODUCTS (R-36–41)




(+)-(R)-5-Benzyl-2-((R)-tert-butylsulfinyl)-3,4-bis(2-hydroxyethyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6(5H)-one (R-36a). Clear brown oil (7.0 mg). **TLC:** R_f 0.44 (1:5 MeOH/EtOAc). $[\alpha]_D^{20}: +52.0^\circ$ (c 0.48, CHCl₃). **IR** (NaCl, film): 3390 (O–H st), 2999, 2864, 1670 (C=O st), 1566, 1221, 1099 (S–O st), 990, 862. **¹H-NMR** (600 MHz): δ 7.48–7.45 (m, 1H), 7.39–7.35 (m, 2H), 7.30–7.22 (m, 2H), 6.39 (s, 1H), 5.68–5.65 (bs, 1H), 5.37–5.31 (bs, 1H), 5.03 (dd, 1H, $J = 8.0, 2.8$), 4.82 (d, 1H, $J = 16.0$), 3.81–3.78 (m, 3H), 3.69–3.64 (m, 1H), 2.81–2.73 (m, 2H), 1.91–1.88 (m, 1H), 1.88–1.84 (m, 2H), 1.38–1.34 (m, 2H), 1.10 (s, 9H). **¹³C-NMR** (150 MHz, CDCl₃): δ 163.7, 153.9, 140.3, 136.5, 128.8, 127.3, 126.1, 122.5, 110.2, 67.7, 65.9, 60.5, 58.5, 50.8, 46.9, 45.6, 39.5, 23.6. **ESI-MS** m/z (rel int): (pos) 441.6 ([M+Na]⁺, 100).




(R)-5-Benzyl-2-((R)-tert-butylsulfinyl)-3-(2-hydroxyethyl)-4-phenyl-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6(5H)-one (R-36b). Light brown oil (3.9 mg). **TLC:** R_f 0.19 (1:10


MeOH/EtOAc). **¹H-NMR** (600 MHz): δ 7.49–7.47 (m, 2H), 7.41–7.38 (m, 4H), 7.36–7.32 (m, 4H), 6.55 (s, 1H), 5.71 (s, 1H), 4.91 (dd, 2H, J = 16.3, 8.2), 4.82 (d, 1H, J = 7.6), 3.83 (d, 1H, J = 16.0), 3.58–3.54 (m, 1H), 3.47–3.41 (m, 1H), 1.52–1.49 (m, 1H), 1.35–1.25 (m, 2H), 0.91 (s, 9H). **ESI-MS** m/z (rel int): (pos) 473.3 ([M+Na]⁺, 100).




(-)-(R)-5-Benzyl-2-((R)-tert-butylsulfinyl)-3-(2-hydroxyethyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6(5H)-one (R-36d). Light brown oil (8.3 mg). **TLC:** R_f 0.18 (1:10 MeOH/EtOAc). $[\alpha]_D^{20}$: -14.8° (c 0.48, CHCl₃). **IR** (NaCl, film): 3399 (O–H st), 3050, 2965, 2853, 1682 (C=O st), 1520, 1403, 1106 (S–O st), 934, 792. **¹H-NMR** (600 MHz): δ 7.45–7.40 (m, 2H), 7.39–7.35 (m, 3H), 7.19 (s, 1H), 6.41 (s, 1H), 5.16 (d, 1H, J = 7.6), 4.78 (d, 2H, J = 14.3), 3.82 (dd, 2H, J = 16.0, 1.4), 3.79–3.73 (m, 2H), 1.89–1.86 (m, 1H), 1.82–1.78 (m, 1H), 1.11 (s, 9H). **¹³C-NMR** (150 MHz, CDCl₃): δ 162.4, 156.4, 136.4, 131.0, 129.0, 128.14, 128.10, 121.2, 112.8, 66.0, 58.6, 58.2, 52.4, 42.7, 40.2, 23.8. **ESI-MS** m/z (rel int): (pos) 397.5 ([M+Na]⁺, 100).




(R)-5-Benzyl-3,4-bis(2-hydroxyethyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6(5H)-one (R-37a). Light brown oil (3.1 mg). **TLC:** R_f 0.44 (1:3 MeOH/EtOAc). **¹H-NMR** (600 MHz): δ 7.32–7.25 (m, 5H), 6.37 (s, 1H), 5.50 (bs, 1H), 5.40–5.32 (bm, 2H), 4.61 (d, 1H, J = 8.0), 4.40–4.37 (m, 2H), 4.28 (d, 1H, J = 12.0), 3.76–3.72 (m, 2H), 3.63–3.56 (m, 2H), 2.81–2.73 (m, 2H), 2.06–2.00 (m, 1H), 1.87–1.80 (m, 1H). **ESI-MS** m/z (rel int): (pos) 315.3 ([M+H]⁺, 100).




(R)-5-Benzyl-3-(2-hydroxyethyl)-4-phenyl-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6(5H)-one (R-37b). Clear oil (8.1 mg). **TLC:** R_f 0.19 (1:5 MeOH/EtOAc). **¹H-NMR** (600 MHz): δ 7.66–7.62 (m, 5H), 7.45–7.39 (m, 2H), 7.37–7.33 (m, 3H), 6.48 (s, 1H), 5.41–5.23 (m, 2H), 5.18 (t, 1H, J = 6.7), 4.78 (d, 2H, J = 15.3), 3.85–3.81 (m, 1H), 3.79–3.73 (m, 1H), 1.94–1.88 (m, 1H), 1.81–1.75 (m, 1H). **ESI-MS** m/z (rel int): (pos) 369.4 ([M+Na]⁺, 100).




(R)-5-Benzyl-3-(2-hydroxyethyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6(5H)-one (R-37d). Light brown oil (3.9 mg). TLC: R_f 0.18 (1:5 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 7.39–7.35 (m, 5H), 7.18 (s, 1H), 6.48 (s, 1H), 5.25 (s, 1H), 5.16 (dd, 1H, J = 12.5, 6.3), 4.53 (d, 1H, J = 14.6), 4.48 (d, 2H, J = 1.4), 4.40 (d, 1H, J = 8.8), 3.72–3.67 (m, 2H), 2.00–1.94 (m, 1H), 1.73–1.66 (m, 1H). ESI-MS m/z (rel int): (pos) 293.1 ([M+Na]⁺, 100).



(R)-5-Benzyl-2-(tert-butylsulfonyl)-3,4-bis(2-hydroxyethyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6(5H)-one (R-38a). Brown oil (7.0 mg). TLC: R_f 0.44 (1:6 MeOH/EtOAc). ¹H-NMR (500 MHz): δ 7.39–7.22 (m, 5H), 6.39 (s, 1H), 5.61 (br s, 1H), 5.42 (br s, 1H), 5.03 (dd, 1H, J = 2.4, 6.5), 4.84 (d, 1H, J = 4.5), 4.80 (d, 2H, J = 16.3), 3.85–3.76 (m, 3H), 3.68 (ddd, 2H, J = 10.3, 6.0, 4.1), 2.79–2.65 (m, 2H), 1.93–1.88 (m, 1H), 1.87–1.80 (m, 1H), 1.16 (s, 9H). ESI-MS m/z (rel int): (pos) 457.6 ([M+Na]⁺, 100).




(R)-5-Benzyl-2-(tert-butylsulfonyl)-3-(2-hydroxyethyl)-4-phenyl-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6(5H)-one (R-38b). Light brown oil (2.1 mg). TLC: R_f 0.19 (1:10 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 7.45–7.41 (m, 10H), 6.55 (d, 1H, J = 5.5), 5.26–5.20 (m, 1H), 4.93 (dd, 1H, J = 7.6, 3.1), 4.53 (t, 1H, J = 8.2), 4.40 (s, 2H), 3.61–3.58 (m, 2H), 1.74–1.70 (m, 2H), 1.52 (s, 9H). ESI-MS m/z (rel int): (pos) 489.3 ([M+Na]⁺, 100).




(R)-5-Benzyl-2-(tert-butylsulfonyl)-3-(2-hydroxyethyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6(5H)-one (R-38d). Light brown oil (3.5 mg). TLC: R_f 0.18 (1:10 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 7.41–7.35 (m, 5H), 7.19 (s, 1H), 6.42 (s, 1H), 5.12 (d, 1H, J = 14.6),


4.99 (t, 1H, $J = 6.3$), 4.93 (t, 1H, $J = 10.7$), 4.71 (dd, 1H, $J = 16.0, 1.4$), 3.81–3.78 (m, 2H), 3.69–3.64 (m, 1H), 1.99–1.84 (m, 1H), 1.69–1.66 (m, 1H), 1.17 (s, 9H). **ESI-MS** m/z (rel int): (pos) 413.4 ($[\text{M}+\text{Na}]^+$, 100).



(-)-(R)-5-Benzyl-2-((R)-tert-butylsulfinyl)-1-(2-hydroxyethyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6(5H)-one (R-39d). Brown oil (7.0 mg). TLC: R_f 0.18 (1:10 MeOH/EtOAc). $[\alpha]_D^{20}$: -64.8° (c 0.44, CHCl₃). **IR** (NaCl, film): 3393 (O-H st), 3087, 2991, 2853, 1676 (C=O st), 1526, 1409, 1106 (S-O st), 934, 792. **¹H-NMR** (600 MHz): δ 7.45–7.41 (m, 2H), 7.38–7.32 (m, 3H), 6.94 (s, 1H), 6.51 (s, 1H), 4.91–4.88 (m, 3H), 4.81 (t, 1H, $J = 6.3$), 4.82 (dd, 1H, $J = 15.2, 1.4$), 3.58–3.54 (m, 1H), 3.44–3.40 (m, 1H), 1.32–1.25 (m, 2H), 0.93 (s, 9H). **¹³C-NMR** (150 MHz, CDCl₃): δ 162.3, 154.0, 136.3, 130.9, 128.9, 128.0, 127.9, 121.1, 112.7, 65.9, 58.5, 58.2, 52.3, 44.8, 40.1, 23.7. **ESI-MS** m/z (rel int): (pos) 397.5 ($[\text{M}+\text{H}]^+$, 100).




(R)-5-Benzyl-1-(2-hydroxyethyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6(5H)-one (R-40d). Light brown oil (2.1 mg). TLC: R_f 0.17 (1:5 MeOH/EtOAc). **¹H-NMR** (600 MHz): δ 7.39–7.35 (m, 5H), 7.18 (s, 1H), 6.59 (s, 1H), 5.21 (s, 1H), 5.03 (dd, 1H, $J = 12.5, 6.3$), 4.71 (d, 1H, $J = 14.6$), 4.48–4.40 (m, 3H), 3.41–3.38 (m, 1H), 3.23–3.18 (m, 1H), 2.90 (s, 1H), 1.49–1.43 (m, 1H), 1.25–1.21 (m, 1H). **ESI-MS** m/z (rel int): (pos) 293.1 ($[\text{M}+\text{Na}]^+$, 100).




(R)-5-Benzyl-2-(tert-butylsulfonyl)-1-(2-hydroxyethyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6(5H)-one (R-41d). Light brown oil (1.9 mg). TLC: R_f 0.16 (1:10 MeOH/EtOAc). **¹H-NMR** (600 MHz): δ 7.38–7.32 (m, 5H), 7.07 (d, 1H, $J = 14.0$), 6.42 (s, 1H), 5.12–5.08 (m, 3H), 4.99 (t, 1H, $J = 6.3$), 4.93 (t, 1H, $J = 8.8$), 4.71 (dd, 1H, $J = 16.0, 1.4$), 3.78–3.72 (m, 2H), 3.69–3.64 (m, 1H), 1.99–1.84 (m, 1H), 1.69–1.66 (m, 1H), 1.17 (s, 9H). **ESI-MS** m/z (rel int): (pos) 413.4 ($[\text{M}+\text{Na}]^+$, 100).


9. NITRILE [2+2+2] CYCLOTIMERIZATION PRODUCTS (R-42–44)




(+)-(R)-Ethyl 2-((R)-tert-butylsulfinyl)-3,4-bis(2-hydroxyethyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-6-carboxylate (R-42a). Light brown oil (7.0 mg). TLC: R_f 0.37 (1:6 hexanes/EtOAc). $[\alpha]_D^{20}$: +23.1° (c 0.40, CHCl₃). IR (NaCl, film): 3344 (O–H st), 3023, 2952, 2835, 1722 (C=O st), 1250, 1106 (S–O st), 913, 758. ¹H-NMR (600 MHz): δ 7.79 (s, 1H), 5.38 (d, 1H, *J* = 8.2), 5.03 (d, 1H, *J* = 16.4), 4.40 (q, 2H, *J* = 10.6), 4.22 (dt, 1H, *J* = 9.8, 6.4), 4.12–4.08 (m, 1H), 3.97 (d, 1H, *J* = 15.2), 3.82–3.78 (m, 1H), 3.72 (ddd, 1H, *J* = 10.2, 6.2, 4.4), 3.12–3.08 (m, 2H), 2.24–2.20 (m, 1H), 1.80 (ddd, 1H, *J* = 18.9, 8.8, 4.4), 1.43 (t, 3H, *J* = 7.1), 1.12 (s, 9H). ¹³C-NMR (150 MHz, CDCl₃): δ 165.4, 164.8, 154.8, 150.5, 140.1, 139.8, 117.6, 68.5, 65.9, 61.9, 61.1, 58.4, 52.9, 46.2, 38.7, 23.7, 14.2; 2 peaks observed in ester carbonyl region. ESI-MS *m/z* (rel int): (pos) 407.5 ([M+Na]⁺, 100).



(+)-(R)-Ethyl 2-((R)-tert-butylsulfinyl)-3-(2-hydroxyethyl)-4-phenyl-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-6-carboxylate (R-42b). Clear oil (4.0 mg). TLC: R_f 0.20 (1:3 hexanes/EtOAc). $[\alpha]_D^{20}$: +12.1° (c 0.48, CHCl₃). IR (NaCl, film): 3401 (O–H st), 3067, 2992, 2918, 2835, 1716 (C=O st), 1267, 1120 (S–O st), 1067 (S–O st), 958. ¹H-NMR (600 MHz): δ 7.93 (s, 1H), 7.44–7.35 (m, 5H), 5.80 (d, 1H, *J* = 7.9), 5.18 (d, 1H, *J* = 15.7), 4.55–4.47 (m, 1H), 4.47–4.39 (m, 1H), 3.99 (d, 1H, *J* = 12.6), 3.66 (td, 1H, *J* = 9.5, 5.0), 3.48–3.40 (m, 1H), 1.72–1.65 (m, 1H), 1.61–1.54 (m, 1H), 1.43 (t, 3H, *J* = 7.1), 0.99 (s, 9H). ¹³C-NMR (150 MHz, CDCl₃): δ 165.2, 154.2, 149.6, 148.4, 138.1, 129.7, 129.4, 129.2, 128.4, 117.9, 62.9, 62.8, 62.3, 58.5, 51.0, 36.1, 22.9, 14.5. ESI-MS *m/z* (rel int): (pos) 417.2 ([M+H]⁺, 100).




(R)-Ethyl 2-((R)-tert-butylsulfinyl)-3-(2-hydroxyethyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-6-carboxylate (R-42d). Clear oil (4.9 mg). TLC: R_f 0.12 (1:3 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 8.62 (s, 1H), 8.00 (s, 1H), 5.33 (t, 1H, *J* = 6.0), 5.09 (d, 1H, *J* = 15.6), 4.48 (q, 2H, *J* = 7.5), 3.99 (d, 1H, *J* = 15.6), 3.83–3.76 (m, 2H), 2.11–2.01 (m, 1H), 1.96–1.87 (m, 1H), 1.44 (t, 3H, *J* = 7.1), 1.07 (s, 9H). ESI-MS *m/z* (rel int): (pos) 340.1 ([M+H]⁺, 100).




(R)-Ethyl 3,4-bis(2-hydroxyethyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-6-carboxylate (R-43a).

(R-43a). Clear oil (4.1 mg). TLC: R_f 0.37 (1:6 MeOH/EtOAc). **¹H-NMR** (600 MHz): δ 7.88 (s, 1H), 5.39 (s, 1H), 5.07 (d, 1H, J = 16.8), 4.40 (q, 2H, J = 10.8), 4.18 (dt, 1H, J = 9.8, 6.4), 4.08 (dt, 1H, J = 9.8, 6.1), 3.75–3.68 (m, 1H), 3.65–3.62 (m, 1H), 3.08 (dd, 1H, J = 13.8, 6.1), 2.91–2.88 (m, 2H), 2.06–1.98 (m, 2H), 1.41 (t, 3H, J = 7.1). **ESI-MS** m/z (rel int): (pos) 281.3 ([M+H]⁺, 100).




(R)-Ethyl 3-(2-hydroxyethyl)-4-phenyl-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-6-carboxylate (R-43b).

(R-43b). Clear oil (2.1 mg). TLC: R_f 0.20 (1:10 MeOH/EtOAc). **¹H-NMR** (600 MHz): δ 7.93 (s, 1H), 7.44–7.35 (m, 5H), 5.41 (s, 1H), 5.12 (d, 1H, J = 15.7), 5.07 (d, 1H, J = 15.7), 4.48–4.44 (m, 2H), 3.99 (t, 1H, J = 10.6), 3.78–3.72 (m, 2H), 2.04–1.98 (m, 1H), 1.43 (t, 3H, J = 7.1). **ESI-MS** m/z (rel int): (pos) 313.2 ([M+H]⁺, 100).




(R)-Ethyl 3-(2-hydroxyethyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-6-carboxylate (R-43d).

Clear oil (7.5 mg). TLC: R_f 0.12 (1:10 MeOH/EtOAc). **¹H-NMR** (600 MHz): δ 8.73 (s, 1H), 8.06 (s, 1H), 5.33 (bt, 1H, J = 6.0), 5.06 (d, 1H, J = 12.4), 4.66 (d, 1H, J = 12.8), 4.50 (q, 2H, J = 7.5), 3.97–3.93 (m, 1H), 3.79–3.74 (m, 1H), 2.08–2.01 (m, 2H), 1.49 (t, 3H, J = 7.2). **ESI-MS** m/z (rel int): (pos) 259.3 ([M+Na]⁺, 100).




(+)-(R)-Ethyl 2-(tert-butylsulfonyl)-3,4-bis(2-hydroxyethyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-6-carboxylate (R-44a).

Brown oil (7.3 mg). TLC: R_f 0.37 (1:3 hexanes/EtOAc). $[\alpha]_D^{20}$: +63.3° (c 0.37, CHCl₃). **IR** (NaCl, film): 3335 (O–H st), 3042, 2971, 2942, 2835, 1735 (C=O st), 1250 (SO₂ st), 1143 (SO₂ st), 968. **¹H-NMR** (600 MHz): δ 7.81 (s, 1H), 5.40 (d, 1H, J = 8.5), 5.01 (d, 1H, J = 15.3), 4.48 (q, 2H, J = 10.5, 7.1), 4.21 (dt, 1H, J = 9.8, 6.3), 4.05 (dt, 1H, J = 9.8, 6.5), 3.97 (d, 1H, J = 13.9), 3.82–3.78 (m, 1H), 3.73–3.68 (m, 2H), 3.12–3.06 (m, 2H), 2.31–2.24 (m, 1H), 1.48 (t, 3H, J = 7.3), 1.16 (s, 9H). **¹³C-NMR** (150 MHz, CDCl₃): δ 165.5, 164.9, 155.0, 150.6, 146.7, 146.4, 117.7, 68.6, 66.2, 62.0, 61.1, 58.4, 52.9, 50.9, 38.8, 25.5, 14.3; 2 peaks observed in ester carbonyl region. **ESI-MS** m/z (rel int): (pos) 423.5 ([M+Na]⁺, 100).




(+)-(R)-Ethyl 2-(tert-butylsulfonyl)-3-(2-hydroxyethyl)-4-phenyl-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-6-carboxylate (R-44b). Clear oil (8.1 mg). TLC: R_f 0.20 (1:2 hexanes/EtOAc). $[\alpha]_D^{20}$: +71.0° (c 0.42, CHCl₃). IR (NaCl, film): 3362 (O—H st), 3029, 2999, 2905, 2881, 1721 (C=O st), 1221 (SO₂ st), 1088 (SO₂ st), 968, 798. ¹H-NMR (600 MHz): δ 7.91 (s, 1H), 7.43–7.39 (m, 5H), 5.80 (d, 1H, J = 7.7), 5.20 (d, 1H, J = 15.2), 4.51–4.48 (m, 1H), 4.42–4.38 (m, 1H), 4.00 (d, 1H, J = 12.6), 3.68 (td, 1H, J = 9.5, 5.3), 3.47–3.41 (m, 1H), 1.79–1.72 (m, 1H), 1.68–1.63 (m, 1H), 1.46 (t, 3H, J = 7.1), 1.25 (s, 9H). ¹³C-NMR (150 MHz, CDCl₃): δ 165.0, 154.1, 149.5, 148.2, 137.9, 129.63, 129.60, 129.0, 128.2, 117.7, 62.7, 62.2, 58.3, 50.9, 50.8, 36.0, 25.1, 14.3. ESI-MS m/z (rel int): (pos) 455.5 ([M+Na]⁺, 100).




(R)-Ethyl 2-(tert-butylsulfonyl)-3-(2-hydroxyethyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-6-carboxylate (R-44d). Clear oil (3.6 mg). TLC: R_f 0.11 (1:2 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 8.66 (s, 1H), 8.02 (s, 1H), 5.58 (d, 1H, J = 6.0), 5.03 (d, 1H, J = 15.6), 4.59 (t, 1H, J = 12.5), 4.48 (q, 2H, J = 7.5), 3.87 (t, 1H, J = 6.4), 3.63–3.61 (m, 1H), 2.11–2.01 (m, 1H), 1.96–1.87 (m, 1H), 1.44 (t, 3H, J = 7.1), 1.41 (s, 9H). ESI-MS m/z (rel int): (pos) 357.3 ([M+H]⁺, 100).


10. SAITO [3+2+2] CYCLOADDITION PRODUCTS (R-45–50)




(E)-2-((R)-2-((R)-tert-Butylsulfinyl)-1,8-bis(2-hydroxyethyl)-2,3,6,7-tetrahydrocyclohepta[c]pyrrol-5(1H)-ylidene)-N-methoxy-N-methylacetamide (R-45a). Yellow oil (4.4 mg). TLC: R_f 0.44 (1:4 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 6.28 (s, 1H), 5.96 (s, 1H), 4.68–4.64 (m, 1H), 4.59 (dt, 1H, J = 12.5, 5.5), 3.94 (d, 1H, J = 16.0), 3.69 (s, 3H), 3.61–3.56 (m, 2H), 3.47–3.41 (m, 2H), 3.21 (s, 3H), 2.60 (t, 1H, J = 8.8), 2.49–2.42 (m, 1H), 1.65–1.58 (m, 1H), 1.52–1.47 (m, 2H), 1.22–1.20 (m, 3H), 0.93 (s, 9H). ESI-MS m/z (rel int): (pos) 449.4 ([M+Na]⁺, 100).




(*–*)(*E*)-2-((*R*)-2-((*R*)-tert-Butylsulfinyl)-1-(2-hydroxyethyl)-8-phenyl-2,3,6,7-tetrahydrocyclohepta[c]pyrrol-5(1*H*)-ylidene)-*N*-methoxy-*N*-methylacetamide (R-45b). Light red oil (3.9 mg). TLC: R_f 0.25 (1:3 hexanes/EtOAc). $[\alpha]_D^{20}$: -24.4° (c 0.35, CHCl₃). IR (NaCl, film): 3320 (O-H st), 3050, 2990, 2881, 1639 (C=O st), 1520, 1087 (S-O st), 968. ¹H-NMR (600 MHz): δ 7.63 (s, 1H), 7.34–7.27 (m, 5H), 5.73 (s, 1H), 4.66 (dd, 1H, *J* = 9.0, 4.2), 4.51 (dd, 1H, *J* = 10.2, 7.1), 3.69–3.65 (m, 4H), 3.58–3.54 (m, 1H), 3.45–3.41 (m, 1H), 3.23 (s, 3H), 2.64–2.60 (m, 2H), 1.63–1.58 (m, 1H), 1.53–1.49 (m, 2H), 0.91 (s, 9H). ¹³C-NMR (150 MHz, CDCl₃): δ 162.3, 154.0, 141.2, 139.8, 136.3, 130.9, 128.9, 128.0, 127.9, 121.1, 112.7, 67.7, 65.9, 60.4, 58.5, 50.8, 46.9, 45.6, 39.5, 33.9, 23.6. ESI-MS *m/z* (rel int): (pos) 459.2 ([M+H]⁺, 100).




(*E*)-2-((*R*)-2-((*R*)-tert-Butylsulfinyl)-1-(2-hydroxyethyl)-2,3,6,7-tetrahydrocyclohepta[c]pyrrol-5(1*H*)-ylidene)-*N*-methoxy-*N*-methylacetamide (R-45d). Light yellow oil (4.1 mg). TLC: R_f 0.41 (1:3 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 6.21 (s, 1H), 6.02 (s, 1H), 5.83 (d, 1H, *J* = 16.0), 4.62 (dd, 1H, *J* = 8.0, 3.5), 4.48 (d, 1H, *J* = 16.9), 3.83 (dd, 1H, *J* = 15.2, 6.4), 3.75–3.73 (m, 2H), 3.69 (s, 3H), 3.49 (d, 1H, *J* = 16.0), 3.20 (s, 3H), 2.53 (dd, 1H, *J* = 16.0, 8.0), 2.10–2.02 (m, 2H), 1.83–1.81 (m, 1H), 1.79–1.69 (m, 1H), 102 (s, 9H). ESI-MS *m/z* (rel int): (pos) 383.2 ([M+H]⁺, 100).




(*R,E*)-2-(1,8-Bis(2-hydroxyethyl)-2,3,6,7-tetrahydrocyclohepta[c]pyrrol-5(1*H*)-ylidene)-*N*-methoxy-*N*-methylacetamide (R-46a). Light yellow oil (2.1 mg). TLC: R_f 0.44 (1:5 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 6.29 (s, 1H), 5.91 (s, 1H), 4.68 (dd, 1H, *J* = 9.1, 2.4), 4.19–4.13 (m, 1H), 3.94 (d, 1H, *J* = 16.5), 3.68–3.65 (m, 4H), 3.64–3.61 (m, 1H), 3.46 (t, 2H, *J* = 6.4), 3.21 (s, 3H), 2.61 (t, 2H, *J* = 8.8), 2.49–2.41 (m, 2H), 1.62–1.59 (m, 1H), 1.52–1.47 (m, 2H), 1.22–1.20 (m, 1H). ESI-MS *m/z* (rel int): (pos) 323.4 ([M+H]⁺, 100).




(*R,E*)-2-(1-(2-Hydroxyethyl)-8-phenyl-2,3,6,7-tetrahydrocyclohepta[c]pyrrol-5(1*H*)-ylidene)-*N*-methoxy-*N*-methylacetamide (R-46b**).** Light red oil (1.6 mg). TLC: R_f 0.25 (1:10 MeOH/EtOAc). $^1\text{H-NMR}$ (600 MHz): δ 7.68 (s, 1H), 7.38–7.25 (m, 5H), 6.08 (s, 1H), 4.82 (dd, 1H, J = 9.0, 4.2), 4.48 (dd, 1H, J = 10.2, 7.1), 3.71–3.68 (m, 4H), 3.63–3.58 (m, 1H), 3.49–3.45 (m, 1H), 3.23 (s, 3H), 2.64–2.60 (bm, 2H), 1.63–1.58 (m, 2H), 1.53–1.49 (m, 2H). **ESI-MS** m/z (rel int): (pos) 355.2 ([M+H] $^+$, 100).




(*R,E*)-2-(1-(2-Hydroxyethyl)-2,3,6,7-tetrahydrocyclohepta[c]pyrrol-5(1*H*)-ylidene)-*N*-methoxy-*N*-methylacetamide (R-46d**).** Light yellow oil (2.0 mg). TLC: R_f 0.41 (1:10 MeOH/EtOAc). $^1\text{H-NMR}$ (600 MHz): δ 6.21 (s, 1H), 6.03 (s, 1H), 5.80 (d, 1H, J = 16.8), 4.59 (dd, 1H, J = 8.8, 3.5), 4.50 (d, 1H, J = 17.1), 3.85 (dd, 1H, J = 15.3, 6.4), 3.75–3.73 (m, 2H), 3.67 (s, 3H), 3.49 (d, 1H, J = 16.0), 3.20 (s, 3H), 2.51 (dd, 1H, J = 16.0, 8.0), 2.10–2.02 (m, 2H), 1.83–1.81 (m, 1H), 1.79–1.69 (m, 1H). **ESI-MS** m/z (rel int): (pos) 279.0 ([M+H] $^+$, 100).




(*R,E*)-2-(2-(tert-Butylsulfonyl)-1,8-bis(2-hydroxyethyl)-2,3,6,7-tetrahydrocyclohepta[c]pyrrol-5(1*H*)-ylidene)-*N*-methoxy-*N*-methylacetamide (R-47a**).** Clear oil (2.9 mg). TLC: R_f 0.44 (1:8 MeOH/EtOAc). $^1\text{H-NMR}$ (600 MHz): δ 6.39 (s, 1H), 6.10 (s, 1H), 4.66–4.63 (m, 1H), 4.59 (dt, 1H, J = 12.0, 5.5), 3.94 (d, 1H, J = 16.0), 3.69 (s, 3H), 3.61–3.56 (m, 1H), 3.47–3.41 (m, 2H), 3.21 (s, 3H), 2.57 (t, 1H, J = 8.8), 2.49–2.42 (m, 2H), 1.65–1.58 (m, 2H), 1.52–1.47 (m, 2H), 1.22–1.20 (m, 2H), 1.2 (s, 9H). **ESI-MS** m/z (rel int): (pos) 465.2 ([M+Na] $^+$, 100).




(*R,E*)-2-(2-(tert-Butylsulfonyl)-1-(2-hydroxyethyl)-8-phenyl-2,3,6,7-tetrahydrocyclohepta[c]pyrrol-5(1*H*)-ylidene)-*N*-methoxy-*N*-methylacetamide (R-47b**).** Brown oil (3.0 mg). TLC: R_f 0.25 (1:15 MeOH/EtOAc). $^1\text{H-NMR}$ (600 MHz): δ 7.67 (s, 1H), 7.32–7.23 (m, 5H), 5.49 (s, 1H), 4.68 (dd, 1H, J = 9.0, 4.2), 4.53 (dd, 1H, J = 10.6, 7.1), 3.72–3.67 (m, 4H), 3.58–3.54 (m, 1H), 3.45–3.41 (m, 1H), 3.25 (s, 3H), 2.64–2.60 (m, 2H), 1.63–1.58 (m, 3H), 1.53–1.49 (m, 3H), 1.09 (s, 9H). **ESI-MS** m/z (rel int): (pos) 475.2 ([M+H] $^+$, 100).




(*R,E*)-2-(2-(*tert*-Butylsulfonyl)-1-(2-hydroxyethyl)-2,3,6,7-tetrahydrocyclohepta[c]pyrrol-5(1*H*)-ylidene)-N-methoxy-N-methylacetamide (R-47d). Light yellow oil (3.3 mg). TLC: *R*_f 0.41 (1:15 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 6.31 (s, 1H), 6.11 (s, 1H), 5.98 (t, 1H, *J* = 8.0), 4.68–4.62 (m, 2H), 4.00 (dd, 1H, *J* = 12.0, 3.5), 3.72–3.69 (m, 4H), 3.52–3.47 (m, 1H), 3.23 (s, 3H), 3.18–3.14 (m, 2H), 2.70–2.60 (m, 1H), 2.57–2.51 (m, 1H), 1.62–1.52 (m, 2H), 1.19 (s, 9H). ESI-MS *m/z* (rel int): (pos) 399.2 ([M+H]⁺, 100).




(*Z*)-2-((*R*)-2-((*R*)-*tert*-Butylsulfinyl)-1,8-bis(2-hydroxyethyl)-2,3,6,7-tetrahydrocyclohepta[c]pyrrol-5(1*H*)-ylidene)-N-methoxy-N-methylacetamide (R-48a). Yellow oil (3.7 mg). TLC: *R*_f 0.44 (1:3 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 6.16 (s, 1H), 6.01 (s, 1H), 4.64–4.62 (m, 1H), 4.53 (dt, 1H, *J* = 12.5, 5.9), 3.94 (d, 1H, *J* = 10.0), 3.65–3.61 (m, 3H), 3.59 (s, 3H), 3.52 (dd, 1H, *J* = 12.5, 6.2), 3.23 (s, 3H), 2.49–2.42 (m, 2H), 2.35–2.31 (m, 1H), 2.24–2.20 (m, 1H), 2.17–2.13 (m, 1H), 1.92–1.87 (m, 1H), 1.72–1.67 (m, 2H), 0.88 (s, 9H). ESI-MS *m/z* (rel int): (pos) 449.4 ([M+Na]⁺, 100).




(*Z*)-2-((*R*)-2-((*R*)-*tert*-Butylsulfinyl)-1-(2-hydroxyethyl)-8-phenyl-2,3,6,7-tetrahydrocyclohepta[c]pyrrol-5(1*H*)-ylidene)-N-methoxy-N-methylacetamide (R-48b). Light red oil (3.1 mg). TLC: *R*_f 0.25 (1:3 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 7.69 (s, 1H), 7.34–7.27 (m, 5H), 5.92 (s, 1H), 4.68 (dd, 1H, *J* = 8.8, 4.2), 4.53 (dd, 1H, *J* = 14.2, 7.1), 3.72–3.69 (m, 4H), 3.58–3.54 (m, 1H), 3.45–3.41 (m, 1H), 3.23 (s, 3H), 2.64–2.60 (m, 2H), 1.61–1.56 (m, 2H), 1.53–1.49 (m, 2H), 0.93 (s, 9H). ESI-MS *m/z* (rel int): (pos) 459.2 ([M+H]⁺, 100).




(Z)-2-((R)-2-((R)-tert-Butylsulfinyl)-1-(2-hydroxyethyl)-2,3,6,7-tetrahydrocyclohepta[c]pyrrol-5(1H)-ylidene)-N-methoxy-N-methylacetamide (R-48d). Clear oil (3.3 mg). TLC: R_f 0.41 (1:3 hexanes/EtOAc). **¹H-NMR** (600 MHz): δ 6.21 (s, 1H), 6.11 (s, 1H), 6.00 (s, 1H), 4.59 (dd, 1H, *J* = 8.0, 3.5), 4.48 (d, 1H, *J* = 15.0), 3.83 (dd, 1H, *J* = 15.2, 5.7), 3.75–3.73 (m, 2H), 3.69 (s, 3H), 3.49 (d, 1H, *J* = 14.3), 3.20 (s, 3H), 2.51 (dd, 1H, *J* = 15.2, 6.2), 2.10–2.02 (m, 2H), 1.83–1.81 (m, 1H), 1.79–1.69 (m, 1H), 1.01 (s, 9H). **ESI-MS** *m/z* (rel int): (pos) 383.2 ([M+H]⁺, 100).




(R,Z)-2-(1,8-Bis(2-hydroxyethyl)-2,3,6,7-tetrahydrocyclohepta[c]pyrrol-5(1H)-ylidene)-N-methoxy-N-methylacetamide (R-49a). Light yellow oil (1.5 mg). TLC: R_f 0.44 (1:5 MeOH/EtOAc). **¹H-NMR** (600 MHz): δ 6.29 (s, 1H), 6.11 (s, 1H), 4.88 (dd, 1H, *J* = 9.0, 2.4), 4.21–4.18 (m, 1H), 3.94 (d, 1H, *J* = 16.0), 3.69 (s, 3H), 3.67–3.63 (m, 2H), 3.48 (t, 2H, *J* = 6.4), 3.21 (s, 3H), 2.61 (t, 2H, *J* = 8.8), 2.49–2.42 (m, 2H), 1.62–1.59 (m, 1H), 1.56–1.52 (m, 3H). **ESI-MS** *m/z* (rel int): (pos) 323.4 ([M+H]⁺, 100).




(R,Z)-2-(1-(2-Hydroxyethyl)-8-phenyl-2,3,6,7-tetrahydrocyclohepta[c]pyrrol-5(1H)-ylidene)-N-methoxy-N-methylacetamide (R-49b). Light orange oil (0.6 mg). TLC: R_f 0.25 (1:10 MeOH/EtOAc). **¹H-NMR** (600 MHz): δ 7.65 (s, 1H), 7.36–7.23 (m, 5H), 5.92 (s, 1H), 4.68 (dd, 1H, *J* = 9.0, 4.8), 4.42 (dd, 1H, *J* = 12.2, 7.1), 3.69–3.65 (m, 4H), 3.61–3.54 (m, 1H), 3.41–3.38 (m, 1H), 3.21 (s, 3H), 2.64–2.60 (bm, 2H), 1.61–1.52 (m, 2H), 1.50–1.47 (m, 2H). **ESI-MS** *m/z* (rel int): (pos) 355.2 ([M+H]⁺, 100).




(R,Z)-2-(1-(2-Hydroxyethyl)-2,3,6,7-tetrahydrocyclohepta[c]pyrrol-5(1H)-ylidene)-N-methoxy-N-methylacetamide (R-49d). Light yellow oil (0.9 mg). TLC: R_f 0.41 (1:10 MeOH/EtOAc). **¹H-NMR** (600 MHz): δ 6.22 (s, 1H), 6.01 (s, 1H), 5.92 (s, 1H), 4.59 (dd, 1H, *J* = 8.8, 3.5), 4.49 (d, 1H, *J* = 17.1), 3.83 (dd, 1H, *J* = 12.4, 6.4), 3.73–3.70 (m, 2H), 3.67 (s, 3H), 3.49 (d, 1H, *J* = 16.0), 3.21 (s, 3H), 2.51 (dd, 1H, *J* = 16.0, 8.0), 2.13–2.04 (m, 2H), 1.81–1.78 (m, 1H), 1.74–1.65 (m, 1H). **ESI-MS** *m/z* (rel int): (pos) 279.0 ([M+H]⁺, 100).



(R,Z)-2-(2-(tert-Butylsulfonyl)-1-(2-hydroxyethyl)-2,3,6,7-tetrahydrocyclohepta[c]pyrrol-5(1H)-ylidene)-N-methoxy-N-methylacetamide (R-50a). Clear oil (3.3 mg). TLC: R_f 0.44 (1:8 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 6.26 (s, 1H), 6.03 (s, 1H), 4.62–4.57 (m, 1H), 4.50 (dd, 2H, J = 12.0, 5.5), 3.84 (d, 1H, J = 11.0), 3.73 (t, 1H, J = 12.0), 3.67 (s, 3H), 3.50 (dd, 2H, J = 12.0, 6.2), 3.23 (s, 3H), 2.53 (dd, 2H, J = 9.1, 8.8), 2.11–1.98 (m, 2H), 1.83–1.78 (m, 2H), 1.72–1.67 (m, 2H), 1.18 (s, 9H). ESI-MS m/z (rel int): (pos) 465.2 ([M+Na]⁺, 100).




(R,Z)-2-(2-(tert-Butylsulfonyl)-1-(2-hydroxyethyl)-8-phenyl-2,3,6,7-tetrahydrocyclohepta[c]pyrrol-5(1H)-ylidene)-N-methoxy-N-methylacetamide (R-50b). Brown oil (3.3 mg). TLC: R_f 0.25 (1:15 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 7.67 (s, 1H), 7.32–7.23 (m, 5H), 5.93 (s, 1H), 4.68 (dd, 1H, J = 9.0, 4.8), 4.53 (dd, 1H, J = 10.7, 7.1), 3.72–3.67 (m, 4H), 3.61–3.58 (m, 1H), 3.47–3.43 (m, 1H), 3.23 (s, 3H), 2.64–2.60 (m, 2H), 1.63–1.58 (m, 2H), 1.53–1.49 (m, 2H), 1.10 (s, 9H). ESI-MS m/z (rel int): (pos) 475.3 ([M+H]⁺, 100).




(R,Z)-2-(2-(tert-Butylsulfonyl)-1-(2-hydroxyethyl)-2,3,6,7-tetrahydrocyclohepta[c]pyrrol-5(1H)-ylidene)-N-methoxy-N-methylacetamide (R-50d). Light yellow oil (2.9 mg). TLC: R_f 0.41 (1:15 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 6.27 (t, 1H, J = 8.0), 6.13 (s, 1H), 6.02 (s, 1H), 4.73 (dd, 1H, J = 14.0, 4.0), 4.52 (dd, 1H, J = 16.0, 4.0), 3.92–3.89 (m, 1H), 3.76–3.70 (m, 2H), 3.56 (s, 3H), 3.21 (s, 3H), 2.48–2.44 (m, 2H), 2.39–2.35 (m, 1H), 2.24–2.20 (m, 1H), 1.94–1.87 (m, 1H), 1.70–1.65 (m, 1H), 1.07 (s, 9H). ESI-MS m/z (rel int): (pos) 399.2 ([M+H]⁺, 100).

F. ANALYTICAL DATA FOR S-SERIES LIBRARY MEMBERS


1. PAUSON-KHAND REACTION PRODUCTS (S-11–13)




(1*S*,3*aS*)-2-((*S*)-*tert*-Butylsulfinyl)-1,6-bis(2-hydroxyethyl)-2,3,3*a*,4-tetrahydrocyclopenta[*c*]-pyrrol-5(1*H*)-one (S-11a).** Clear oil (7.0 mg). TLC: R_f 0.40 (1:9 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 5.85 (dt, 1H, *J* = 8.8, 6.1), 5.16 (d, 1H, *J* = 10.0), 5.03 (d, 1H, *J* = 8.2), 4.51 (s, 1H), 3.92 (dd, 1H, *J* = 12.5, 8.2), 3.78–3.72 (m, 2H), 3.56–3.52 (m, 2H), 2.48 (t, 1H, *J* = 5.6), 1.83–1.78 (m, 3H), 1.64–1.61 (m, 1H), 1.21 (s, 9H). ESI-MS *m/z* (rel int): (pos) 310.4 ([M-CO+Na]⁺, 100).




(1*S*,3*S*)-2-((*S*)-*tert*-Butylsulfinyl)-1-(2-hydroxyethyl)-6-phenyl-2,3,3*a*,4-tetrahydrocyclopenta[*c*]pyrrol-5(1*H*)-one (S-11b). Clear oil (7.5 mg). TLC: R_f 0.24 (1:4 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 7.39–7.31 (m, 5H) 6.02 (dt, 1H, *J* = 8.4, 2.4), 5.30 (d, 1H, *J* = 14.3), 5.16 (d, 1H, *J* = 8.8), 4.82 (t, 1H, *J* = 8.8), 3.98 (dd, 1H, *J* = 10.2, 4.4), 3.89 (dd, 1H, *J* = 8.8, 3.5), 3.70–3.65 (m, 2H), 2.04–1.98 (m, 2H), 1.31 (s, 9H). ESI-MS *m/z* (rel int): (pos) 370.5 ([M+Na]⁺, 100).




(1*S*,3*S*)-2-((*S*)-*tert*-Butylsulfinyl)-1-(2-hydroxyethyl)-2,3,3*a*,4-tetrahydrocyclopenta[*c*]-pyrrol-5(1*H*)-one (S-11d). Light yellow oil (7.3 mg). TLC: R_f 0.27 (1:6 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 5.92 (dt, 1H, *J* = 5.5, 2.6), 5.16 (d, 1H, *J* = 12.0), 5.03 (d, 1H, *J* = 8.2), 4.59 (t, 1H, *J* = 8.7), 3.98 (s, 1H), 3.96 (dd, 1H, *J* = 10.7, 8.6), 3.85 (dd, 1H, *J* = 9.1, 10.7), 3.54–3.49 (m, 2H), 1.81–1.74 (m, 2H), 1.21 (s, 9H). ESI-MS *m/z* (rel int): (pos) 240.4 ([M+Na]⁺, 100).




(1*S*,3*aS*)-1,6-Bis(2-hydroxyethyl)-2,3,3*a*,4-tetrahydrocyclopenta[*c*]pyrrol-5(1*H*)-one (S-12a).** Clear oil (2.6 mg). TLC: R_f 0.31 (1:5 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 5.96 (dt, 1H, *J* = 8.8, 6.2), 5.18 (d, 1H, *J* = 10.0), 5.05 (d, 1H, *J* = 8.2), 4.62 (s, 1H), 4.08 (dd, 1H, *J* = 12.5, 8.2), 3.92–3.88 (m, 1H), 3.76–3.72 (m, 1H), 3.52–3.50 (m, 1H), 2.96–2.92 (m, 1H), 2.48 (t, 1H, *J* = 5.6), 1.89–1.85 (m, 1H), 1.74–1.70 (m, 1H), 1.61–1.58 (m, 2H). ESI-MS *m/z* (rel int): (pos) 234.4 ([M+Na]⁺, 100).




(1*S*,3*aS*)-1-(2-Hydroxyethyl)-6-phenyl-2,3,3*a*,4-tetrahydrocyclopenta[*c*]pyrrol-5(1*H*)-one (S-12b).** Clear oil (2.8 mg). TLC: R_f 0.48 (1:9 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 7.34–7.32 (m, 2H), 7.29–7.27 (m, 3H), 6.02 (dt, 1H, *J* = 8.8, 6.2), 5.21 (d, 1H, *J* = 10.0), 5.16 (d, 1H, *J* = 8.2), 4.82 (s, 1H), 4.04 (bs, 1H), 3.98 (dd, 1H, *J* = 12.5, 8.2), 3.88 (dd, 1H, *J* = 10.0, 6.2), 3.67–3.61 (m, 2H), 3.46–3.42 (m, 1H), 2.06–2.02 (m, 2H), 1.70 (bs, 1H). ESI-MS *m/z* (rel int): (pos) 267.2 ([M+Na]⁺, 100).




(1*S*,3*aS*)-1-(2-Hydroxyethyl)-2,3,3*a*,4-tetrahydrocyclopenta[*c*]pyrrol-5(1*H*)-one (S-12d).** Clear oil (3.7 mg). TLC: R_f 0.26 (1:5 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 5.86 (dt, 1H, *J* = 8.8, 6.2), 5.12 (d, 1H, *J* = 10.0), 5.03 (d, 1H, *J* = 8.2), 4.52 (s, 1H), 4.17 (dt, 1H, *J* = 12.5, 8.2), 3.92–3.88 (m, 1H), 3.76–3.72 (m, 1H), 3.52–3.50 (m, 1H), 2.96–2.92 (m, 1H), 2.37 (s, 1H), 1.78–1.74 (m, 2H). ESI-MS *m/z* (rel int): (pos) 190.2 ([M+Na]⁺, 100).



(1*S*,3*aS*)-2-(tert-Butylsulfonyl)-1,6-bis(2-hydroxyethyl)-2,3,3*a*,4-tetrahydrocyclopenta[*c*]pyrrol-5(1*H*)-one (S-13a).** Clear oil (7.4 mg). TLC: R_f 0.40 (1:6 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 5.92 (dt, 1H, *J* = 8.8, 6.1), 5.16 (d, 1H, *J* = 10.0), 5.03 (d, 1H, *J* = 8.2), 4.62–4.57 (m, 1H), 4.13–4.04 (m, 1H), 3.92 (dd, 1H, *J* = 14.3, 8.2), 3.68–3.61 (m, 1H), 3.50–3.45 (m, 1H), 2.99 (dd, 1H, *J* = 5.6, 3.5), 1.93–1.87 (m, 1H), 1.81 (dd, 2H, *J* = 7.5, 6.8), 1.61–1.56 (m, 2H), 1.31 (s, 9H). ESI-MS *m/z* (rel int): (pos) 354.4 ([M+Na]⁺, 100).




(1S,3aS)-2-(tert-Butylsulfonyl)-1-(2-hydroxyethyl)-6-phenyl-2,3,3a,4-tetrahydrocyclopenta[c]pyrrol-5(1H)-one (S-13b). Clear oil (7.0 mg). TLC: R_f 0.24 (1:6 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 7.39–7.31 (m, 5H), 5.98 (dt, 1H, J = 8.4, 2.4), 5.21 (d, 1H, J = 14.3), 5.03 (d, 1H, J = 8.8), 4.91 (d, 1H, J = 8.8, 6.1), 4.13 (d, 1H, J = 10.2), 4.02 (t, 1H, J = 8.0), 3.81–3.76 (m, 1H), 3.56–3.52 (m, 1H), 2.91 (s, 1H), 2.04–1.98 (m, 1H), 2.48 (dt, 1H, J = 10.1, 8.8), 1.44 (s, 9H). ESI-MS m/z (rel int): (pos) 386.5 ([M+Na]⁺, 100).




(1S,3aS)-2-(tert-Butylsulfonyl)-1-(2-hydroxyethyl)-2,3,3a,4-tetrahydrocyclopenta[c]pyrrol-5(1H)-one (S-13d). Light yellow oil (7.1 mg). TLC: R_f 0.27 (1:4 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 5.92 (dt, 1H, J = 5.5, 1.5), 5.16 (d, 1H, J = 12.0), 5.03 (d, 1H, J = 8.2), 4.69 (dd, 1H, J = 5.3, 8.7), 4.13 (d, 1H, J = 12.0), 3.96 (dd, 1H, J = 10.7, 8.6), 3.68 (dt, 1H, J = 9.1, 10.7), 3.50 (dt, 1H, J = 6.3, 6.1), 2.80 (s, 1H), 1.98 (dd, 1H, J = 7.1, 5.5), 1.81–1.78 (m, 1H), 1.41 (s, 9H). ESI-MS m/z (rel int): (pos) 310.4 ([M+Na]⁺, 100).


2. KRISCHE REDUCTIVE CYCLIZATION PRODUCTS (S-14–19)




(Z)-3-((2S,4S)-1-((S)-tert-Butylsulfinyl)-2-(2-hydroxyethyl)-4-methylpyrrolidin-3-ylidene)-propan-1-ol (S-14a). Colorless oil (8.2 mg). TLC: R_f 0.53 (1:2 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 5.02 (t, 1H, J = 7.1), 4.49 (t, 1H, J = 7.6), 4.09–4.03 (m, 1H), 3.68–3.62 (m, 2H), 3.19 (d, 1H, J = 8.8), 3.04–2.98 (m, 2H), 2.78–2.71 (m, 1H), 2.31 (s, 1H), 1.91–1.87 (m, 2H), 1.82–1.76 (m, 2H), 1.21 (s, 9H), 1.05 (d, 3H, J = 6.8). ESI-MS m/z (rel int): (pos) 312.2 ([M+Na]⁺, 100).




2-((2S,4S,Z)-3-Benzylidene-1-((S)-tert-butylsulfinyl)-4-methylpyrrolidin-2-yl)ethanol (S-14b). Colorless oil (8.8 mg). **TL**C: R_f 0.40 (1:1 hexanes/EtOAc). **1H-NMR** (600 MHz): δ 7.43–7.40 (m, 2H), 7.36 (d, 1H, J = 4.0), 7.23–7.18 (m, 2H), 6.41 (s, 1H), 5.43 (bs, 1H), 4.95 (s, 1H), 3.82–3.79 (m, 1H), 3.76–3.71 (m, 1H), 3.65–3.61 (m, 1H), 3.03 (s, 1H), 2.83 (t, 1H, J = 9.5), 1.95–1.89 (m, 1H), 1.87–1.81 (m, 1H) 1.19 (s, 9H), 1.16 (d, 3H, J = 6.5). **ESI-MS** m/z (rel int): (pos) 218.2 ([M+H]⁺, 100).




2-((2S,4S)-1-((S)-tert-Butylsulfinyl)-4-methyl-3-methylenepyrrolidin-2-yl)ethanol (S-14d). Colorless oil (7.4 mg). **TL**C: R_f 0.33 (1:1 hexanes/EtOAc). **1H-NMR** (600 MHz): δ 4.91 (s, 2H), 4.21 (t, 1H, J = 5.5), 3.73–3.69 (m, 2H), 3.11 (t, 1H, J = 9.3), 3.00 (t, 1H, J = 9.3), 2.76–2.61 (m, 1H), 1.94–1.86 (m, 1H), 1.77–1.72 (m, 1H), 1.16 (s, 9H), 1.08 (d, 3H, J = 6.7). **ESI-MS** m/z (rel int): (pos) 268.1 ([M+Na]⁺, 100).



(Z)-3-((2S,4S)-2-(2-Hydroxyethyl)-4-methylpyrrolidin-3-ylidene)propan-1-ol (S-15a). Colorless oil (4.1 mg). **TL**C: R_f 0.53 (1:10 MeOH/EtOAc). **1H-NMR** (600 MHz): δ 5.11 (t, 1H, J = 7.1), 4.48 (t, 1H, J = 5.8), 3.71–3.63 (m, 2H), 3.61–3.58 (m, 2H), 3.10 (t, 1H, J = 9.6), 2.96 (t, 1H, J = 8.3), 2.64 (s, 1H), 2.30–2.23 (m, 2H), 1.78 (q, 2H, J = 6.5), 1.06 (d, 3H, J = 6.7). **ESI-MS** m/z (rel int): (pos) 208.2 ([M+Na]⁺, 100).




2-((2S,4S,Z)-3-Benzylidene-4-methylpyrrolidin-2-yl)ethanol (S-15b). Colorless oil (8.1 mg). **TL**C: R_f 0.40 (1:20 MeOH/EtOAc). **1H-NMR** (600 MHz): δ 7.31–7.25 (m, 3H) 7.19–7.14 (m, 2H), 6.43 (s, 1H), 4.93 (d, 1H, J = 9.2), 3.76 (t, 1H, J = 8.6), 3.68–3.54 (m, 2H), 3.05 (t, 1H, J = 6.7), 2.78 (t, 1H, J = 7.5), 1.92–1.90 (m, 1H), 1.79–1.76 (m, 1H), 1.30 (d, 3H, J = 6.5). **ESI-MS** m/z (rel int): (pos) 218.0 ([M+H]⁺, 100).




2-((2S,4S)-4-Methyl-3-methylenepyrrolidin-2-yl)ethanol (S-15d). Colorless oil (7.5 mg).

TLC: R_f 0.33 (1:20 MeOH/EtOAc). **$^1\text{H-NMR}$** (600 MHz): δ 5.10 (d, 1H, J = 11.8), 5.03 (d, 1H, J = 11.8), 4.24 (t, 1H, J = 5.7), 3.90 (t, 1H, J = 6.7), 3.78 (t, 1H, J = 6.6), 3.58 (t, 1H, J = 6.4), 3.30 (bs, 1H), 2.92 (dd, 1H, J = 9.5, 7.1), 2.75 (dd, 1H, J = 7.1, 5.2), 2.01–1.96 (m, 2H), 1.18 (d, 3H, J = 6.7). **ESI-MS** m/z (rel int): (pos) 164.1 ([M+Na]⁺, 100).




(Z)-3-((2S,4S)-1-(tert-Butylsulfonyl)-2-(2-hydroxyethyl)-4-methylpyrrolidin-3-ylidene)propan-1-ol (S-16a). Colorless oil (8.3 mg). **TLC:** R_f 0.53 (1:1 hexanes/EtOAc). **$^1\text{H-NMR}$** (600 MHz): δ 4.89 (t, 1H, J = 7.1), 4.51 (d, 1H, J = 7.6), 4.22 (t, 2H, J = 6.9), 3.72–3.66 (m, 2H), 3.55 (d, 1H, J = 8.8), 2.55–2.49 (m, 1H), 2.41–2.38 (m, 1H), 1.98–1.95 (m, 1H), 1.89–1.85 (m, 2H), 1.76 (t, 1H, J = 6.5), 1.52 (bs, 1H), 1.21 (s, 12H). **ESI-MS** m/z (rel int): (pos) 328.4 ([M+Na]⁺, 100).




2-((2S,4S,Z)-3-Benzylidene-1-(tert-butylsulfonyl)-4-methylpyrrolidin-2-yl)ethanol (S-16b).

Colorless oil (9.2 mg). **TLC:** R_f 0.40 (3:2 hexanes/EtOAc). **$^1\text{H-NMR}$** (600 MHz): δ 7.36–7.31 (m, 2H), 7.28–7.23 (m, 2H), 7.20–7.16 (m, 1H), 6.35 (s, 1H), 5.15 (d, 1H, J = 10.1), 3.97 (dd, 1H, J = 10.1, 7.1), 3.79–3.76 (m, 1H), 3.64–3.61 (m, 1H), 3.11–3.03 (m, 1H), 3.01–2.98 (m, 1H), 2.48 (bs, 1H), 1.88–1.83 (m, 1H), 1.52–1.48 (m, 1H), 1.24 (d, 3H, J = 6.9), 1.18 (s, 9H). **ESI-MS** m/z (rel int): (pos) 360.2 ([M+Na]⁺, 100).




2-((2S,4S)-1-(tert-Butylsulfonyl)-4-methyl-3-methylenepyrrolidin-2-yl)ethanol (S-16d).


Colorless oil (9.1 mg). **TLC:** R_f 0.33 (3:2 hexanes/EtOAc). **$^1\text{H-NMR}$** (600 MHz): δ 7.49.2 (s, 2H), 4.28 (t, 1H, J = 5.5), 3.81–3.69 (bm, 2H), 3.18 (t, 1H, J = 6.7), 3.05 (t, 1H, J = 7.4), 2.79 (s, 1H), 1.92–1.86 (m, 2H), 1.82–1.78 (m, 1H), 1.25 (s, 9H), 1.11 (d, 3H, J = 6.7). **ESI-MS** m/z (rel int): (pos) 284.4 ([M+Na]⁺, 100).




(Z)-3-((2S,4R)-1-((S)-tert-butylsulfinyl)-2-(2-hydroxyethyl)-4-methylpyrrolidin-3-ylidene)propan-1-ol (S-17a). Colorless oil (8.1 mg). TLC: R_f 0.53 (1:2 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 5.21 (t, 1H, J = 7.3), 4.47 (d, 1H, J = 9.3), 3.91 (t, 1H, J = 10.9), 3.71–3.68 (m, 2H), 3.62–3.58 (m, 2H), 2.64–2.61 (m, 1H), 2.51 (dd, 1H, J = 9.0, 11.2), 2.31–2.25 (m, 2H), 2.31–2.25 (m, 2H), 1.08 (s, 9H), 1.02 (d, 3H, J = 6.9). ESI-MS m/z (rel int): (pos) 642.5 ([M+H]⁺, 25); 312.2 ([M+Na]⁺, 100).




2-((2S,4R,Z)-3-Benzylidene-1-((S)-tert-butylsulfinyl)-4-methylpyrrolidin-2-yl)ethanol (S-17b). Colorless oil (8.3 mg). TLC: R_f 0.40 (1:1 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 7.43–7.40 (m, 2H), 7.36 (d, 1H, J = 4.2), 7.23–7.18 (m, 2H), 6.44 (s, 1H), 5.81 (bs, 1H), 4.93 (s, 1H), 3.75–3.73 (m, 1H), 3.71–3.67 (m, 1H), 3.65–3.61 (m, 1H), 3.05 (s, 1H), 2.77 (t, 1H, J = 6.5), 1.95–1.89 (m, 1H), 1.87–1.81 (m, 1H), 1.21 (s, 9H), 1.16 (d, 3H, J = 6.5). ESI-MS m/z (rel int): (pos) 218.2 ([M+H]⁺, 100).




(Z)-3-((2S,4R)-2-(2-Hydroxyethyl)-4-methylpyrrolidin-3-ylidene)propan-1-ol (S-18a). Colorless oil (4.0 mg). TLC: R_f 0.53 (1:10 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 5.21 (t, 1H, J = 7.1), 4.44 (t, 1H, J = 5.8), 3.92 (dt, 1H, J = 9.6, 5.3), 3.71–3.63 (m, 2H), 3.61–3.58 (m, 2H), 2.71 (s, 1H), 2.59 (dd, 1H, J = 8.3, 7.1), 2.30–2.23 (m, 2H), 1.83 (q, 2H, J = 6.5), 1.06 (d, 3H, J = 6.7). ESI-MS m/z (rel int): (pos) 208.2 ([M+Na]⁺, 100).



2-((2S,4R,Z)-3-Benzylidene-4-methylpyrrolidin-2-yl)ethanol (S-18b). Colorless oil (8.0 mg). TLC: R_f 0.40 (1:20 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 7.30–7.25 (m, 3H), 7.20–7.15 (m, 2H), 6.47 (s, 1H), 4.96 (d, 1H, J = 9.2), 4.01 (br, 1H), 3.76 (t, 1H, J = 8.6), 3.64–3.62 (m, 1H), 3.48 (t, 1H, J = 8.2), 3.04 (t, 1H, J = 6.5), 2.93 (t, 1H, J = 7.2), 1.79–1.73 (m, 1H), 1.69–1.62 (m, 1H), 1.39 (d, 3H, J = 6.5). ESI-MS m/z (rel int): (pos) 218.1 ([M+H]⁺, 100).




(Z)-3-((2S,4R)-1-(tert-Butylsulfonyl)-2-(2-hydroxyethyl)-4-methylpyrrolidin-3-ylidene)propan-1-ol (S-19a). Colorless oil (7.3 mg). TLC: R_f 0.53 (1:1 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 5.08 (dt, 1H, J = 2.0, 7.1), 4.49 (t, 1H, J = 7.6), 4.97 (t, 1H, J = 6.9), 3.69–3.62 (m, 2H), 3.60–3.55 (m, 2H), 3.08 (dd, 1H, J = 3.1, 8.8), 3.01 (dd, 1H, J = 3.2, 6.5), 2.98–2.93 (m, 1H), 2.76 (bs, 1H), 2.24–2.19 (m, 1H), 2.15 (bs, 1H), 1.88–1.85 (m, 1H), 1.77–1.72 (m, 1H), 1.61–1.54 (m, 1H), 1.19 (s, 12H). ESI-MS m/z (rel int): (pos) 328.4 ([M+Na]⁺, 100).




2-((2S,4R,Z)-3-Benzylidene-1-(tert-butylsulfonyl)-4-methylpyrrolidin-2-yl)ethanol (S-19b). Colorless oil (8.5 mg). TLC: R_f 0.40 (3:2 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 7.44–7.39 (m, 2H), 7.33–7.28 (m, 2H), 7.22–7.18 (m, 1H), 6.41 (s, 1H), 5.24 (s, 1H), 4.01 (t, 1H, J = 8.0), 3.78–3.65 (m, 1H), 3.10–3.01 (m, 2H), 2.05–1.96 (m, 2H), 1.54–1.51 (m, 1H), 1.36 (d, 3H, J = 6.9), 1.30 (s, 9H). ESI-MS m/z (rel int): (pos) ([M+Na]⁺, 100).


3. EVANS BUTADIENE [4+2+2] CYCLOADDITION PRODUCTS (S-20)



2,2'-(1S,3aS,6Z,9Z)-2-(tert-Butylsulfonyl)-2,3,3a,4,5,8-hexahydro-1H-cycloocta[c]pyrrole-1,9-diyl)diethanol (S-20a). Light yellow oil (4.5 mg). TLC: R_f 0.39 (1:1 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 5.78–5.74 (m, 1H), 5.67–5.61 (m, 1H), 4.82 (s, 1H), 3.79–3.76 (m, 2H), 3.70 (t, 1H, J = 6.8), 3.67–3.58 (m, 2H), 3.36 (dd, 1H, J = 12.5, 6.8), 3.14 (bs, 1H), 2.93 (dd, 1H, J = 7.9, 14.6), 2.53–2.48 (m, 3H), 2.38 (dd, 1H, J = 6.8, 14.7), 2.31–2.26 (m, 3H), 1.83–1.78 (m, 3H), 1.43 (s, 9H). ESI-MS m/z (rel int): (pos) 358.3 ([M+H]⁺, 100).




2-((1*S*,3*aS*,6*Z*,9*Z*)-2-(*tert*-Butylsulfonyl)-9-phenyl-2,3,3*a*,4,5,8-hexahydro-1*H*-cycloocta[*c*]pyrrol-1-yl)ethanol (S-20b).** Light yellow oil (7.2 mg). TLC: R_f 0.36 (1:1 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 7.36–7.31 (m, 3H), 7.8–7.09 (m, 2H), 5.65–5.62 (m, 1H), 5.60–5.56 (m, 1H), 4.91 (s, 1H), 3.50 (s, 1H), 3.44–3.38 (m, 2H), 3.31–3.28 (m, 1H), 2.81 (dd, 1H, *J* = 6.1, 15.2), 2.47–2.41 (m, 1H), 1.881.69 (m, 2H), 1.65–1.58 (m, 3H), 1.42–1.36 (m, 3H), 1.33 (s, 9H). ESI-MS *m/z* (rel int): (pos) 270.2 ([M–SO₂*t*Bu+H]⁺, 15); 390.2 ([M+H]⁺, 100).




2-((1*S*,3*aS*,6*Z*,9*E*)-2-(*tert*-Butylsulfonyl)-2,3,3*a*,4,5,8-hexahydro-1*H*-cycloocta[*c*]pyrrol-1-yl)ethanol (S-20d).** Light yellow oil (7.0 mg). TLC: R_f 0.40 (1:1 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 5.69–5.61 (m, 1H), 5.58–5.49 (m, 1H), 5.38 (s, 1H), 3.65–3.49 (bm, 2H), 3.73–3.70 (m, 2H), 3.43 (d, 1H, *J* = 11.1), 3.24 (dd, 1H, *J* = 6.5, 12.1), 3.19–3.11 (m, 1H), 2.88–2.65 (bm, 2H), 2.40–2.33 (m, 1H), 1.93–1.81 (m, 2H), 1.66–1.61 (m, 1H), 1.55–1.49 (m, 1H), 1.49 (s, 9H). ESI-MS *m/z* (rel int): (pos) 336.2 ([M+Na]⁺, 100).


4. ENYNE METATHESIS PRODUCTS (S-21–23)




3-((*S*)-1-((*S*)-*tert*-Butylsulfinyl)-2-(2-hydroxyethyl)-2,5-dihydro-1*H*-pyrrol-3-yl)but-3-en-1-ol (S-21a). Clear oil (8.8 mg). TLC: R_f 0.46 (1:2 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 5.79 (s, 1H), 5.06 (s, 1H), 5.01 (s, 1H), 4.91 (t, 1H, *J* = 6.8), 4.50 (d, 2H, *J* = 15.7), 3.61–3.55 (m, 3H), 3.52 (d, 1H, *J* = 12.6) 2.51–2.49 (m, 1H), 2.41–2.37 (m, 1H), 2.01–1.95 (m, 1H), 1.92–1.88 (m, 1H), 1.09 (s, 9H). ESI-MS *m/z* (rel int): (pos) 310.4 ([M+Na]⁺, 100).




2-((S)-1-((S)-tert-Butylsulfinyl)-3-(1-phenylvinyl)-2,5-dihydro-1H-pyrrol-2-yl)ethanol (S-21b). Clear oil (8.6 mg). TLC: R_f 0.31 (1:1 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 7.45–7.34 (m, 3H), 7.32–7.28 (m, 2H), 5.49 (s, 1H), 5.26 (s, 1H), 5.24 (s, 1H), 4.99–4.95 (m, 1H), 4.48 (d, 1H, J = 15.2), 4.13 (t, 1H, J = 5.3), 3.85–3.78 (m, 1H), 3.75–3.70 (m, 1H), 3.09 (s, 1H), 2.20–2.13 (m, 1H), 1.86–1.77 (m, 1H), 1.07 (s, 9H). ESI-MS m/z (rel int): (pos) 342.5 ([M+Na]⁺, 100).




2-((S)-1-((S)-tert-Butylsulfinyl)-3-vinyl-2,5-dihydro-1H-pyrrol-2-yl)ethanol (S-21d). Yellow oil (7.8 mg). TLC: R_f 0.28 (1:1 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 6.32 (dd, 1H, J = 17.3, 11.0), 5.71 (s, 1H), 5.20 (d, 1H, J = 17.8), 5.09 (d, 1H, J = 11.0), 4.85 (s, 1H), 4.49 (d, 1H, J = 15.1), 3.72–3.68 (m, 2H), 3.50 (d, 1H, J = 15.3), 1.98–1.89 (m, 2H), 1.12 (s, 9H). ESI-MS m/z (rel int): (pos) 266.3 ([M+Na]⁺, 100).




(S)-3-(2-(2-Hydroxyethyl)-2,5-dihydro-1H-pyrrol-3-yl)but-3-en-1-ol (S-22a). Clear colorless oil (1.2 mg). TLC: R_f 0.46 (1:10 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 5.81 (ddd, 1H, J = 10.0, 7.9, 6.8), 5.25 (d, 1H, J = 11.0), 5.16 (d, 1H, J = 8.4), 4.48 (t, 1H, J = 9.7), 3.99–3.94 (m, 2H), 3.70–3.66 (m, 2H), 3.41 (dd, 1H, J = 10.9, 4.4), 2.15–2.11 (m, 1H), 1.92–1.87 (m, 2H), 1.54–1.47 (m, 2H). ESI-MS m/z (rel int): (pos) 206.8 ([M+Na]⁺, 100).




(S)-2-(3-(1-Phenylvinyl)-2,5-dihydro-1H-pyrrol-2-yl)ethanol (S-22b). Clear yellow oil (1.5 mg). TLC: R_f 0.31 (1:20 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 7.45–7.34 (m, 5H), 5.81 (dd, 1H, J = 7.1, 6.8), 5.30 (d, 1H, J = 14.3), 5.21 (d, 1H, J = 10.6), 4.60 (dd, 1H, J = 8.8, 7.1), 4.04 (dd, 1H, J = 15.2, 7.1), 3.85–3.78 (m, 2H), 3.47 (dd, 1H, J = 14.3, 7.1), 2.20–2.13 (m, 1H), 2.04–2.00 (m, 1H), 1.52 (s, 1H). ESI-MS m/z (rel int): (pos) 216.3 ([M+H]⁺, 100).




(S)-2-(3-Vinyl-2,5-dihydro-1*H*-pyrrol-2-yl)ethanol (S-22d). Clear oil (0.9 mg). TLC: R_f 0.28 (1:20 MeOH/EtOAc). **¹H-NMR** (600 MHz): δ 6.37 (ddd, 1H, J = 17.8, 11.0, 8.0), 5.69 (s, 1H), 5.21 (d, 1H, J = 17.8), 5.17 (d, 1H, J = 11.0), 4.88 (s, 1H), 4.48 (d, 1H, J = 15.9), 3.78–3.74 (m, 1H), 3.73–3.68 (m, 1H), 3.45 (d, 1H, J = 15.9), 2.12–2.05 (m, 1H), 1.78–1.71 (m, 1H). **ESI-MS** m/z (rel int): (pos) 162.3 ([M+Na]⁺, 100).



(S)-3-(1-(*tert*-Butylsulfonyl)-2-(2-hydroxyethyl)-2,5-dihydro-1*H*-pyrrol-3-yl)but-3-en-1-ol (S-23a). Colorless oil (7.7 mg). TLC: R_f 0.46 (1:2 hexanes/EtOAc). **¹H-NMR** (600 MHz): δ 5.65 (t, 1H, J = 7.1), 5.08 (d, 2H, J = 11.0), 4.93 (t, 1H, J = 4.4), 4.49 (d, 1H, J = 8.1), 4.16 (d, 1H, J = 7.8), 3.73–3.69 (m, 1H), 3.68–3.61 (m, 2H), 2.99–2.96 (m, 1H), 2.49–2.47 (m, 1H), 2.05–2.01 (m, 1H), 1.68–1.64 (m, 1H), 1.53–1.47 (m, 1H), 1.03 (s, 9H). **ESI-MS** m/z (rel int): (pos) 326.4 ([M+Na]⁺, 100).




(S)-2-(1-(*tert*-Butylsulfonyl)-3-(1-phenylvinyl)-2,5-dihydro-1*H*-pyrrol-2-yl)ethanol (S-23b). Clear yellow oil (7.6 mg). TLC: R_f 0.31 (1:1 hexanes/EtOAc). **¹H-NMR** (600 MHz): δ 7.45–7.34 (m, 3H), 7.32–7.28 (m, 2H), 5.49 (s, 1H), 5.19 (s, 1H), 5.12 (s, 1H), 4.98 (s, 1H), 4.40 (d, 1H, J = 13.2), 4.07–4.01 (m, 1H), 3.75–3.70 (m, 2H), 3.49 (s, 1H), 2.15–2.08 (m, 2H), 1.25 (s, 9H). **ESI-MS** m/z (rel int): (pos) 358.5 ([M+Na]⁺, 100).




(S)-2-(1-(*tert*-Butylsulfonyl)-3-vinyl-2,5-dihydro-1*H*-pyrrol-2-yl)ethanol (S-23d). Yellow oil (7.0 mg). TLC: R_f 0.28 (1:1 hexanes/EtOAc). **¹H-NMR** (600 MHz): δ 6.41 (dd, 1H, J = 17.8, 11.0), 5.73 (s, 1H), 5.16 (dd, 2H, J = 17.8, 11.3), 5.01 (s, 1H), 4.47 (d, 1H, J = 15.9), 4.01 (d, 1H, J = 12.8), 3.80–3.76 (m, 1H), 3.65–3.61 (m, 1H), 2.05–1.97 (m, 1H), 1.53–1.48 (m, 1H), 1.41 (s, 9H). **ESI-MS** m/z (rel int): (pos) 282.4 ([M+Na]⁺, 100).


5. MALEIMIDE DIELS-ALDER PRODUCTS (S-24)



(3a*R*,6*S*,8*aR*,8*bS*)-7-(*tert*-Butylsulfonyl)-5,6-bis(2-hydroxyethyl)-2-phenyl-3*a*,4,6,7,8,8*a*-hexahydropyrrolo[3,4-*e*]isoindole-1,3(2*H*,8*bH*)-dione (S-24a). Clear oil (8.1 mg). TLC: R_f 0.50 (1:2 hexanes/EtOAc). $^1\text{H-NMR}$ (600 MHz): δ 7.49–7.36 (m, 5H), 5.92 (t, 1H, J = 6.8), 4.51 (d, 1H, J = 12.0), 4.49–4.32 (m, 2H), 4.09 (dd, 1H, J = 7.9, 13.0), 3.98 (t, 1H, J = 10.0), 3.82–3.78 (m, 2H), 3.63–3.59 (m, 1H), 3.40–3.32 (m, 1H), 2.99 (dd, 1H, J = 7.4, 12.5), 2.71–2.63 (m, 1H), 1.75–1.70 (m, 2H), 1.66–1.59 (m, 2H), 1.45 (s, 9H). ESI-MS m/z (rel int): (pos) 499.6 ($[\text{M}+\text{Na}]^+$, 100).




(3a*R*,6*S*,8*aS*,8*bS*)-7-(*tert*-Butylsulfonyl)-6-(2-hydroxyethyl)-2,5-diphenyl-3*a*,4,6,7,8,8*a*-hexahydropyrrolo[3,4-*e*]isoindole-1,3(2*H*,8*bH*)-dione (S-24b). Light yellow oil (5.0 mg). TLC: R_f 0.40 (1:2 hexanes/EtOAc). $^1\text{H-NMR}$ (600 MHz): δ 7.49–7.43 (m, 3H), 7.41–7.38 (m, 4H), 7.36–7.34 (m, 3H), 5.83 (s, 1H), 4.91 (dd, 1H, J = 13.1, 2.1), 4.13 (d, 1H, J = 13.1), 3.74–3.70 (m, 1H), 3.48 (dd, 1H, J = 8.0, 9.1), 3.23–3.21 (m, 1H), 3.14–3.12 (m, 2H), 3.05–3.01 (m, 1H), 2.73–2.68 (m, 1H), 2.53–2.48 (m, 1H), 1.62–1.57 (m, 1H), 1.41 (s, 9H). ESI-MS m/z (rel int): (pos) 531.3 ($[\text{M}+\text{Na}]^+$, 100).




(3a*R*,6*S*,8*aS*,8*bS*)-7-(*tert*-Butylsulfonyl)-6-(2-hydroxyethyl)-2-phenyl-3*a*,4,6,7,8,8*a*-hexahydropyrrolo[3,4-*e*]isoindole-1,3(2*H*,8*bH*)-dione (S-24d). Clear oil (7.5 mg). TLC: R_f 0.32 (1:2 hexanes/EtOAc). $^1\text{H-NMR}$ (600 MHz): δ 7.99 (s, 1H), 7.63–7.67 (m, 2H), 7.50–7.37 (m, 3H), 5.98–5.95 (m, 1H), 5.01 (d, 1H, J = 11.8), 4.52 (d, 1H, J = 12.5), 4.48–4.35 (m, 2H), 3.55–3.49 (m, 2H), 3.29–3.24 (m, 2H), 1.88–1.65 (bm, 2H), 1.64–1.59 (m, 1H), 1.45 (s, 9H). ESI-MS m/z (rel int): (pos) 433.4 ($[\text{M}+\text{H}]^+$, 100).


6. DMAD DIELS–ALDER PRODUCTS (S-25)



(S)-Dimethyl 2-(tert-butylsulfonyl)-1,7-bis(2-hydroxyethyl)isoindoline-4,5-dicarboxylate (S-25a). Colorless oil (4.2 mg). TLC: R_f 0.43 (1:3 hexanes/EtOAc). $^1\text{H-NMR}$ (600 MHz): δ 7.63 (s, 1H), 5.62 (s, 1H), 5.03 (d, 1H, $J = 16.0$), 4.51 (d, 1H, $J = 16.0$), 3.88 (s, 6H), 3.85–3.81 (m, 2H), 3.65–3.61 (m, 2H), 2.86–2.79 (m, 2H), 2.11–1.99 (m, 2H), 1.31 (s, 9H). ESI-MS m/z (rel int): (pos) 466.3 [$\text{M}+\text{Na}^+$, 100].




(S)-Dimethyl 2-(tert-butylsulfonyl)-1-(2-hydroxyethyl)-7-phenylisoindoline-4,5-dicarboxylate (S-25b). Colorless oil (4.8 mg). TLC: R_f 0.38 (1:2 hexanes/EtOAc). $^1\text{H-NMR}$ (600 MHz): δ 7.61 (s, 1H), 7.45–7.37 (m, 5H), 5.89 (s, 1H), 5.12 (d, 1H, $J = 16.4$), 4.53 (d, 1H, $J = 15.8$), 3.91 (s, 6H), 3.47–3.43 (m, 1H), 3.39–3.35 (m, 1H), 1.80–1.74 (m, 1H), 1.57–1.51 (m, 1H), 1.38 (s, 9H). ESI-MS m/z (rel int): (pos) 476.5 [$\text{M}+\text{H}^+$, 100].




(S)-Dimethyl 2-(tert-butylsulfonyl)-1-(2-hydroxyethyl)isoindoline-4,5-dicarboxylate (S-25d). Colorless oil (8.6 mg). TLC: R_f 0.34 (1:2 hexanes/EtOAc). $^1\text{H-NMR}$ (600 MHz): δ 7.74 (d, 1H, $J = 4$), 7.42 (d, 1H, $J = 3.9$), 5.49 (s, 1H), 5.08 (d, 1H, $J = 15.1$), 4.64 (d, 1H, $J = 15.2$), 3.91 (s, 6H), 3.69–3.62 (m, 1H), 2.40 (s, 1H), 2.05–1.98 (m, 1H), 1.84–1.79 (m, 1H), 1.35 (s, 9H). ESI-MS m/z (rel int): (pos) 422.5 ($[\text{M}+\text{Na}]^+$, 100).

7. ALKYNE [2+2+2] CYCLOTIMERIZATION PRODUCTS (S-30–35)




2,2'-(S)-2-((S)-tert-Butylsulfinyl)-5-(hydroxymethyl)isoindoline-1,7-diyl diethanol (S-30a). Light brown oil (8.9 mg). TLC: R_f 0.31 (1:3 hexanes/EtOAc). $^1\text{H-NMR}$ (600 MHz): δ 7.09 (s,


1H), 7.05 (s, 1H), 5.30 (d, 1H, $J = 7.9$), 4.93 (d, 1H, $J = 14.3$), 4.57 (s, 2H), 3.94 (d, 1H, $J = 14.3$), 3.84 (t, 2H, $J = 7.0$), 3.80–3.72 (m, 1H), 3.63–3.59 (m, 1H), 2.85 (dt, 2H, $J = 12.5, 6.0$), 2.15–2.07 (m, 1H), 1.92–1.84 (m, 1H), 1.15 (s, 9H). **ESI-MS** m/z (rel int): (pos) 364.5 ([M+Na]⁺, 100).




2-((S)-2-((S)-tert-Butylsulfinyl)-5-(hydroxymethyl)isoindolin-1-yl)ethanol (S-30b). Brown oil (8.3 mg). **TLC:** R_f 0.22 (1:3 hexanes/EtOAc). **¹H-NMR** (600 MHz): δ 7.40–7.34 (m, 5H), 7.18 (s, 1H), 7.16 (s, 1H), 5.58 (d, 1H, $J = 8.0$), 5.08 (d, 1H, $J = 14.3$), 4.69 (d, 2H, $J = 5.7$), 3.99 (dd, 1H, $J = 14.0, 4.0$), 3.61 (ddd, 1H, $J = 10.0, 8.5, 6.2$), 3.38–3.34 (m, 1H), 1.68–1.63 (m, 1H), 1.44–1.38 (m, 1H), 0.91 (s, 9H). **ESI-MS** m/z (rel int): (pos) 374.4 ([M+H]⁺, 100).



2-((S)-2-((S)-tert-Butylsulfinyl)-5-(hydroxymethyl)isoindolin-1-yl)ethanol (S-30d). Light brown oil (7.8 mg). **TLC:** R_f 0.15 (1:2 hexanes/EtOAc). **¹H-NMR** (600 MHz): δ 7.18 (s, 1H), 7.05 (d, 1H, $J = 7.0$), 6.99 (d, 1H, $J = 7.0$), 5.03 (t, 1H, $J = 6.0$), 4.53 (s, 2H), 3.96 (d, 1H, $J = 14.9$), 3.72 (ddd, 1H, $J = 10.6, 7.5, 5.5$), 3.63 (dt, 1H, $J = 10.4, 6.6$), 2.77 (s, 1H), 1.99–1.93 (m, 2H), 1.26 (t, 1H, $J = 7.1$), 1.21 (s, 9H). **ESI-MS** m/z (rel int): (pos) 320.4 ([M+Na]⁺, 100).




(S)-2,2'-(5-(Hydroxymethyl)isoindoline-1,7-diyl)diethanol (S-31a). Light brown oil (1.1 mg). **TLC:** R_f 0.31 (1:3 hexanes/EtOAc). **¹H-NMR** (600 MHz): δ 7.04 (s, 1H), 7.02 (s, 1H), 5.52 (d, 1H, $J = 14.5$), 4.61 (d, 2H, $J = 7.1$), 3.96 (d, 1H, $J = 14.6$), 3.86 (t, 1H, $J = 7.0$), 3.85–3.79 (m, 1H), 3.69–3.64 (m, 1H), 2.85 (dt, 2H, $J = 12.6, 6.5$), 2.15–2.07 (m, 1H), 1.88–1.84 (m, 1H), 1.78–1.76 (m, 2H). **ESI-MS** m/z (rel int): (pos) 238.2 ([M+H]⁺, 100).




(S)-2-(5-(Hydroxymethyl)-7-phenylisoindolin-1-yl)ethanol (S-31b). Light brown oil (7.9 mg). **TLC:** R_f 0.22 (1:2 hexanes/EtOAc). **¹H-NMR** (500 MHz): δ 7.42 (s, 1H), 7.34–7.26 (m, 6H),


5.71 (t, 1H, $J = 7.1$), 5.01 (d, 2H, $J = 14.1$), 4.39 (d, 2H, $J = 14.0$), 4.38–4.34 (m, 2H), 2.20–2.13 (m, 2H). **ESI-MS** m/z (rel int): (pos) 292.2 ($[M+Na]^+$, 100).




(S)-2-(5-(Hydroxymethyl)isoindolin-1-yl)ethanol (S-31d). Light brown oil (2.1 mg). **TLC:** R_f 0.15 (1:2 hexanes/EtOAc). **¹H-NMR** (600 MHz): δ 7.18–7.14 (m, 2H), 7.09 (d, 1H, $J = 7.2$), 5.18 (d, 1H, $J = 6.0$), 4.95 (d, 1H, $J = 14.0$), 4.55–4.51 (m, 3H), 3.96 (d, 1H, $J = 15.6$), 3.81 (ddd, 1H, $J = 10.7, 7.6, 5.6$), 3.72 (ddd, 1H, $J = 10.7, 7.6, 5.6$), 2.07–1.95 (m, 1H). **ESI-MS** m/z (rel int): (pos) 270.3 ($[M+H]^+$, 100).



(S)-2,2'-(2-(tert-Butylsulfonyl)-5-(hydroxymethyl)isoindoline-1,7-diyl)diethanol (S-32a). Brown oil (8.8 mg). **TLC:** R_f 0.31 (1:2 hexanes/EtOAc). **¹H-NMR** (600 MHz): δ 6.99 (s, 1H), 6.93 (s, 1H), 5.17 (d, 1H, $J = 7.8$), 4.83 (d, 1H, $J = 12.5$), 4.51 (s, 2H), 3.91 (d, 1H, $J = 14.6$), 3.79 (t, 2H, $J = 7.3$), 3.78–3.73 (m, 1H), 3.65–3.62 (m, 1H), 2.83 (dt, 2H, $J = 12.6, 6.5$), 2.07–1.99 (m, 1H), 1.78–1.71 (m, 1H), 1.08 (s, 9H). **ESI-MS** m/z (rel int): (pos) 380.5 ($[M+Na]^+$, 100).




(S)-2-(2-(tert-Butylsulfonyl)-5-(hydroxymethyl)-7-phenylisoindolin-1-yl)ethanol (S-32b). Brown oil (5.0 mg). **TLC:** R_f 0.22 (1:1 hexanes/EtOAc). **¹H-NMR** (600 MHz): δ 7.38–7.32 (m, 5H), 7.18 (s, 1H), 7.14 (s, 1H), 5.58 (d, 1H, $J = 8.0$), 5.08 (d, 1H, $J = 14.3$), 4.71 (d, 2H, $J = 6.2$), 3.99 (d, 1H, $J = 14.0$), 3.63 (ddd, 1H, $J = 10.0, 8.5, 6.2$), 3.38–3.34 (m, 1H), 1.68 (t, 1H, $J = 6.0$), 1.44–1.38 (m, 1H), 1.19 (s, 9H). **ESI-MS** m/z (rel int): (pos) 390.3 ($[M+H]^+$, 100).




(S)-2-(2-(tert-Butylsulfonyl)-5-(hydroxymethyl)isoindolin-1-yl)ethanol (S-32d). Light brown oil (7.1 mg). **TLC:** R_f 0.15 (1:1 hexanes/EtOAc). **¹H-NMR** (500 MHz): δ 7.01 (d, 1H, $J = 7.0$), 6.94 (d, 1H, $J = 7.0$), 6.89 (s, 1H), 5.01 (t, 1H, $J = 6.0$), 4.78 (d, 1H, $J = 12.0$), 4.46 (s, 2H), 3.79


(d, 1H, $J = 12.5$), 3.64 (ddd, 1H, $J = 10.1, 7.3, 5.6$), 3.56 (dt, 1H, $J = 10.0, 6.9$), 1.91–1.86 (m, 2H), 1.08 (s, 9H). **ESI-MS** m/z (rel int): (pos) 336.4 ([M+Na]⁺, 100).




2-((S)-2-((S)-tert-Butylsulfinyl)-6-(hydroxymethyl)-7-phenylisoindolin-1-yl)ethanol (S-33b). Light brown oil (4.9 mg). TLC: R_f 0.22 (4:6 hexanes/EtOAc). **¹H-NMR** (600 MHz): δ 7.49–7.41 (m, 5H), 7.19 (t, 2H, $J = 4.0$), 5.58 (d, 1H, $J = 8.0$), 5.12 (d, 1H, $J = 14.3$), 4.71 (d, 2H, $J = 8.8$), 4.55 (dd, 1H, $J = 8.5, 6.2$), 4.04 (d, 1H, $J = 14.0$), 3.38–3.34 (m, 1H), 3.28 (dd, 1H, $J = 8.5, 6.2$), 1.99 (s, 1H), 1.80 (s, 1H), 1.68–1.63 (m, 1H), 1.44–1.38 (m, 1H), 1.20 (s, 9H). **ESI-MS** m/z (rel int): (pos) 396.5 ([M+Na]⁺, 100).



2-((S)-2-((S)-tert-Butylsulfinyl)-6-(hydroxymethyl)isoindolin-1-yl)ethanol (S-33d). Clear oil (7.2 mg). TLC: R_f 0.15 (1:2 hexanes/EtOAc). **¹H-NMR** (600 MHz): δ 7.20 (d, 1H, $J = 7.0$), 7.16 (d, 1H, $J = 7.0$), 7.09 (s, 1H), 5.16 (t, 1H, $J = 6.0$), 5.01 (d, 1H, $J = 14.0$), 4.62 (s, 2H), 3.98 (d, 1H, $J = 14.9$), 3.81 (ddd, 1H, $J = 10.6, 7.9, 5.7$), 3.71 (dt, 1H, $J = 10.2, 6.6$), 2.71 (s, 1H), 2.07–2.01 (m, 2H), 1.56 (s, 1H), 1.19 (s, 9H). **ESI-MS** m/z (rel int): (pos) 320.4 ([M+Na]⁺, 100).




(S)-2-(6-Hydroxymethyl)-7-phenylisoindolin-1-yl)ethanol (S-34b). Clear oil (3.5 mg). TLC: R_f 0.22 (1:2 hexanes/EtOAc). **¹H-NMR** (600 MHz): δ 7.42–7.37 (m, 6H), 7.18 (d, 1H, $J = 7.1$), 5.21 (dd, 1H, $J = 8.0, 6.4$), 4.88 (d, 1H, $J = 14.3$), 4.62 (d, 2H, $J = 3.9$), 3.92 (d, 1H, $J = 14.0$), 3.79 (ddd, 1H, $J = 10.0, 8.5, 6.2$), 3.68–3.64 (m, 1H), 2.11–2.08 (m, 1H), 1.83–1.81 (m, 1H). **ESI-MS** m/z (rel int): (pos) 269.6 ([M+Na]⁺, 100).




(S)-2-(6-Hydroxymethyl)isoindolin-1-yl)ethanol (S-34d). Light brown oil (1.0 mg). TLC: R_f 0.15 (1:2 hexanes/EtOAc). **¹H-NMR** (600 MHz): δ 7.21 (d, 1H, $J = 7.2$), 7.09 (d, 1H, $J =$

7.2), 7.11 (s, 1H), 5.18 (t, 1H, $J = 6.0$), 4.98 (d, 1H, $J = 14.0$), 4.55–4.51 (m, 3H), 3.96 (d, 1H, $J = 15.6$), 3.81 (ddd, 1H, $J = 10.7, 7.6, 5.6$), 3.72 (ddd, 1H, $J = 10.7, 7.6, 5.6$), 2.07–1.95 (m, 2H), 1.26 (tt, 1H, $J = 7.1, 6.2$). **ESI-MS** m/z (rel int): (pos) 270.3 ([M+H]⁺, 100).




(S)-2-(2-(tert-Butylsulfonyl)-6-(hydroxymethyl)isoindolin-1-yl)ethanol (S-35d). Light brown oil (7.3 mg). TLC: R_f 0.15 (1:1 hexanes/EtOAc). **¹H-NMR** (600 MHz): δ 7.08 (s, 2H), 6.99 (d, 1H, $J = 7.2$), 5.08 (t, 1H, $J = 6.2$), 4.93 (d, 1H, $J = 14.0$), 4.52 (d, 2H), 3.90 (dd, 1H, $J = 14.9, 6.7$), 3.80 (ddd, 1H, $J = 10.7, 7.6, 5.6$), 3.73 (dt, 1H, $J = 10.4, 6.6$), 1.96–1.83 (m, 2H), 1.26 (t, 1H, $J = 7.1$), 1.08 (s, 9H). **ESI-MS** m/z (rel int): (pos) 336.4 ([M+Na]⁺, 100).


8. ISOCYANATE [2+2+2] CYCLOTIMERIZATION PRODUCTS (S-36–41)




(S)-5-Benzyl-2-((S)-tert-butylsulfinyl)-3,4-bis(2-hydroxyethyl)-2,3-dihydro-1H-pyrrolo-[3,4-c]pyridin-6(5H)-one (S-36a). Clear brown oil (7.5 mg). TLC: R_f 0.44 (1:5 MeOH/EtOAc). **¹H-NMR** (600 MHz): δ 7.48–7.45 (m, 1H), 7.39–7.35 (m, 2H), 7.30–7.22 (m, 2H), 6.39 (s, 1H), 5.66 (bs, 1H), 5.35 (bs, 1H), 5.03 (dd, 1H, $J = 8.0, 2.8$), 4.82 (d, 1H, $J = 16.0$), 3.81–3.78 (m, 3H), 3.69–3.64 (m, 1H), 2.81–2.73 (m, 2H), 1.91–1.88 (m, 1H), 1.88–1.84 (m, 2H), 1.38–1.34 (m, 2H), 1.10 (s, 9H). **ESI-MS** m/z (rel int): (pos) 441.6 ([M+Na]⁺, 100).




(S)-5-Benzyl-2-((S)-tert-butylsulfinyl)-3-(2-hydroxyethyl)-4-phenyl-2,3-dihydro-1H-pyrrolo-[3,4-c]pyridin-6(5H)-one (S-36b). Light brown oil (4.3 mg). TLC: R_f 0.19 (1:10 MeOH/EtOAc). **¹H-NMR** (600 MHz): δ 7.49–7.47 (m, 2H), 7.41–7.38 (m, 4H), 7.36–7.32 (m, 4H), 6.55 (s, 1H), 5.71 (s, 1H), 4.91 (dd, 2H, $J = 16.3, 8.2$), 4.82 (d, 1H, $J = 7.6$), 3.83 (d, 1H, $J = 16.0$), 3.58–3.54 (m, 1H), 3.47–3.41 (m, 1H), 1.52–1.49 (m, 1H), 1.35–1.25 (m, 2H), 0.91 (s, 9H). **ESI-MS** m/z (rel int): (pos) 473.3 ([M+Na]⁺, 100).




(S)-5-Benzyl-2-((S)-tert-butylsulfinyl)-3-(2-hydroxyethyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6(5H)-one (S-36d). Light brown oil (8.1 mg). TLC: R_f 0.18 (1:10 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 7.45–7.40 (m, 2H), 7.39–7.35 (m, 3H), 7.19 (s, 1H), 6.41 (s, 1H), 5.16 (d, 1H, J = 7.6), 4.78 (d, 2H, J = 14.3), 3.82 (dd, 2H, J = 16.0, 1.4), 3.79–3.73 (m, 2H), 1.89–1.86 (m, 1H), 1.82–1.78 (m, 1H), 1.11 (s, 9H). ESI-MS m/z (rel int): (pos) 397.5 ([M+Na]⁺, 100).




(S)-5-Benzyl-3,4-bis(2-hydroxyethyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6(5H)-one (S-37a). Light brown oil (4.9 mg). TLC: R_f 0.44 (1:3 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 7.32–7.25 (m, 5H), 6.37 (s, 1H), 5.50 (bs, 1H), 5.40–5.32 (bm, 2H), 4.61 (d, 1H, J = 8.0), 4.40–4.37 (m, 2H), 4.28 (d, 1H, J = 12.0), 3.76–3.72 (m, 2H), 3.63–3.56 (m, 2H), 2.81–2.73 (m, 2H), 2.06–2.00 (m, 1H), 1.87–1.80 (m, 1H). ESI-MS m/z (rel int): (pos) 315.3 ([M+H]⁺, 100).




(S)-5-Benzyl-3-(2-hydroxyethyl)-4-phenyl-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6(5H)-one (S-37b). Clear oil (7.9 mg). TLC: R_f 0.19 (1:5 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 7.66–7.62 (m, 5H), 7.45–7.39 (m, 2H), 7.37–7.33 (m, 3H), 6.48 (s, 1H), 5.41–5.23 (m, 2H), 5.18 (t, 1H, J = 6.7), 4.78 (d, 2H, J = 15.3), 3.85–3.81 (m, 1H), 3.79–3.73 (m, 1H), 1.94–1.88 (m, 1H), 1.81–1.75 (m, 1H). ESI-MS m/z (rel int): (pos) 369.4 ([M+Na]⁺, 100).




(S)-5-Benzyl-3-(2-hydroxyethyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6(5H)-one (S-37d). Light brown oil (3.5 mg). TLC: R_f 0.18 (1:5 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 7.39–7.35 (m, 5H), 7.18 (s, 1H), 6.48 (s, 1H), 5.25 (s, 1H), 5.16 (dd, 1H, J = 12.5, 6.3), 4.53 (d, 1H, J = 14.6), 4.48 (d, 2H, J = 1.4), 4.40 (d, 1H, J = 8.8), 3.72–3.67 (m, 2H), 2.00–1.94 (m, 1H), 1.73–1.66 (m, 1H). ESI-MS m/z (rel int): (pos) 293.1 ([M+Na]⁺, 100).




(S)-5-Benzyl-2-(*tert*-butylsulfonyl)-3,4-bis(2-hydroxyethyl)-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6(5*H*)-one (S-38a). Brown oil (7.8 mg). TLC: R_f 0.44 (1:6 MeOH/EtOAc). ¹H-NMR (500 MHz): δ 7.39–7.22 (m, 5H), 6.39 (s, 1H), 5.61 (bs, 1H), 5.42 (bs, 1H), 5.03 (dd, 1H, *J* = 2.4, 6.5), 4.84 (d, 1H, *J* = 4.5), 4.80 (d, 2H, *J* = 16.3), 3.85–3.76 (m, 3H), 3.68 (ddd, 2H, *J* = 10.3, 6.0, 4.1), 2.79–2.65 (m, 2H), 1.93–1.88 (m, 1H), 1.87–1.80 (m, 1H), 1.16 (s, 9H). ESI-MS *m/z* (rel int): (pos) 457.6 ([M+Na]⁺, 100).




(S)-5-Benzyl-2-(*tert*-butylsulfonyl)-3-(2-hydroxyethyl)-4-phenyl-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6(5*H*)-one (S-38b). Light brown oil (3.9 mg). TLC: R_f 0.19 (1:10 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 7.45–7.41 (m, 10H), 6.55 (d, 1H, *J* = 5.5), 5.26–5.20 (m, 1H), 4.93 (dd, 1H, *J* = 7.6, 3.1), 4.53 (t, 1H, *J* = 8.2), 4.40 (s, 2H), 3.61–3.58 (m, 2H), 1.74–1.70 (m, 2H), 1.52 (s, 9H). ESI-MS *m/z* (rel int): (pos) 489.3 ([M+Na]⁺, 100).




(S)-5-Benzyl-2-(*tert*-butylsulfonyl)-3-(2-hydroxyethyl)-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6(5*H*)-one (S-38d). Light brown oil (3.1 mg). TLC: R_f 0.18 (1:10 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 7.41–7.35 (m, 5H), 7.19 (s, 1H), 6.42 (s, 1H), 5.12 (d, 1H, *J* = 14.6), 4.99 (t, 1H, *J* = 6.3), 4.93 (t, 1H, *J* = 10.7), 4.71 (dd, 1H, *J* = 16.0, 1.4), 3.81–3.78 (m, 2H), 3.69–3.64 (m, 1H), 1.99–1.84 (m, 1H), 1.69–1.66 (m, 1H), 1.17 (s, 9H). ESI-MS *m/z* (rel int): (pos) 413.4 ([M+Na]⁺, 100).



(S)-5-Benzyl-2-((S)-tert-butylsulfinyl)-1-(2-hydroxyethyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6(5H)-one (S-39d). Brown oil (8.5 mg). TLC: R_f 0.18 (1:10 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 7.45–7.41 (m, 2H), 7.38–7.32 (m, 3H), 6.94 (s, 1H), 6.51 (s, 1H), 4.91–4.88 (m, 3H), 4.81 (t, 1H, J = 6.3), 4.82 (dd, 1H, J = 15.2, 1.4), 3.58–3.54 (m, 1H), 3.44–3.40 (m, 1H), 1.32–1.25 (m, 2H), 0.93 (s, 9H). ESI-MS m/z (rel int): (pos) 397.5 ([M+H]⁺, 100).




(S)-5-Benzyl-1-(2-hydroxyethyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6(5H)-one (S-40d). Light brown oil (4.1 mg). TLC: R_f 0.17 (1:5 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 7.39–7.35 (m, 5H), 7.18 (s, 1H), 6.59 (s, 1H), 5.21 (s, 1H), 5.03 (dd, 1H, J = 12.5, 6.3), 4.71 (d, 1H, J = 14.6), 4.48–4.40 (m, 3H), 3.41–3.38 (m, 1H), 3.23–3.18 (m, 1H), 2.90 (s, 1H), 1.49–1.43 (m, 1H), 1.25–1.21 (m, 1H). ESI-MS m/z (rel int): (pos) 293.1 ([M+Na]⁺, 100).




(S)-5-Benzyl-2-(tert-butylsulfonyl)-1-(2-hydroxyethyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6(5H)-one (S-41d). Light brown oil (2.9 mg). TLC: R_f 0.16 (1:10 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 7.38–7.32 (m, 5H), 7.07 (d, 1H, J = 14.0), 6.42 (s, 1H), 5.12–5.08 (m, 3H), 4.99 (t, 1H, J = 6.3), 4.93 (t, 1H, J = 8.8), 4.71 (dd, 1H, J = 16.0, 1.4), 3.78–3.72 (m, 2H), 3.69–3.64 (m, 1H), 1.99–1.84 (m, 1H), 1.69–1.66 (m, 1H), 1.17 (s, 9H). ESI-MS m/z (rel int): (pos) 413.4 ([M+Na]⁺, 100).

9. NITRILE [2+2+2] CYCLOTIMERIZATION PRODUCTS (S-42–44)




(S)-Ethyl 2-((S)-tert-butylsulfinyl)-3,4-bis(2-hydroxyethyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-6-carboxylate (S-42a). Light brown oil (7.4 mg). TLC: R_f 0.37 (1:6 hexanes/EtOAc).


¹H-NMR (600 MHz): δ 7.79 (s, 1H), 5.38 (d, 1H, J = 8.2), 5.03 (d, 1H, J = 16.4), 4.40 (q, 2H, J = 10.6), 4.22 (dt, 1H, J = 9.8, 6.4), 4.12–4.08 (m, 1H), 3.97 (d, 1H, J = 15.2), 3.82–3.78 (m, 1H), 3.72 (ddd, 1H, J = 10.2, 6.2, 4.4), 3.12–3.08 (m, 2H), 2.24–2.20 (m, 1H), 1.80 (ddd, 1H, J = 18.9, 8.8, 4.4), 1.43 (t, 3H, J = 7.1), 1.12 (s, 9H). **ESI-MS** m/z (rel int): (pos) 407.5 ([M+Na]⁺, 100).




(S)-Ethyl 2-((S)-tert-butylsulfinyl)-3-(2-hydroxyethyl)-4-phenyl-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-6-carboxylate (S-42b). Clear oil (4.1 mg). TLC: R_f 0.20 (1:3 hexanes/EtOAc). **¹H-NMR** (600 MHz): δ 7.93 (s, 1H), 7.44–7.35 (m, 5H), 5.80 (d, 1H, J = 7.9), 5.18 (d, 1H, J = 15.7), 4.55–4.47 (m, 1H), 4.47–4.39 (m, 1H), 3.99 (d, 1H, J = 12.6), 3.66 (td, 1H, J = 9.5, 5.0), 3.48–3.40 (m, 1H), 1.72–1.65 (m, 1H), 1.61–1.54 (m, 1H), 1.43 (t, 3H, J = 7.1), 0.99 (s, 9H). **ESI-MS** m/z (rel int): (pos) 417.2 ([M+H]⁺, 100).




(S)-Ethyl 2-((S)-tert-butylsulfinyl)-3-(2-hydroxyethyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-6-carboxylate (S-42d). Clear oil (4.6 mg). TLC: R_f 0.12 (1:3 hexanes/EtOAc). **¹H-NMR** (600 MHz): δ 8.62 (s, 1H), 8.00 (s, 1H), 5.33 (t, 1H, J = 6.0), 5.09 (d, 1H, J = 15.6), 4.48 (q, 2H, J = 7.5), 3.99 (d, 1H, J = 15.6), 3.83–3.76 (m, 2H), 2.11–2.01 (m, 1H), 1.96–1.87 (m, 1H), 1.44 (t, 3H, J = 7.1), 1.07 (s, 9H). **ESI-MS** m/z (rel int): (pos) 340.1 ([M+H]⁺, 100).




(S)-Ethyl 3,4-bis(2-hydroxyethyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-6-carboxylate (S-43a). Clear oil (3.5 mg). TLC: R_f 0.37 (1:6 MeOH/EtOAc). **¹H-NMR** (600 MHz): δ 7.88 (s, 1H), 5.39 (s, 1H), 5.07 (d, 1H, J = 16.8), 4.40 (qq, 2H, J = 10.8, 7.1), 4.18 (dt, 1H, J = 9.8, 6.4), 4.08 (dt, 1H, J = 9.8, 6.1), 3.75–3.68 (m, 1H), 3.65–3.62 (m, 1H), 3.08 (dd, 1H, J = 13.8, 6.1), 2.91–2.88 (m, 2H), 2.06–1.98 (m, 2H), 1.41 (t, 3H, J = 7.1). **ESI-MS** m/z (rel int): (pos) 281.3 ([M+H]⁺, 100).




(S)-Ethyl 3-(2-hydroxyethyl)-4-phenyl-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-6-carboxylate (S-43b). Clear oil (2.6 mg). TLC: R_f 0.20 (1:10 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 7.93 (s, 1H), 7.44–7.35 (m, 5H), 5.41 (s, 1H), 5.12 (d, 1H, J = 15.7), 5.07 (d, 1H, J = 15.7), 4.48–4.44 (m, 2H), 3.99 (t, 1H, J = 10.6), 3.78–3.72 (m, 2H), 2.04–1.98 (m, 1H), 1.43 (t, 3H, J = 7.1). ESI-MS m/z (rel int): (pos) 313.2 ([M+H]⁺, 100).




(S)-Ethyl 3-(2-hydroxyethyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-6-carboxylate (S-43d). Clear oil (7.1 mg). TLC: R_f 0.12 (1:10 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 8.73 (s, 1H), 8.06 (s, 1H), 5.33 (bt, 1H, J = 6.0), 5.06 (d, 1H, J = 12.4), 4.66 (d, 1H, J = 12.8), 4.50 (q, 2H, J = 7.5), 3.97–3.93 (m, 1H), 3.79–3.74 (m, 1H), 2.08–2.01 (m, 2H), 1.49 (t, 3H, J = 7.2). ESI-MS m/z (rel int): (pos) 259.3 ([M+Na]⁺, 100).



(S)-Ethyl 2-(tert-butylsulfonyl)-3,4-bis(2-hydroxyethyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-6-carboxylate (S-44a). Brown oil (8.0 mg). TLC: R_f 0.37 (1:3 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 7.81 (s, 1H), 5.40 (d, 1H, J = 8.5), 5.01 (d, 1H, J = 15.3), 4.48 (q, 2H, J = 10.5, 7.1), 4.21 (dt, 1H, J = 9.8, 6.3), 4.05 (dt, 1H, J = 9.8, 6.5), 3.97 (d, 1H, J = 13.9), 3.82–3.78 (m, 1H), 3.73–3.68 (m, 2H), 3.12–3.06 (m, 2H), 2.31–2.24 (m, 1H), 1.48 (t, 3H, J = 7.3), 1.16 (s, 9H). ESI-MS m/z (rel int): (pos) 423.5 ([M+Na]⁺, 100).




(S)-Ethyl 2-(tert-butylsulfonyl)-3-(2-hydroxyethyl)-4-phenyl-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-6-carboxylate (S-44b). Clear oil (7.5 mg). TLC: R_f 0.20 (1:2 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 7.91 (s, 1H), 7.43–7.39 (m, 5H), 5.80 (d, 1H, J = 7.7), 5.20 (d, 1H, J = 15.2), 4.51–4.48 (m, 1H), 4.42–4.38 (m, 1H), 4.00 (d, 1H, J = 12.6), 3.68 (td, 1H, J = 9.5, 5.3), 3.47–3.41 (m, 1H), 1.79–1.72 (m, 1H), 1.68–1.63 (m, 1H), 1.46 (t, 3H, J = 7.1), 1.25 (s, 9H). ESI-MS m/z (rel int): (pos) 455.5 ([M+Na]⁺, 100).




(S)-Ethyl 2-(tert-butylsulfonyl)-3-(2-hydroxyethyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-6-carboxylate (S-44d). Clear oil (3.1 mg). TLC: R_f 0.11 (1:2 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 8.66 (s, 1H), 8.02 (s, 1H), 5.58 (d, 1H, J = 6.0), 5.03 (d, 1H, J = 15.6), 4.59 (t, 1H, J = 12.5), 4.48 (q, 2H, J = 7.5), 3.87 (t, 1H, J = 6.4), 3.63–3.61 (m, 1H), 2.11–2.01 (m, 1H), 1.96–1.87 (m, 1H), 1.44 (t, 3H, J = 7.1), 1.41 (s, 9H). ESI-MS m/z (rel int): (pos) 357.3 ([M+H]⁺, 100).


10. SAITO [3+2+2] CYCLOADDITION PRODUCTS (S-45–50)




(E)-2-((S)-2-((S)-tert-Butylsulfinyl)-1,8-bis(2-hydroxyethyl)-2,3,6,7-tetrahydrocyclohepta[c]-pyrrol-5(1H)-ylidene)-N-methoxy-N-methylacetamide (S-45a). Yellow oil (1.7 mg). TLC: R_f 0.44 (1:4 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 6.28 (s, 1H), 5.96 (s, 1H), 4.68–4.64 (m, 1H), 4.59 (dt, 1H, J = 12.5, 5.5), 3.94 (d, 1H, J = 16.0), 3.69 (s, 3H), 3.61–3.56 (m, 2H), 3.47–3.41 (m, 2H), 3.21 (s, 3H), 2.60 (t, 1H, J = 8.8), 2.49–2.42 (m, 1H), 1.65–1.58 (m, 1H), 1.52–1.47 (m, 2H), 1.22–1.20 (m, 3H), 0.93 (s, 9H). ESI-MS m/z (rel int): (pos) 449.4 ([M+Na]⁺, 100).




(E)-2-((S)-2-((S)-tert-Butylsulfinyl)-1-(2-hydroxyethyl)-8-phenyl-2,3,6,7-tetrahydrocyclohepta[c]pyrrol-5(1H)-ylidene)-N-methoxy-N-methylacetamide (S-45b). Light red oil (5.1 mg). TLC: R_f 0.25 (1:3 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 7.63 (s, 1H), 7.34–7.27 (m, 5H), 5.73 (s, 1H), 4.66 (dd, 1H, J = 9.0, 4.2), 4.51 (dd, 1H, J = 10.2, 7.1), 3.69–3.65 (m, 4H), 3.58–3.54 (m, 1H), 3.45–3.41 (m, 1H), 3.23 (s, 3H), 2.64–2.60 (m, 2H), 1.63–1.58 (m, 1H), 1.53–1.49 (m, 2H), 0.91 (s, 9H). ESI-MS m/z (rel int): (pos) 459.2 ([M+H]⁺, 100).




(E)-2-((S)-2-((S)-tert-Butylsulfinyl)-1-(2-hydroxyethyl)-2,3,6,7-tetrahydrocyclohepta[c]pyrrol-5(1H)-ylidene)-N-methoxy-N-methylacetamide (S-45d). Light yellow oil (4.9 mg). TLC: R_f 0.41 (1:3 hexanes/EtOAc). ¹H-NMR (600 MHz): δ 6.21 (s, 1H), 6.02 (s, 1H), 5.83 (d, 1H, J = 16.0), 4.62 (dd, 1H, J = 8.0, 3.5), 4.48 (d, 1H, J = 16.9), 3.83 (dd, 1H, J = 15.2, 6.4), 3.75–3.73 (m, 2H), 3.69 (s, 3H), 3.49 (d, 1H, J = 16.0), 3.20 (s, 3H), 2.53 (dd, 1H, J = 16.0, 8.0), 2.10–2.02 (m, 2H), 1.83–1.81 (m, 1H), 1.79–1.69 (m, 1H), 102 (s, 9H). ESI-MS m/z (rel int): (pos) 383.2 ([M+H]⁺, 100).




(S,E)-2-(1,8-Bis(2-hydroxyethyl)-2,3,6,7-tetrahydrocyclohepta[c]pyrrol-5(1H)-ylidene)-N-methoxy-N-methylacetamide (S-46a). Light yellow oil (2.5 mg). TLC: R_f 0.44 (1:5 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 6.29 (s, 1H), 5.91 (s, 1H), 4.68 (dd, 1H, J = 9.1, 2.4), 4.19–4.13 (m, 1H), 3.94 (d, 1H, J = 16.5), 3.68–3.65 (m, 4H), 3.64–3.61 (m, 1H), 3.46 (t, 2H, J = 6.4), 3.21 (s, 3H), 2.61 (t, 2H, J = 8.8), 2.49–2.41 (m, 2H), 1.62–1.59 (m, 1H), 1.52–1.47 (m, 2H), 1.22–1.20 (m, 1H). ESI-MS m/z (rel int): (pos) 323.4 ([M+H]⁺, 100).




(S,E)-2-(1-(2-Hydroxyethyl)-8-phenyl-2,3,6,7-tetrahydrocyclohepta[c]pyrrol-5(1H)-ylidene)-N-methoxy-N-methylacetamide (S-46b). Light red oil (2.1 mg). TLC: R_f 0.25 (1:10 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 7.68 (s, 1H), 7.38–7.25 (m, 5H), 6.08 (s, 1H), 4.82 (dd, 1H, J = 9.0, 4.2), 4.48 (dd, 1H, J = 10.2, 7.1), 3.71–3.68 (m, 4H), 3.63–3.58 (m, 1H), 3.49–3.45 (m, 1H), 3.23 (s, 3H), 2.64–2.60 (bm, 2H), 1.63–1.58 (m, 2H), 1.53–1.49 (m, 2H). ESI-MS m/z (rel int): (pos) 355.2 ([M+H]⁺, 100).




(S,E)-2-(1-(2-Hydroxyethyl)-2,3,6,7-tetrahydrocyclohepta[c]pyrrol-5(1H)-ylidene)-N-methoxy-N-methylacetamide (S-46d). Light yellow oil (1.9 mg). TLC: R_f 0.41 (1:10 MeOH/EtOAc). ¹H-NMR (600 MHz): δ 6.21 (s, 1H), 6.03 (s, 1H), 5.80 (d, 1H, J = 16.8), 4.59 (dd, 1H, J = 8.8, 3.5), 4.50 (d, 1H, J = 17.1), 3.85 (dd, 1H, J = 15.3, 6.4), 3.75–3.73 (m, 2H), 3.67 (s, 3H), 3.49 (d, 1H, J = 16.0), 3.20 (s, 3H), 2.51 (dd, 1H, J = 16.0, 8.0), 2.10–2.02 (m, 2H), 1.83–1.81 (m, 1H), 1.79–1.69 (m, 1H). ESI-MS m/z (rel int): (pos) 279.0 ([M+H]⁺, 100).




(*S,E*)-2-(2-(*tert*-Butylsulfonyl)-1-(2-hydroxyethyl)-2,3,6,7-tetrahydrocyclohepta[c]pyrrol-5(1*H*)-ylidene)-N-methoxy-N-methylacetamide (S-47a). Clear oil (3.9 mg). **TLC:** R_f 0.44 (1:8 MeOH/EtOAc). **¹H-NMR** (600 MHz): δ 6.39 (s, 1H), 6.10 (s, 1H), 4.66–4.63 (m, 1H), 4.59 (dt, 1H, J = 12.0, 5.5), 3.94 (d, 1H, J = 16.0), 3.69 (s, 3H), 3.61–3.56 (m, 1H), 3.47–3.41 (m, 2H), 3.21 (s, 3H), 2.57 (t, 1H, J = 8.8), 2.49–2.42 (m, 2H), 1.65–1.58 (m, 2H), 1.52–1.47 (m, 2H), 1.22–1.20 (m, 2H), 1.2 (s, 9H). **ESI-MS** m/z (rel int): (pos) 465.2 ([M+Na]⁺, 100).




(*S,E*)-2-(2-(*tert*-Butylsulfonyl)-1-(2-hydroxyethyl)-8-phenyl-2,3,6,7-tetrahydrocyclohepta[c]pyrrol-5(1*H*)-ylidene)-N-methoxy-N-methylacetamide (S-47b). Brown oil (4.5 mg). **TLC:** R_f 0.25 (1:15 MeOH/EtOAc). **¹H-NMR** (600 MHz): δ 7.67 (s, 1H), 7.32–7.23 (m, 5H), 5.49 (s, 1H), 4.68 (dd, 1H, J = 9.0, 4.2), 4.53 (dd, 1H, J = 10.6, 7.1), 3.72–3.67 (m, 4H), 3.58–3.54 (m, 1H), 3.45–3.41 (m, 1H), 3.25 (s, 3H), 2.64–2.60 (m, 2H), 1.63–1.58 (m, 1H), 1.53–1.49 (m, 3H), 1.09 (s, 9H). **ESI-MS** m/z (rel int): (pos) 475.2 ([M+H]⁺, 100).




(*S,E*)-2-(2-(*tert*-Butylsulfonyl)-1-(2-hydroxyethyl)-2,3,6,7-tetrahydrocyclohepta[c]pyrrol-5(1*H*)-ylidene)-N-methoxy-N-methylacetamide (S-47d). Light yellow oil (4.1 mg). **TLC:** R_f 0.41 (1:15 MeOH/EtOAc). **¹H-NMR** (600 MHz): δ 6.31 (s, 1H), 6.11 (s, 1H), 5.98 (t, 1H, J = 8.0), 4.68–4.62 (m, 2H), 4.00 (dd, 1H, J = 12.0, 3.5), 3.72–3.69 (m, 4H), 3.52–3.47 (m, 1H), 3.23 (s, 3H), 3.18–3.14 (m, 2H), 2.70–2.60 (m, 1H), 2.57–2.51 (m, 1H), 1.62–1.52 (m, 2H), 1.19 (s, 9H). **ESI-MS** m/z (rel int): (pos) 399.2 ([M+H]⁺, 100).




(Z)-2-((S)-2-((S)-tert-Butylsulfinyl)-1,8-bis(2-hydroxyethyl)-2,3,6,7-tetrahydrocyclohepta[c]-pyrrol-5(1H)-ylidene)-N-methoxy-N-methylacetamide (S-48a). Yellow oil (2.2 mg). TLC: R_f 0.44 (1:3 hexanes/EtOAc). $^1\text{H-NMR}$ (600 MHz): δ 6.16 (s, 1H), 6.01 (s, 1H), 4.64–4.62 (m, 1H), 4.53 (dt, 1H, J = 12.5, 5.9), 3.94 (d, 1H, J = 10.0), 3.65–3.61 (m, 3H), 3.59 (s, 3H), 3.52 (dd, 1H, J = 12.5, 6.2), 3.23 (s, 3H), 2.49–2.42 (m, 2H), 2.35–2.31 (m, 1H), 2.24–2.20 (m, 1H), 2.17–2.13 (m, 1H), 1.92–1.87 (m, 1H), 1.72–1.67 (m, 2H), 0.88 (s, 9H). **ESI-MS** m/z (rel int): (pos) 449.4 ([M+Na]⁺, 100).




(Z)-2-((S)-2-((S)-tert-Butylsulfinyl)-1-(2-hydroxyethyl)-8-phenyl-2,3,6,7-tetrahydrocyclohepta[c]pyrrol-5(1H)-ylidene)-N-methoxy-N-methylacetamide (S-48b). Light red oil (4.2 mg). TLC: R_f 0.25 (1:3 hexanes/EtOAc). $^1\text{H-NMR}$ (600 MHz): δ 7.69 (s, 1H), 7.34–7.27 (m, 5H), 5.92 (s, 1H), 4.68 (dd, 1H, J = 8.8, 4.2), 4.53 (dd, 1H, J = 14.2, 7.1), 3.72–3.69 (m, 4H), 3.58–3.54 (m, 1H), 3.45–3.41 (m, 1H), 3.23 (s, 3H), 2.64–2.60 (m, 2H), 1.61–1.56 (m, 2H), 1.53–1.49 (m, 2H), 0.93 (s, 9H). **ESI-MS** m/z (rel int): (pos) 459.2 ([M+H]⁺, 100).




(Z)-2-((S)-2-((S)-tert-Butylsulfinyl)-1-(2-hydroxyethyl)-2,3,6,7-tetrahydrocyclohepta[c]-pyrrol-5(1H)-ylidene)-N-methoxy-N-methylacetamide (S-48d). Clear oil (4.5 mg). TLC: R_f 0.41 (1:3 hexanes/EtOAc). $^1\text{H-NMR}$ (600 MHz): δ 6.21 (s, 1H), 6.11 (s, 1H), 6.00 (s, 1H), 4.59 (dd, 1H, J = 8.0, 3.5), 4.48 (d, 1H, J = 15.0), 3.83 (dd, 1H, J = 15.2, 5.7), 3.75–3.73 (m, 2H), 3.69 (s, 3H), 3.49 (d, 1H, J = 14.3), 3.20 (s, 3H), 2.51 (dd, 1H, J = 15.2, 6.2), 2.10–2.02 (m, 2H), 1.83–1.81 (m, 1H), 1.79–1.69 (m, 1H), 1.01 (s, 9H). **ESI-MS** m/z (rel int): (pos) 383.2 ([M+H]⁺, 100).




(S,Z)-2-(1,8-Bis(2-hydroxyethyl)-2,3,6,7-tetrahydrocyclohepta[c]pyrrol-5(1H)-ylidene)-N-methoxy-N-methylacetamide (S-49a). Light yellow oil (2.1 mg). TLC: R_f 0.44 (1:5 MeOH/EtOAc). **$^1\text{H-NMR}$** (600 MHz): δ 6.29 (s, 1H), 6.11 (s, 1H), 4.88 (dd, 1H, J = 9.0, 2.4), 4.21–4.18 (m, 1H), 3.94 (d, 1H, J = 16.0), 3.69 (s, 3H), 3.67–3.63 (m, 2H), 3.48 (t, 2H, J = 6.4), 3.21 (s, 3H), 2.61 (t, 2H, J = 8.8), 2.49–2.42 (m, 2H), 1.62–1.59 (m, 1H), 1.56–1.52 (m, 3H). **ESI-MS** m/z (rel int): (pos) 323.4 ([M+H]⁺, 100).




(S,Z)-2-(1-(2-Hydroxyethyl)-8-phenyl-2,3,6,7-tetrahydrocyclohepta[c]pyrrol-5(1H)-ylidene)-N-methoxy-N-methylacetamide (S-49b). Light orange oil (1.4 mg). TLC: R_f 0.25 (1:10 MeOH/EtOAc). **$^1\text{H-NMR}$** (600 MHz): δ 7.65 (s, 1H), 7.36–7.23 (m, 5H), 5.92 (s, 1H), 4.68 (dd, 1H, J = 9.0, 4.8), 4.42 (dd, 1H, J = 12.2, 7.1), 3.69–3.65 (m, 4H), 3.61–3.54 (m, 1H), 3.41–3.38 (m, 1H), 3.21 (s, 3H), 2.64–2.60 (bm, 2H), 1.61–1.52 (m, 2H), 1.50–1.47 (m, 2H). **ESI-MS** m/z (rel int): (pos) 355.2 ([M+H]⁺, 100).




(S,Z)-2-(1-(2-Hydroxyethyl)-2,3,6,7-tetrahydrocyclohepta[c]pyrrol-5(1H)-ylidene)-N-methoxy-N-methylacetamide (S-49d). Light yellow oil (1.2 mg). TLC: R_f 0.41 (1:10 MeOH/EtOAc). **$^1\text{H-NMR}$** (600 MHz): δ 6.22 (s, 1H), 6.01 (s, 1H), 5.92 (s, 1H), 4.59 (dd, 1H, J = 8.8, 3.5), 4.49 (d, 1H, J = 17.1), 3.83 (dd, 1H, J = 12.4, 6.4), 3.73–3.70 (m, 2H), 3.67 (s, 3H), 3.49 (d, 1H, J = 16.0), 3.21 (s, 3H), 2.51 (dd, 1H, J = 16.0, 8.0), 2.13–2.04 (m, 2H), 1.81–1.78 (m, 1H), 1.74–1.65 (m, 1H). **ESI-MS** m/z (rel int): (pos) 279.0 ([M+H]⁺, 100).



(S,Z)-2-(2-(tert-Butylsulfonyl)-1,8-bis(2-hydroxyethyl)-2,3,6,7-tetrahydrocyclohepta[c]-pyrrol-5(1H)-ylidene)-N-methoxy-N-methylacetamide (S-50a). Clear oil (3.3 mg). TLC: R_f 0.44 (1:8 MeOH/EtOAc). **$^1\text{H-NMR}$** (600 MHz): δ 6.26 (s, 1H), 6.03 (s, 1H), 4.62–4.57 (m, 1H), 4.50 (dd, 2H, J = 12.0, 5.5), 3.84 (d, 1H, J = 11.0), 3.73 (t, 1H, J = 12.0), 3.67 (s, 3H), 3.50 (dd, 2H, J = 12.0, 6.2), 3.23 (s, 3H), 2.53 (dd, 2H, J = 9.1, 8.8), 2.11–1.98 (m, 2H), 1.83–1.78 (m, 2H), 1.72–1.67 (m, 2H), 1.18 (s, 9H). **ESI-MS** m/z (rel int): (pos) 465.2 ([M+Na]⁺, 100).



(S,Z)-2-(2-(tert-Butylsulfonyl)-1-(2-hydroxyethyl)-8-phenyl-2,3,6,7-tetrahydrocyclohepta[c]pyrrol-5(1H)-ylidene)-N-methoxy-N-methylacetamide (S-50b). Brown oil (3.5 mg). **TLC:** R_f 0.25 (1:15 MeOH/EtOAc). **$^1\text{H-NMR}$** (600 MHz): δ 7.67 (s, 1H), 7.32–7.23 (m, 5H), 5.93 (s, 1H), 4.68 (dd, 1H, J = 9.0, 4.8), 4.53 (dd, 1H, J = 10.7, 7.1), 3.72–3.67 (m, 4H), 3.61–3.58 (m, 1H), 3.47–3.43 (m, 1H), 3.23 (s, 3H), 2.64–2.60 (m, 2H), 1.63–1.58 (m, 2H), 1.53–1.49 (m, 2H), 1.10 (s, 9H). **ESI-MS** m/z (rel int): (pos) 475.3 ([M+H]⁺, 100).



(S,Z)-2-(2-(tert-Butylsulfonyl)-1-(2-hydroxyethyl)-2,3,6,7-tetrahydrocyclohepta[c]pyrrol-5(1H)-ylidene)-N-methoxy-N-methylacetamide (S-50d). Light yellow oil (3.1 mg). **TLC:** R_f 0.41 (1:15 MeOH/EtOAc). **$^1\text{H-NMR}$** (600 MHz): δ 6.27 (t, 1H, J = 8.0), 6.13 (s, 1H), 6.02 (s, 1H), 4.73 (dd, 1H, J = 14.0, 4.0), 4.52 (dd, 1H, J = 16.0, 4.0), 3.92–3.89 (m, 1H), 3.76–3.70 (m, 2H), 3.56 (s, 3H), 3.21 (s, 3H), 2.48–2.44 (m, 2H), 2.39–2.35 (m, 1H), 2.24–2.20 (m, 1H), 1.94–1.87 (m, 1H), 1.70–1.65 (m, 1H), 1.07 (s, 9H). **ESI-MS** m/z (rel int): (pos) 399.2 ([M+H]⁺, 100).

G. PRINCIPAL COMPONENT ANALYSIS (PCA)

A total of 330 compounds were compared by principal component analysis:⁴

- 40 top selling brand-name small molecule drugs by revenue in 2006.^{4,5}
- 60 natural products with diverse structures⁴
- 20 polycyclic alkaloid and terpenoid natural products (Figure S1)^{4b}
- 10 drug-like pyrrazolecarboxamides in the MLSMR from ChemBridge⁴
- 10 drug-like dihydrotriazolopyrimidines in the MLSMR from Chem Div⁴
- 190 alkaloid/terpenoid-like library members synthesized herein

PCA was performed using 20 structural and physicochemical parameters as previously described.⁴ Complete data and results are included as an Excel spreadsheet file attached to this Supporting Information. Average values for each parameter by compound class are shown in Table S2 below. A total of 81% of the variance in the overall dataset is represented in the first two principal components (Table S3). Component loadings are shown graphically in Figure S2 below. High-resolution versions of Figure 1a–d from the manuscript are reproduced below as Figures S3, S4, S5, and S6.

Table S2. Average structural and physicochemical parameters by compound series. [†] = nStereo ÷ MW × 1000 for clarity.

AVGs	Drug	NP	AlkTerp	ChBr	ChDv	Multi
MW	361	629	267	381	446	333
N	2.2	2.6	0.6	4.3	4.7	1.4
O	2.9	9.7	3.3	3.1	3.4	3.5
XLogP	2.7	1.5	1.6	2.9	1.8	0.8
HBD	1.5	4.9	1.9	1.1	1.9	1.8
HBA	5.4	10.8	3.8	5.9	7.7	5.0
RotB	6.3	9.7	2.2	5.3	6.1	5.7
tPSA	69	183	63	103	94	71
ALOGPs	2.8	2.1	1.8	3.3	2.7	1.3
ALOGpS	-3.9	-3.8	-2.6	-4.0	-3.8	-2.5
nStereo	1.4	9.1	3.6	0.0	1.0	1.7
R	0.6	4.1	1.3	0.0	0.5	0.9
S	0.8	5.0	2.3	0.0	0.5	0.8
nStMW [†]	3.7	13.9	12.7	0.0	2.2	5.4
RSdelta	-0.2	-0.9	-1.0	0.0	0.0	0.0
Rings	2.9	3.8	2.7	3.2	4.2	2.3
RngAr	2.1	1.0	0.5	2.9	2.9	0.8
RngSys	2.1	2.0	1.3	3.1	3.1	1.5
RngLg	8.4	15.8	10.2	6.3	9.4	8.3
RRSys	1.4	2.3	2.3	1.0	1.4	1.6

⁴ (a) Bauer, R. A.; Wurst, J. M.; Tan, D. S. *Curr. Opin. Chem. Biol.* **2010**, *14*, 308–314. (b) Bauer, R. A.; DiBlasi, C. M.; Tan, D. S. *Org. Lett.* **2010**, *12*, 2084–2087.

⁵ Drug Topics Website – “Top 200 brand-name drugs by retail dollars in 2006”:

<http://drugtopics.modernmedicine.com/drugtopics/Pharmacy+Facts+%26+Figures/Top-200-brand-name-drugs-by-retail-dollars-in-2006/ArticleStandard/Article/detail/405100?contextCategoryId=7604>





Figure S1. Collection of 20 polycyclic alkaloid and terpenoid natural products having scaffolds related to those synthesized herein.

Table S3. Standard deviation and percent contribution for each principal component (R summary).

	PC1	PC2	PC3	PC4	PC5	PC6	PC7	PC8	PC9	PC10
Standard deviation	3.303	1.232	1.021	0.727	0.614	0.560	0.484	0.284	0.275	0.239
Proportion of Variance	0.714	0.099	0.068	0.035	0.025	0.021	0.015	0.005	0.005	0.004
Cumulative Proportion	0.714	0.813	0.882	0.916	0.941	0.961	0.977	0.982	0.987	0.991

**Figure S2.** Plot of PCA component loadings generated using the biplot function of R.




Figure S3. High-resolution version of Figure 1a from the manuscript. Principal component analysis of 20 structural and physicochemical descriptors of the 40 top-selling drugs (red circles), 60 diverse natural products (open blue triangles), 20 polycyclic alkaloids and terpenoids (filled blue triangles), 20 ChemBridge and Chem Div library members (crosses), and 190 multiscaffold library members (green diamonds).




Figure S4. High-resolution version of Figure 1b from the manuscript. Influence of the scaffold: enyne-derived scaffolds (filled diamonds), diyne-derived scaffolds (filled squares).




Figure S5. High-resolution version of Figure 1c from the manuscript. Influence of the R² substituent: CH₂CH₂OH (green fill), Ph (yellow fill), H (pink fill).




Figure S6. High-resolution version of Figure 1d from the manuscript. Influence of the R^3 N-capping group: sulfinamides (green fill), free amines (pink fill), sulfonamides (yellow fill).

H. PRINCIPAL MOMENT OF INERTIA (PMI) ANALYSIS

Normalized principal moments of inertia were calculated for the 95 *R*-series library members by Dr. Lakshmi B. Akella (Broad Institute) as previously described.⁶ Enantiomers are not distinguished in this analysis. Briefly, low energy conformations were calculated using MOE (Molecular Operating Environment; <http://www.chemcomp.com/software.htm>), resulting in a total of 97 structures (two low-energy conformations were identified for Saito [3+2+2] cycloaddition products **45a** and **47a**). Principal moment of inertia ratios were calculated, then normalized. The results were plotted using Spotfire (<http://spotfire.tibco.com/>), with the boundary triangle added manually at coordinates {0,1} (rod), {1,1} (sphere), and {0.5,0.5} (disc).




Figure S7. PMI analysis of *R*-series library members, coded by scaffold. Products derived from reductive cyclization (yellow circles), enyne metathesis (cyan pentagons), and isocyanate [2+2+2] cyclotrimerization (blue triangles) exhibited relatively more sphere-like character.

⁶ (a) Sauer, W. H. B.; Schwarz, M. K. *J. Chem. Inf. Comput. Sci.* **2003**, *43*, 987–1003. (b) Akella, L. B.; DeCaprio, D. *Curr. Opin. Chem. Biol.* **2010**, *14*, 325–330.




Figure S8. PMI analysis of R -series library members, coded by R^2 substituent.









Figure S9. PMI analysis of R -series library members, coded by R^3 N-capping group.





I. ^1H -NMR AND SELECTED ^{13}C -NMR SPECTRA



1. ^1H-NMR and selected ^{13}C-NMR spectra for <i>R</i>-series library members	S72
a. Pauson–Khand reaction products (<i>R-11–13</i>)	S72
b. Krische reductive cyclization products (<i>R-14–19</i>)	S77
c. Evans butadiene [4+2+2] cycloaddition products (<i>R-20</i>)	S87
d. Enyne metathesis products (<i>R-21–23</i>)	S90
e. Maleimide Diels–Alder products (<i>R-24</i>)	S95
f. DMAD Diels–Alder products (<i>R-25</i>)	S97
g. Alkyne [2+2+2] cyclotrimerization products (<i>R-30–35</i>)	S100
h. Isocyanate [2+2+2] cyclotrimerization products (<i>R-36–41</i>)	S110
i. Nitrile [2+2+2] cyclotrimerization products (<i>R-42–44</i>)	S118
j. Saito [3+2+2] cycloaddition products (<i>R-45–50</i>)	S125
2. ^1H-NMR spectra for <i>S</i>-series library members	S136
a. Pauson–Khand reaction products (<i>S-11–13</i>)	S136
b. Krische Reductive cyclization products (<i>S-14–19</i>)	S141
c. Evans Butadiene [4+2+2] cycloaddition products (<i>S-20</i>)	S149
d. Enyne metathesis products (<i>S-21–23</i>)	S151
e. Maleimide Diels–Alder products (<i>S-24</i>)	S156
f. DMAD Diels–Alder products (<i>S-25</i>)	S158
g. Alkyne [2+2+2] cyclotrimerization products (<i>S-30–35</i>)	S160
h. Isocyanate [2+2+2] cyclotrimerization products (<i>S-36–41</i>)	S168
i. Nitrile [2+2+2] cyclotrimerization products (<i>S-42–44</i>)	S175
j. Saito [3+2+2] cycloaddition products (<i>S-45–50</i>)	S180


1. ^1H -NMR AND SELECTED ^{13}C -NMR SPECTRA FOR R-SERIES LIBRARY MEMBERS**a. Pauson–Khand reaction products (R-11–13)**


















b. Krische reductive cyclization products (*R*-14–19)




































c. Evans butadiene [4+2+2] cycloaddition products (*R*-20)







d. Enyne metathesis products (*R*-21–23)















e. Maleimide Diels–Alder products (*R*-24)








f. DMAD Diels–Alder products (*R*-25)












g. Alkyne [2+2+2] cyclotrimerization products (*R*-30–35)

































h. Isocyanate [2+2+2] cyclotrimerization products (*R*-36–41)


























i. Nitrile [2+2+2] cyclotrimerization products (*R*-42–44)























j. Saito [3+2+2] cycloaddition products (*R*-45–50)











































2. ^1H -NMR SPECTRA FOR S-SERIES LIBRARY MEMBERS**a. Pauson–Khand reaction products (S-11–13)**

















b. Krische reductive cyclization products (S-14–19)





























c. Evans butadiene [4+2+2] cycloaddition products (S-20)






d. Enyne metathesis products (S-21–23)



















e. Maleimide Diels–Alder products (S-24)







f. DMAD Diels–Alder products (S-25)





g. Alkyne [2+2+2] cyclotrimerization products (S-30–35)





























h. Isocyanate [2+2+2] cyclotrimerization products (S-36–41)























i. Nitrile [2+2+2] cyclotrimerization products (S-42–44)









j. Saito [3+2+2] cycloaddition products (S-45–50)